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Besnoitia besnoiti is an apicomplexan parasite responsible for bovine besnoitiosis, a 
disease with a high prevalence in tropical and subtropical regions and re-emerging in 
Europe. Despite the great economical losses associated with besnoitiosis, this disease has 
been underestimated and poorly studied, and neither an effective therapy nor a vaccine to be 
used in Europe is available. Protein disulfide isomerase (PDI) is an essential enzyme for the 
acquisition of the correct three-dimensional structure of proteins. Current evidence suggests 
that in Neospora caninum and Toxoplasma gondii, which are closely related to B. besnoiti, 
PDI plays an important role in host cell invasion, is a relevant target for the host immune 
response, and represents a promising drug target and/or vaccine candidate. In this work, we 
presented the nucleotide sequence of the B. besnoiti PDI gene and a 3D theoretical model 
was built by comparative homology using Swiss-Model server. B. besnoiti expresses a PDI 
with 471 amino acids, structurally similar to human and yeast PDIs, with four thioredoxin-like 
domains a, b, b’, a’ and a C-terminal extension c. The a and a’ domains present the 
characteristic active site pattern CxxC, in this case CGHC and CGYC, respectively. Analysis 
of the phylogenetic tree for PDI within the phylum Apicomplexa reinforced the close 
relationship among B. besnoiti, N. caninum and T. gondii. Recombinant B. besnoiti PDI 
(recBbPDI) and truncated versions corresponding to domains a, b, b’ and a’c were 
expressed in a heterologous system. Mice were immunized with recBbPDI for the production 
of monoclonal antibodies (mAbs) by hybridoma technology and four mAbs were produced 
and characterized. RecBbPDI and domain a’c (recBb-a’c) were functionally active and 
exhibited a dose dependent cross-linking activity of insulin. In the presence of bacitracin, 
tocinoic acid, 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) and 4-chloromercuribenzoic acid 
(pCMBA) activity of both enzymes was inhibited, in a dose dependent manner. The same 
happened with recBbPDI in the presence of mAbs (with the exception of T8a), but not with 
recBb-a’c, whose activity was not sensitive to the presence of mAbs. In vitro proliferation of 
B. besnoiti tachyzoites was diminished in the presence of PDI inhibitors and anti-PDI mAbs, 
indicating that this enzyme seems to intervene in the process of host cell adhesion/invasion. 
In this way, considering the inhibitions obtained, both in the host cell invasion ability and in 
the enzyme catalytic activity, PDI can represent a potential target for addressing the 
treatment and/or prevention of besnoitiosis. The panel of monoclonal antibodies here 
developed represents an important tool for future studies. 
 











Título: A enzima isomerase de dissulfureto como alvo terapêutico contra a besnoitiose 
bovina. Caracterização molecular e estudo do seu papel na infeção e na resposta imunitária. 
Resumo 
 
Besnoitia besnoiti, o agente etiológico da besnoitiose bovina, pertence ao filo 
Apicomplexa, família Sarcocystidae, subfamília Toxoplasmatinae, estando filogeneticamente 
próximo dos géneros Neospora e Toxoplasma. A besnoitiose bovina é uma doença severa 
mas geralmente não fatal, endémica em vastas áreas tropicais e subtropicais de África e 
responsável por elevadas perdas económicas. Na Europa, após as primeiras descrições há 
mais de um século, em França e Portugal, a doença recebeu pouca atenção até finais do 
século XX, altura em que a sua incidência começou a aumentar com relatos em Portugal, 
Espanha, Itália e França. Mais recentemente o avanço geográfico da doença é relatado com 
casos na Grécia, Suíça, Alemanha, Hungria, Croácia e Irlanda. A fase aguda da doença é 
marcada por alterações respiratórias, febre, anasarca, diarreia e, por vezes, aborto. Na fase 
crónica, o animal apresenta grande espessamento da pele (elefantíase) com soluções de 
continuidade, muitas vezes complicadas por infecções oportunistas, má condição corporal e, 
nos machos, orquite necrosante e aspermia. Apesar de ser conhecida há mais de um 
século, assim como a sua etiologia parasitária, a besnoitiose bovina mantém muitos 
aspectos da sua epidemiologia desconhecidos, incluindo o ciclo de vida do seu agente 
etiológico. Outras espécies do género Besnoitia têm um ciclo heteroxeno mantido por uma 
relação presa-predador entre pequenos mamíferos e o gato. Acredita-se que o ciclo de vida 
de B. besnoiti seja semelhante, mas até à data ainda não foi identificado um hospedeiro 
definitivo. A transmissão homoxena de bradizoítos e taquizoítos de B. besnoiti foi 
comprovada experimentalmente, em bovinos e em diversos animais de laboratório, e uma 
maior incidência da doença nos meses mais quentes do ano, quando existe maior actividade 
de insetos hematófagos, sugere um papel destes na transmissão de B besnoiti. No entanto, 
o verdadeiro modo de transmissão deste parasita na natureza mantém-se desconhecido. A 
doença pode atingir uma elevada taxa de morbilidade, o que, associado à gravidade das 
manifestações clínicas e à inexistência de vacina segura ou tratamento eficaz, justifica a 
necessidade de aprofundar o conhecimento sobre a biologia deste parasita, tentando 
desenvolver novas abordagens à terapêutica e à formulação de vacinas. 
A enzima isomerase de dissulfureto (PDI, do inglês protein disulfide isomerase), uma das 
mais abundantes do retículo endoplasmático, catalisa a formação de pontes dissulfureto e o 
rearranjo de emparelhamentos dissulfureto incorrectos, permitindo que as proteínas 





sido implicadas em doenças neurodegenerativas como Alzheimer ou Parkinson ou na 
capacidade proliferativa de células neoplásicas. Sabe-se hoje que, para além da sua 
localização maioritariamente reticular, a PDI está presente à superfície das células, onde 
participa em diversas funções biológicas, como a ativação e agregação plaquetária, a 
adesão leucocitária ou a internalização de agentes patogénicos como alguns vírus e 
clamídias. Em diversos parasitas do filo Apicomplexa, incluindo Neospora caninum e 
Toxoplasma gondii, foram já identificadas PDIs na superfície dos taquizoítos e foi 
demonstrado que a inibição desta proteína, através de drogas ou anticorpos específicos, 
tem um efeito negativo sobre a capacidade de proliferação dos parasitas, evidenciando o 
papel que esta parece desempenhar no processo de adesão/invasão da célula hospedeira. 
Por outro lado, a PDI parece ter um papel relevante na resposta imunitária do hospedeiro, 
uma vez que foi identificada como uma proteína imunodominante e que foi demonstrada a 
presença de anticorpos anti-T. gondii-PDI e anti-N. caninum-PDI no repertório inato do 
homem e da vaca, respetivamente. Em conjunto, estas evidências sublinham a importância 
da PDI no processo de invasão celular e na resposta imunitária do hospedeiro. 
Neste trabalho determinámos a sequência completa do gene da PDI em B. besnoiti, 
clonámos o respectivo cDNA e expressámos a proteína recombinante, assim como versões 
truncadas da mesma, num sistema heterólogo. A PDI de B. besnoiti (BbPDI) pertence à 
superfamília das tiorredoxinas (cluster 00388), estando incluída na família PDI_a (cluster 
defined cd02961) e subfamília PDI_a_PDI_a’_c (cd02995). Construímos um modelo 
tridimensional da BbPDI por homologia de comparação usando o software disponível no 
servidor Swiss-Model e tendo como modelo a estrutura cristalográfica da Tapasina-ERp57 
(código do PDB: 3F8U chain C). Verificámos que B. besnoiti expressa uma PDI composta 
por 471 aminoácidos, com a organização típica descrita para a PDI humana e de levedura, 
ou seja os 4 domínios estruturalmente semelhantes à tiorredoxina, domínio a, b, b’, a’, com 
uma extensão C-terminal c. Os domínios activos a e a’ apresentam os característicos 
centros ativos CxxC, no caso de B. besnoiti com a sequência aminoacídica CGHC e CGYC, 
respectivamente. A análise filogenética para a PDI colocou a B. besnoiti no mesmo ramo 
que a N. caninum e T. gondii. Com a PDI recombinante de B. besnoiti (recBbPDI), 
imunizámos murganhos com o objetivo final de produzir anticorpos monoclonais (mAbs) 
anti-PDI, pela tecnologia de hibridomas. Obtivemos 4 mAbs, que foram caracterizados no 
reconhecimento das versões truncadas de PDI, correspondentes aos domínios a, b, b’ e a’c 
e na capacidade de reconhecerem cruzadamente a PDI de N. caninum e T. gondii. Todos os 
anticorpos produzidos, T8a, S4a, R60b e S16p, reconhecem a proteína recombinante e a 
natural de B. besnoiti, tanto em condições desnaturantes como em condições nativas. Dois 
mAbs (T8a e S4a) reconhecem o domínio a’c, um anticorpo reconhece o domínio b’ (R60b) 





específico para a PDI de B. besnoiti, enquanto os restantes reagem cruzadamente com a 
PDI de N. caninum e T. gondii, quando testados por western blot e ELISA. Foi avaliada a 
actividade cinética da proteína recombinante pelo método da agregação da insulina. Este 
consiste na avaliação turbidimétrica da precipitação da insulina como resultado da formação 
de pontes dissulfureto, ação que é catalisada pela PDI. Foram avaliadas as versões 
truncadas dos domínios ativos (a e a’c) e a proteína integral, tendo-se verificado ausência 
de atividade para a versão truncada correspondente ao domínio a. Contudo, a versão 
truncada a’c (recBb-a’c) e recBbPDI mostraram-se funcionalmente ativas. Na presença de 
bacitracina, ácido tocinóico, ácido ditionitrobenzoico (DTNB) e ácido p-cloromercurobenzóico 
(pCMBA) a atividade destas enzimas foi, de uma forma geral, inibida de um modo dose-
dependente. O mesmo aconteceu com a atividade catalítica da recBbPDI quando testada na 
presença dos mAbs produzidos (excepto mAb T8a), mas não na actividade de recBb-a’c, 
que não foi inibida por nenhum dos mAbs. Verificou-se a presença de PDI no produto de 
secreção/excreção de taquizoítos e, para avaliar o envolvimento desta no processo de 
invasão da célula hospedeira, foram colocados taquizoítos de B. besnoiti sobre um tapete 
confluente de células Vero na presença das drogas e dos mAbs acima mencionados. Após 
uma hora, removeram-se os inibidores e os taquizoítos em suspensão e as culturas foram 
incubadas por mais onze horas para permitir a fácil visualização dos vacúolos parasitóforos, 
por imunofluorescência indireta. A presença de inibidores da PDI e de mAbs anti-PDI 
permitiram diminuir a taxa de invasão de B. besnoiti, demonstrando a acção desta enzima 
no processo de adesão/invasão da célula hospedeira. Tendo em conta os resultados de 
inibição obtidos, quer na capacidade de invasão de célula hospedeira, quer na atividade 
cinética da enzima, a PDI pode de facto representar um alvo para o desenvolvimento de 
estratégias terapêuticas e/ou profilácticas contra a besnoitiose bovina. O painel de 
anticorpos monoclonais aqui desenvolvidos representa uma ferramenta importante para 
estudos futuros.  
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BbPDI Besnoitia besnoiti protein disulfide isomerase 
BCR B-cell receptor 
BPTI Bovine pancreatic trypsin inhibitor  
cDNA  Complementary DNA 
DAPI  4',6-diamidino-2-phenylindole 
DMEM Dulbeco’s Minimal Essential Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DsbA Disulfide bond formation protein A (thiol-disulfide oxidoreductase enzyme) 
DTNB 5,5′-dithiobis(2-nitrobenzoic acid) 
DTT 1,4-Dithiothreitol 
EFSA European Food Safety Authority 
ELISA Enzyme-linked immunosorbent assay  
EM Electron microscopy 
ER Endoplasmic Reticulum  
FBS Fetal bovine serum 
FITC Fluorescein isothiocyanate 
GR Glutathione reductase 
GSH Reduced glutathione 
GSSG Oxidized glutathione 
GST Glutathione S-transferase 
HAT Hypoxanthine, Aminopterin, Thymidine 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HGPRT Hypoxanthine guanine phosphoribosyl transferase 
hPDI Human protein disulfide isomerase 
ICW Inner cyst wall  
IFAT Immunofluorescence antibody test 
Ig Immunoglobulin(s) 
IgA Immunoglobulin, isotype A 
IgG Immunoglobulin, isotype G 
IgM Immunoglobulin, isotype M 
IMC Inner membrane complex 





mAb Monoclonal antibody 
NADPH Nicotinamide adenine dinucleotide phosphate 
NTZ Nitazoxanide 
OCW Outer cyst wall  
ORF Open reading frame 
pCMBA 4-chloromercuribenzoic acid, p-chloromercuribenzoic acid   
pCMBS p-chloromercuribenzenesulfonic acid  
PCR Polymerase chain reaction 
PDB Protein data base 
PDI Protein disulfide isomerase 
PEG Polyethylene glycol  
PMDB Protein model database 
PMDs Protein misfolding disorders 
p-NPP p- Nitrophenylphosphate  
PV Parasitophorous vacuole 
PVDF Polyvinylidene difluoride 
rDNA Ribossomal DNA 
recBbPDI Recombinant B. besnoiti protein disulfide isomerase 
RMS Root mean square 
RNA Ribonucleic acid 
RNase Ribonuclease 
RT-PCR Reverse transcription polymerase chain reaction 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SSU Small (ribosomal) subunit 
TEM Transmission electron microscopy 
TRITC Tetramethylrhodamine 
TRX  Thioredoxin 
UV Ultra violet 
WB Western blot 



















1.1 Bovine besnoitiosis 
Besnoitiosis is a protozoal disease of cattle caused by the cyst-forming apicomplexan 
parasite Besnoitia besnoiti. It is a severe but usually non-fatal disease that leads to important 
economic losses due to significant reduction in productivity (Agosti, Belloli, Morini & Vacirca, 
1994; Basso et al., 2013; Bigalke, 1968; Cortes et al., 2003; European Food Safety Authority 
[EFSA], 2010; Juste, Cuervo, Marco & Oregui, 1990; Olias et al., 2011; Pols, 1960). The first 
mention related to bovine besnoitiosis was published in 1884, when Cadéac described a skin 
disease in cattle from southern France, that he then, having no knowledge of the etiology, 
named bovine elephantiasis and anasarca («l’elephantiasis et de l’anasarque du boeuf») 
(Cadéac, 1884). The history of bovine besnoitiosis is, in fact, plenty of confusion and 
uncertainty concerning the identity of the etiological agent and the name of the disease, 
which conduced to different synonym based on the clinical aspects of the disease or the 
succeeding denominations for the parasite. With the investigations of Besnoit and Robin 
(1912), that revealed the presence of a large number of thick-walled cysts harboring 
numerous spores in the skin and subcutaneous tissues of affected cattle, the parasitic 
etiology of the disease was established. They realized that it was a new parasite, and 
suggested that it might be a Sarcocystis sp., designating the disease as (cutaneous) 
sarcosporidiosis. In the same year, Marotel (1912) pointed out that nothing similar had been 
found previously in cattle and, despite noting morphological characteristics that clearly 
differentiate this parasite from the known Sarcocystis spp. at the time, he proposed the 
species name of Sarcocystis besnoiti. The following year, Henry (1913), considering this 
morphological distinction, argued that the protozoa of Besnoit and Robin could not be placed 
in the genus Sarcocystis. He proposed the creation of the genus Besnoitia and that the 
parasite be referred as Besnoitia besnoiti, keeping the authorship of the species to Marotel. 
Meanwhile, in Portugal, Franco and Borges (1915, 1916) conducted a detailed description of 
the disease, in 67 animals they encountered in Lisbon abattoir from 1885 to 1914. In 
agreement with Henry (1913), they noticed the distinct characteristics that differentiated this 
parasite from the genus Sarcocystis and proposed also the name of Besnoitia besnoiti. 
However, in 1920 (Nöller), in a revision of the relevant literature up to the year of 1918 about 
the generic nomenclature of the genera Globidium, Gastrocystis, Ileocystis, Lymphocystis, 
Haplogastrocystis and Besnoitia, regarded that the parasites with unknown complete life 
cycle should be included in the genus Globidium, for the sake of simplicity. He then 
suggested the name Globidium besnoiti for the etiological agent of the Besnoit and Robin’s 
sarcosporidiosis. This suggestion was followed by other authors in subsequent publications 





subsequent years, the debate on how to classify this protozoan continued, but the consensus 
about the Besnoitia genus came in the mid twentieth century. 
1.1.1 The genus Besnoitia and B. besnoiti 
1.1.1.1 Life cycle and biological features 
Besides B. besnoiti (type species), the genus Besnoitia comprises other three named 
species infecting large ungulates (Besnoitia caprae, Besnoitia bennetti and Besnoitia tarandi) 
and six infecting small mammals and lizards (Besnoitia akodoni, Besnoitia darlingi, Besnoitia 
jellisoni, Besnoitia neotomofelis, Besnoitia oryctofelisi and Besnoitia wallacei) (Cortes, Leitao, 
Gottstein & Hemphill, 2014; Olias et al., 2011). Presently, there are still questions regarding 
the differentiation of some of these species and their taxonomic status because only four 
have their life cycle clarified and morphological and molecular differences among the 
remaining species are poorly defined (Dubey, van Wilpe, Blignaut, Schares & Williams, 2013; 
EFSA, 2010; Olias et al., 2011).  
It has been suggested that Besnoitia species, like other cyst-forming coccidian, have a 
facultative heteroxenous life cycle with a predator as a definite host and a prey as 
intermediate host (Basso, Schares, Gollnick, Rutten & Deplazes, 2011; Olias et al., 2011). 
The life cycle is well characterized only for four Besnoitia species found in small mammals 
from the American continent (B. darlingi, B. neotomofelis, B. oryctofelisi and B. wallacei), for 
which the cat was found to act as the definite host (Dubey & Lindsay, 2003; Dubey et al., 
2002; Dubey et al., 2003b; Dubey & Yabsley, 2010; Frenkel, 1977; Smith & Frenkel, 1977, 
1984; Wallace & Frenkel, 1975). Nevertheless, it is important to point that not all life forms 
(cysts/bradyzoites, tachyzoites or oocysts) of these parasites have been identified in nature. 
For B. darlingi, B. neotomofelis and B. oryctofelisi, the tissue cysts, containing bradyzoites, 
were identified in the intermediate host and the cat experimentally infected (Dubey & 
Lindsay, 2003; Dubey et al., 2002; Dubey et al., 2003b; Dubey & Yabsley, 2010; Smith & 
Frenkel, 1977, 1984), while for B. wallacei, the oocysts were isolated in the feces of one 
stray cat and susceptible intermediate hosts (Rattus norvegicus, R. exulans, and Mus 
musculus) experimentally infected (Frenkel, 1977; Wallace & Frenkel, 1975). In this way, 
while the life cycle of these species was experimentally maintained through a cat-prey-cat 
cycle, the natural intermediate host for B. wallacei remains unknown, as well as the cat real 
role in nature for the remaining species. No definite host for B. jellisoni and B. akodoni has 





In regard to the Besnoitia species infecting large ungulates, although they have been 
studied for more than a century now (namely B. besnoiti, (Besnoit & Robin, 1912)), the 
definite host in the putative heteroxenous life cycle is still to be found (Alvarez-Garcia, Frey, 
Mora & Schares, 2013; Cortes et al., 2014; Olias et al., 2011). Homoxenous, direct 
transmission of bradyzoites and tachyzoites between intermediate hosts has been 
established experimentally in ungulates and several laboratory animals (Basso et al., 2011; 
Bigalke, 1968; Ng'ang'a & Kasigazi, 1994; Pols, 1960). Whether sexual reproduction really 
exists for all species of this genus is unknown, but since the closely related T. gondii, N. 
caninum and Hammondia spp. use terrestrial carnivores to fulfill this process and the cat has 
been identified has definite host in four Besnoitia species, it is very suggestive that large 
ungulate Besnoitia species also have a two-host life cycle (Olias et al., 2011). There have 
been several attempts to identify a definite host for these Besnoitia species, but only 
Peteshev, back in 1974, stated that both domestic cats and a wild cat (Felis Iybica), shed 
oocysts after ingestion of B. besnoiti cyst-containing tissues (Peteshev, Galuzo & 
Polomoshov, 1974). This observation, however, was never sustained by other authors. 
Diesing et al. (1988), fed domestic cats (Felis domestica), a dog (Canis familiaris), jungle 
cats (Felis chaus), caracals (Caracal caracal), small spotted genets (Genetta genetta), a lion 
(Panthera leo), leopards (Panthera pardus), cheetahs (Acinonys jubatus), banded 
mongooses (Mungos mungo), black-backed jackals (Canis mesomelas), a cape fox (Vulpes 
chama), six species of snakes and white-backed vultures (Gyps africanus), with B. besnoiti 
cystic material from chronically infected cattle and concluded that none of these species 
represents the definitive host of B. besnoiti, as no oocysts were found in their feces. 
Recently, these results were confirmed in experimental infections in domestic cats and 
beagle dogs (Basso et al., 2011). In the same way, experimental infections with B. tarandi 
failed in studies with domestic cats (Ayroud, Leighton & Tessaro, 1995), domestic cats and 
dogs (Dubey et al., 2004) and raccoon (Procyon lotor), domestic cat and arctic fox (Alopex 
lagopus) (Glover, Swendrowski & Cawthorn, 1990), as well as experimental infections with B. 
caprae in cats (Ng'ang'a & Kasigazi, 1994). Evidences of a definitive host also fail in a 
serological survey of B. besnoiti in free-living carnivores in Spain (Millan et al., 2012) 
Apart from the search for the missing final host it should be considered that ungulates 
may in fact represent accidental hosts, playing a role as a reservoir of the parasite in a 
sylvatic life cycle (Basso et al., 2011; Diesing et al., 1988; EFSA, 2010; Kiehl et al., 2010; 
Olias et al., 2011). To the present date, there is no evidence of parasites of the genus 





1.1.1.2 Taxonomy and phylogeny 
The obligate intracellular protozoan parasites of the genus Besnoitia are classified in the 
sub-family Toxoplasmatinae of the family Sarcocystidae, within the phylum Apicomplexa 
(Ellis et al., 2000; Olias et al., 2011; Tenter et al., 2002). Phylogenetic analysis based on 18S 
rDNA sequences of B. besnoiti, B. jellisoni, B. caprae, Hammondia hammondi, Isospora 
spp., Frenkelia spp., Neospora caninum, Sarcocystis spp. and Toxoplasma gondii showed 
that Besnoitia species comprise a monophyletic and sister group to a clade containing other 
medically and veterinary important parasitic protozoa, such as Toxoplasma gondii, and 
Neospora caninum (Figure 1) (Ellis et al., 2000; Olias et al., 2011). These results were 






Figure 1. Phylogenetic tree based on 18S rDNA sequences. 
Tree constructed from the parsimony analysis of the structure alignment of 
the SSU rDNA, representing the relationships amongst the cyst-forming 
coccidia sequences. Isospora robini was used as the outgroup. The 
numbers at the nodes represent the bootstrap values (% out of 500) 





Evolutionary relationships among Besnoitia species have been only scarcely investigated 
and are hindered by the deficit of gene sequences published for the different species and 
from different geographic regions. A striking example, is the fact that for B. wallacei, despite 
being known for forty years now (Wallace & Frenkel, 1975), there is no publically available 
sequence [GenBank search (http://www.ncbi.nlm.nih.gov/genbank/) for the term “Besnoitia 
wallacei”; accessed on 18 February 2016]. The published phylogenetic analyses on the 
genus Besnoitia have been based on the availability of ITS1 gene sequences. Although 
sequence information is not entirely complete for all species, it was possible to identify a 
Besnoitia genus-specific cluster within the ITS1 region, which, by multiple alignments, was 
demonstrated to be independent from other apicomplexans (Cortes et al., 2014). Phylogeny 
suggests that the Besnoitia genus is comprised of two distinct groups. One group includes 
the Besnoitia isolates from large ungulates (B. besnoiti, B. bennetti, B. caprae and B. 
tarandi), while the other contains Besnoitia isolates from small mammals from the American 
continent (B. akodoni, B. darlingi, B. jellisoni, B. oryctofelisi and B. neotomofelis) (Dubey & 
Yabsley, 2010; Kiehl et al., 2010; Olias et al., 2011). According to the Olias et al. (2011) 
analysis of available ITS1 sequences, that did not include the recently described B. 
neotomofelis (Dubey & Yabsley, 2010), small mammal Besnoitia spp group show a genetic 
divergence to large ungulate species group of 23.1% to 25.5%. Within the small mammal 
Besnoitia species there is a higher degree of ITS1 sequence variation, between 1.6 to 5.9%, 
while within large mammal Besnoitia species the sequences showed no variation (Figure 2). 
These differences might result from the contribution of the diploid phase, during the parasites 
differentiation and life cycle, where there is a bigger chance of recombination to occur. As 
previously discussed, in the case of B. besnoiti, the oral route of infection through oocysts 
shed by a definitive host has not been identified to date. However, it was demonstrated that 
transmission can occur by blood feeding insects such as horse flies and the stable fly, 
Stomoxys calcitrans (Bigalke, 1968), therefore simply bypassing the sexual cycle and 
promoting the parasite clonality (Cortes et al., 2014). This scenario is supported by 
comparison of the ITS1 sequences of B. besnoiti from different geographic regions, that 
show a lower degree of sequence variation for mechanically transmitted Besnoitia species. 
Olias et al. (2011) compared B. besnoiti ITS1 sequences from Israel, Portugal and South 
Africa and encountered no variation, while Kiehl et al. (2010) analyzed sequences from 
isolates of Israel, Portugal, Spain and Germany and found nearly identical sequences, with 














Phylogenetic analysis of the ITS1 sequence of B. neotomofelis, the latest identified 
Besnoitia specie, placed it in a clade with B. jellisoni, which is a sister clade to one containing 
B. akodoni, B. darlingi, and B. oryctofelisi within the small mammal clade (Dubey & Yabsley, 
2010) of the genus Besnoitia (Figure 3).  
 
Figure 2. Phylogenetic tree of the ITS1 region of parasite isolates in the genus Besnoitia. 
Tree constructed by unrooted neighbor-joining method. Eight out of 10 named Besnoitia 
species shown, as well as their known natural intermediate host (in gray). No natural definitive 
hosts are known for these species and the cat here depicted was established experimentally. 
Scale bar indicates genetic distance (reprinted from Olias, Schade & Mehlhorn, 2011, with 










Molecular analysis set in motion the debate about species differentiation that, especially in 
the case of coccidian, was traditionally based on phenotypic characters that include the 
morphology/ultrastructure of the available parasite stage and the host specificity. One 
problem with this approach is that in most cases only the oocyst stage and the ‘host’ by 
which it was shed were known when a new species was named. Such incomplete species 
descriptions are confounded by the fact that the ‘host’ described for the new species may not 
be its true natural host, because many animals may passage oocysts through their intestine 
without being a host for these parasites (Tenter et al., 2002). This may be further 
complicated in the case of heteroxenous or polyxenous parasites, where an incomplete 
understanding of the parasite life cycle can lead to different named species based on 
phenotypic characters such as the host specificity. An example of this situation is the well-
known T. gondii, that, before the discovery of the oocyst and it’s heteroxenous life cycle 
(more than 60 years later from the description of the first stage of the parasite in the gondi 
(Ctenodactylus gundi)), several other species of Toxoplasma were named in accordance to 
the host species in which they were detected (Levine, 1977; Tenter et al., 2002). Besnoitia 
spp. may or may not be writing the same history than Toxoplasma and only further research, 
both at the molecular level and biological/epidemiological level, can elucidate this matter. 
Presently, we should deduce the status of a species from the analysis of molecular, 
morphological, biochemical, and/or ecological data all together (Kiehl et al., 2010). In the 
case of Besnoitia species, looking into the ITS1 sequences of large ungulates, we might be 
Figure 3. Phylogenetic tree based on ITS1 region sequences of Besnoitia 
neotomofelis and related organisms. 
Percentages of 1000 bootstrap samplings that supported clades are shown on 
branches for Neighbor-joining analysis (reprinted from Dubey & Yabsley, 2010, 





drawn to conclude that presently there is no sufficient genetic evidence to consider B. 
caprae, B. tarandi, B. bennetti and B. besnoiti separated species, since all published 
sequences to date are identical or different with only one or two base insertions when 
compared to B. besnoiti (Ellis et al., 2000; Olias et al., 2011). Nevertheless, some points 
should be considered in this matter: first, as previously mentioned, genetic data available for 
these parasites from different isolates is limited and for sure represents a biased sampling of 
the biological diversity of Besnoitia spp. (Tenter et al., 2002); second, phylogenic definition of 
a species is almost impossible based in molecular data derived only from one gene, 
especially when there are no hints in which degree of diversity is needed to define a specie 
(Kiehl et al., 2010); Nevertheless, the size and sequence content of the ITS1 is recognized 
as a well-characterized species-specific marker amongst the coccidian such that parasite 
populations sharing the same, or highly similar, ITS1 sequences are likely to be derived from 
the same specie (Ellis et al., 2000); third, biological and ultrastructural details indicate 
substantial differences that, as stated, have to be weighed along with molecular data. Still, 
the Toxoplasma example shows us that we can have virulent and avirulent populations of T. 
gondii, which differ in their biological (e.g. spectrum of disease in the mouse) and genetic 
(e.g. SAG2 and RAPD PCR profiles) properties, possess identical ITS1 sequences (Ellis et 
al., 2000). When comparing B. besnoiti and B. caprae, we can found significant 
ultrastructural differences (Njenga, Bwangamoi, Kangethe, Mugera & Mutiga, 1995) and 
differences in host susceptibility: B. besnoiti is infectious for rabbits, mice, guinea pigs, 
hamsters, rats, sheep and cattle but B. caprae is not (Ng'ang'a & Kasigazi, 1994; Njenga, 
Bwangamoi, Mutiga, Kangethe & Mugera, 1993). Similarly, we can find differences in the 
ultrastructure and host susceptibility between B. besnoiti and B. tarandi (Dubey, Shkap, 
Pipano, Fish & Fritz, 2003a; Dubey et al., 2004), and between B. besnoiti and B. bennetti 
(Bigalke, 1970; Dubey et al., 2005; Pols, 1960). In this way, what we can presently sustain is 
that either B. caprae, B. tarandi and B. bennetti are different species with the same ITS1 
sequence than B. besnoiti or that they represent distinct populations/strains of B. besnoiti. 
Clearly, additional information is required to resolve this controversy. 
1.1.1.3 Morphological features 
The rapidly dividing B. besnoiti tachyzoites represent the parasite proliferative stage 
responsible for the acute phase of the disease. With the onset of the host immune response 
and the presence of other physiological factors, tachyzoites differentiate into the slowly 
replicating encysted bradyzoites and a persistent tissue cyst infection is established along 
with the chronic phase of the disease (Alvarez-Garcia, Garcia-Lunar, Gutierrez-Exposito, 





Jacquiet, Lienard & Franc, 2010; Lyons, McLeod & Roberts, 2002). Tachyzoites and tissue 
cysts (containing bradyzoites) are the two tissue stages of B. besnoiti (and other Besnoitia 
species) found in intermediate hosts (Alvarez-Garcia et al., 2014b; Dubey et al., 2013). 
B. besnoiti tachyzoites are typically crescent-shaped with a slightly pointed anterior 
compared with the rounded posterior end (Langenmayer et al., 2015; Shkap, Yakobson & 
Pipano, 1988), measuring about 6-7.5 x 2.5-3.9 μm in cell culture (Reis et al., 2006). Similar 
to T. gondii and N. caninum, these tachyzoites can invade a wide range of host cells in vitro, 
with an asexual multiplication by endodyogeny (Cortes et al., 2014; Göbel, Widauer, 
Reimann & Munz, 1985), that takes place in the parasitophorus vacuole, a cytoplasmic 
compartment formed upon entry of the parasite into the host cell. By light microscopy 
tachyzoites of B. besnoiti, N. caninum or T. gondii cannot be distinguished. In vitro replication 
rates depend largely on the cell line used, going from 0.14 (on Vero cells) to 20 (on BHK21 
cells) tachyzoites per hour per tachyzoite inoculated (Schares et al., 2009). Bradyzoites 
however, show a replication rate more than 100 times slower than that of cell cultures 
inoculated with tachyzoites (Schares et al., 2009). Morphologically they are very similar to 
tachyzoites, but reported measures fluctuate accordingly the author (Dubey et al., 2003a; 
Pols, 1960; Rostaher, Mueller, Majzoub, Schares & Gollnick, 2010; Sannusi, 1991), differing 
from 4.6 x 1.8 μm (Cortes et al., 2003) to 7-9 x 2.0 μm (Mehlhorn et al., 2009).  
As with other apicomplexans, B. besnoiti bradyzoites persist for extended periods of time 
in the chronically infected animal, harbored in cysts in long living tissues, mainly the skin and 
aponevrosis (Cortes et al., 2014; Walker et al., 2014). The typical morphology of B. besnoiti 
tissue cysts is a strikingly large host cell containing a parasitophorous vacuole (PV) with 
large numbers of bradyzoites surrounded by a thick wall. They can grow up to 0.6 mm 
diameter (Pols, 1960) and are morphologically unusual because the host cell nuclei is 
incorporated inside the cyst and is hypertrophied (Dubey & Lindsay, 2003; Dubey et al., 
2003b; Dubey et al., 2003c; Dubey et al., 2013; Dubey & Yabsley, 2010; Ernst, Chobotar, 
Oaksec & Hammond, 1968; Paperna & Lainson, 2001; Wobeser, 1976). This originates the 
characteristic double layer cyst-wall, that clearly distinguishes B. besnoiti cysts from its 
related apicomplexans (Cortes et al., 2014). Accurate morphological description of Besnoitia 
cysts is complicated by observed variation in cysts size and the thickness of the cyst wall, 
features that depend largely on the host affinity (natural or experimental host), tissue affinity 
and duration of infection (Dubey et al., 2003a). For B. besnoiti, although the existence of 
several studies that describe the cysts structure in naturally infected cattle, the nomenclature 
regarding the composition of the cysts varies significantly between authors. For example, 
Dubey et al. (2003a) and Cortes et al. (2006c) describe the cyst structures in a similar way 
(from in to out): intracellular cyst wall delineated by the parasitophorous vacuole membrane, 





primary cyst wall and a secondary cyst wall; Later, Dubey et al. (2013) described B. besnoiti 
tissue cysts has having 3 layers or compartments: the outer layer with connective-like tissue, 
the middle layer incorporating host nuclei, and the cyst proper containing the bradyzoites. 
Recently, Langenmayer et al. (2014), in a study that followed cyst development on cattle 
through an 84-day trial post natural infection, proposed a new nomenclature for describing B. 
besnoiti tissue cysts: 1) structures within the host cell should be called by their respective 
name (bradyzoites, parasitophorous vacuole, membrane of the parasitophorous vacuole, 
host cell cytoplasm, nuclei, host cell membrane, etc.). 2) For the outermost acellular layer, 
they proposed the term outer cyst wall (OCW). The OCW is composed of interwoven 
collagenous material, is about 10-12 μm in thickness (Cortes et al., 2006c; Dubey et al., 
2003a) and seems to be the result of the host physiological response (Cortes et al., 2014). 3) 
For the cyst wall of undeveloped cysts, which in developed cysts lies between the OCW and 
the membrane of the host cell, they proposed the name of inner cyst wall (ICW). This is a 
thick layer of up to 1 μm, also acellular, consisting of proteoglycan particles and fine 
filaments. Both OCW and the ICW seem to be the result of the host physiological response 
(Cortes et al., 2014). 4) The whole hypertrophied host cell, including the ICW and, if present, 
the OCW, is called a tissue cyst. 
The parasitophorous vacuole is limited by a single cell membrane, frequently lined on the 
luminal side by a granular layer of approximately 0.2 μm thick (Dubey et al., 2003a; 
Langenmayer et al., 2015; Mehlhorn et al., 2009). No septation exists inside Besnoitia cysts 
as it is characteristic for Sarcocystis species (Mehlhorn et al., 2009). The host cell cytoplasm 
usually contains multiple large nuclei with occasional invaginations of the nuclear membrane. 
The organelles consisted mostly of dilated tubules of the ER, normal or swollen mitochondria 
and lysosomes. They are arranged in a circular manner around the PV, which occupies most 
of the host cell cytoplasm (Langenmayer et al., 2015; Mehlhorn et al., 2009). 
1.1.1.4 Bradyzoite and tachyzoites ultrastructure features 
The phylum Apicomplexa consists of intracellular parasites that have a characteristically 
polarized cell structure and a complex cytoskeletal and organellar arrangement at their apical 
end (Black & Boothroyd, 2000). Because the Apicomplexa are obligate intracellular 
parasites, survival depends on their ability to invade host cells (evading the host humoral 
immune response), avoid degradation by the host cell machinery (by blocking/modulating 
fusion of the vacuole with lysosomes, blocking vacuolar acidification and delaying premature 
cell death until parasite development is complete), and propagate intracellularly (recruiting 
cell resources and optimizing nutrient acquisition) (Binder & Kim, 2004; Nyalwidhe, Maier & 





a complex assemblage of unique structural and secretory elements at the apical end of the 
parasite invasive life-cycle stages, named apical complex, that is intimately associated with 
these functions. (Binder & Kim, 2004; Katris et al., 2014; Kreier & Baker, 1987; Tenter et al., 
2002).  
The apical complex plays a key role in the mechanism of parasite motility, adhesion, 
invasion and formation of the parasitophorous vacuole, by providing both a semi-rigid 
framework to the parasite cell and a focal point for secretory organelles that release 
numerous invasion factors that mediate these functions. The apical complex is organized 
around an apical polar ring that serves as a microtubule organizing center that nucleates an 
array of subpellicular microtubules that descend toward the posterior of the cell (Katris et al., 
2014; Morrissette & Sibley, 2002). These microtubules subtend flattened membrane sacs, or 
alveoli, that line most of the plasma membrane. A fibrous proteinaceous membrane skeleton 
supports the alveolar sacs against the microtubules. The alveoli and the proteinaceous 
skeleton form a structure called the inner membrane complex (IMC), which, together with the 
subpellicular microtubules, provides the shape and stability of the cell (Black & Boothroyd, 
2000; Katris et al., 2014; Morrissette & Sibley, 2002). The plasma membrane is closely 
apposed over the IMC, forming together a structure called pellicle (Morrissette & Sibley, 
2002). The apical polar ring marks the apical extremity of the IMC. A mobile conoid, 
consisting of tightly bent tubulin filaments fused to form a tapered hollow barrel, sits within 
the apical polar ring (Katris et al., 2014). The conoid can either be recessed in the cell, so 
that its tip is even with the apical polar ring, or, during invasion, be extruded from the apical 
polar ring to form an extended point to the cell. At the tip of the conoid are two preconoidal 
rings, and a pair of short microtubules sit eccentrically within the conoid. These preconoidal 
rings and interconoidal microtubules move together with the conoid during extrusion. The 
structural elements of the apical complex provide orientation to the cell, and the focal point 
for arrays of secretory organelles, micronemes and rhoptries and dense granules, that are 
organized towards the base of the conoid in readiness for a staged sequence of release 
(Katris et al., 2014). The electron-opaque dense granules are evenly distributed throughout 
the parasite cytoplasm, while the large club-shaped rhoptries and the small rod shaped 
micronemes are strictly confined to the anterior third of the cell (Carruthers, 1999). Several 
studies in other apicomplexans, especially T. gondii, have shown that microneme contents 
are secreted first, prior to invasion, and coat the parasite with proteins that facilitate host cell 
adhesion, gliding motility, and contribute to formation of an annular moving junction with the 
host plasma membrane through which the parasite enters the cell. During invasion rhoptries 
secrete further elements of the moving junction, as well as proteins that establish the 
properties of the parasitophorous vacuole in which the parasite will reside intracellularly 





be thought of as a “ring of contact” between the invading tachyzoite and the host cell 
membrane and is used by the parasite to forcibly enter the host cell. Once the parasite is 
completely inside the host cell, the moving junction disappears as the parasitophorous 
vacuole is sealed (Dubremetz, 2007; Walker et al., 2014). Finally, as the complete 
parasitophorous vacuole is detaching from the plasma membrane, dense granules penetrate 
the IMC within the apical region and liberate their content, by exocytosis, to the vacuole. 
Dense granule secretion coincides with the formation of a network of membrane tubules in 
the vacuole (named vacuolar network) and continues during the intracellular residence of the 






Figure 4. Schematic representation of host cell invasion. 
There is a sequential exocytosis of micronemes (green), rhoptries (red) and 
dense granules (blue) from different cellular locations. ER, host endoplasmic 
reticulum; Mi, host cell mitochondria; MJ, Moving junction PM, host cell 
plasma membrane; VM, vacuole membrane; VN, vacuole network; VP, 






The elements of the apical complex are highly conserved throughout Apicomplexa (Katris 
et al., 2014), as it is the presence of the apicoplast, a plastid without photosynthetic ability 
(Arisue & Hashimoto, 2015). There are however some variations within the taxon and some 
species lack one or other feature of the apical complex (conoid in piroplasms, for example) or 
even lack the apicoplast (e.g. cryptosporidea) (Adl et al., 2012). B. besnoiti, being a 
coccidian, features the complete apical complex and the apicoplast and its ultrastructure is 
schematically presented in Figure 5. Here we can see the previously described elements, as 
well as other organelles and structures, including the nucleus, endoplasmic reticulum, Golgi 
complex, mitochondria, micropore, amylopectin granules and inclusion bodies (Dubey et al., 
2013; Langenmayer et al., 2015; Shkap et al., 1988), similar to what is described for T. gondii 
(Dubey, Lindsay & Speer, 1998). The nucleus is usually situated in the middle or posterior 
third of the parasite (Langenmayer et al., 2015). In B. besnoiti zoites twenty two subpellicular 
microtubules radiate from the polar ring and extend far more than the 2/3 of the parasite 
length, sometimes reaching 4/5 of the cell body (Reis et al., 2006), as was defined for B. 
jellisoni (D'Haese, Mehlhorn & Peters, 1977). 
  
Figure 5. Schematic representation of the ultrastructure of Besnoitia besnoiti. 







First reported cases of bovine besnoitiosis occurred more than a century ago in Europe, 
first in France (Besnoit & Robin, 1912; Cadéac, 1884) and after in Portugal (Franco & 
Borges, 1915, 1916). For years, besnoitiosis was considered an endemic sub-Saharan 
disease, because of the succeeding cases reported here and the lack of new cases reported 
in Europe. In Africa, the occurrence of bovine besnoitiosis was first discovered in 1945, by 
the South African state veterinary Christian Hofmeyr (Hofmeyr, 1945), with several other 
cases reported both in South Africa (Pols, 1960) and other countries, like Swaziland, 
Botswana, Namibia, Zimbabwe, Angola, Congo, Kenya, Tanzania, Uganda, Sudan, 
Cameroon and Nigeria (EFSA, 2010). In Asia the disease was reported in Israel (Goldman & 
Pipano, 1983; Neuman, 1972; Shkap, Reske, Pipano, Fish & Baszler, 2002; Shkap, Pipano 
& Greenblatt, 1987b), South Korea (Lee, Bak, Moon & Shin, 1970) and Russia (Krasov, 
Omarov Zh, Uvaliev & Khvan, 1975; Peteshev et al., 1974).  
Bovine besnoitiosis remained silent in Europe until the last decade of the twentieth 
century, when new cases were described in northern Spain (Juste et al., 1990) and in 
Alentejo (Malta & Silva, 1991). But was until the beginnings of the twenty first century that the 
disease started to be a concern, having spread from southern France over western and 
central France (Alzieu, Dorchies, Schelcher & Gottstein, 2007; Bourdeau et al., 2004) and 
propagated within Portugal (Cortes et al., 2006c; Cortes et al., 2003; Cortes et al., 2005) and 
Spain (Castillo, Marcén, Ortega-Mora & Álvarez-García, 2009; Fernandez-Garcia et al., 
2010; Fernandez-Garcia et al., 2009a; Fernandez-Garcia et al., 2009b; Irigoien et al., 2000). 
B. besnoiti is considered endemic in large areas in Spain, Portugal and France, and recently 
this status was also proposed for Italy (Gazzonis et al., 2014; Gentile et al., 2012a). Isolated 
outbreaks, described as resulting from the introduction of infected cattle from endemic areas, 
have been reported in Germany (Mehlhorn et al., 2009), Switzerland (Basso et al., 2013; 
Lesser et al., 2012), Italy (Agosti et al., 1994; Gentile et al., 2012b; Gollnick, Gentile & 
Schares, 2010; Mangili et al., 2012; Manuali et al., 2011; Mutinelli et al., 2011), Greece 
(Papadopoulos et al., 2014), Hungary (Hornok, Fedak, Baska, Hofmann-Lehmann & Basso, 
2014), Croatia (Beck, Štoković & Pleadin, 2013) and Ireland (Ryan et al., 2016). The growing 
numbers of animals affected and the geographic expansion lead the European Food Safety 
Authority (EFSA) to consider bovine besnoitiosis as an emerging disease in Europe (EFSA, 
2010). 
There are still many aspects of the epidemiology of bovine besnoitiosis that are poorly 
understood, including prevalence and incidence data in endemic areas, routes of 
transmission and risk-factors associated to infection and disease. The complete life cycle of 





of infected tissues, has not been identified yet, despite several studies with that purpose 
(Basso et al., 2011; Diesing et al., 1988; Millan et al., 2012). Hitherto, the only experimentally 
confirmed modes of transmission among cattle are mechanically, either through 
hematophagous insects, or iatrogenically through hypodermic needles (Bigalke, 1968; Pols, 
1960). However, until now, no natural transmission of Besnoitia species has been proven 
and it is very likely that livestock trade of infected animals serves as a very important vehicle 
for long distance horizontal transmission of B. besnoiti (Frey et al., 2013; Olias et al., 2011), 
as it is discussed for recent outbreaks in France, Germany, Italy, Switzerland and Hungary 
(Agosti et al., 1994; Basso et al., 2013; Hornok et al., 2014; Mehlhorn et al., 2009; Mutinelli et 
al., 2011). After long-distance transport of single infected animals, the parasite might find 
adequate conditions to be transmitted locally to contact cattle, presumably by insect vectors 
and/or by direct contact between animals (Bigalke, 1968). Bigalke (1968), experimentally 
infected cattle orally with tachyzoites (bradyzoites were non-infective) and through the naso-
pharyngeal route, with the inoculation of bradyzoites in the nostrils, but in nature, a feasible 
mechanism for the release of viable parasites (in infective quantities) from a chronically 
infected animal would have to be found. Skin cysts that might occasionally be exposed by 
trauma or spontaneously rupture to the surface are most unlikely to form a sufficiently 
reliable source of infection (Bigalke, 1968). The same should hold true when considering the 
venereal transmission of B. besnoiti, even though it has been suggested as possible (Frey et 
al., 2013; Gentile et al., 2012a; Gollnick, Scharr, Schares & Langenmayer, 2015). 
Consequently, the epidemiological significance of these modes of transmission is still 
unknown and further investigation is required. Moreover, it is not known if there are 
differences in the host specificity among B. besnoiti isolates from different parts of the world, 
or if other intermediate hosts than bovids are involved in the epidemiology of bovine 
besnoitiosis (Basso et al., 2011). In Europe, B. besnoiti natural infections were only 
confirmed in cattle, but in South Africa it was also described in wild ungulates (kudu 
(Tragelus strepsiceros), blue wildebeest (Connochaetes taurinus) and an impala (Aepyceros 
melanpus) (McCully, Basson, Van Niekerk & Bigalke, 1966). For this reason, and also 
because it can experimentally infect small mammals, the EFSA (2010) stated that wild 
ruminants and rodents should not be disregarded as reservoirs of the parasite. A serological 
survey in wild ungulates in Spain detected specific antibodies against Besnoitia spp. in a red 
deer (Cervus elaphus) and a roe deer (Capreolus capreolus) from the endemic region of the 
Pyrenees, suggesting a link between the sylvatic and domestic life cycles of Besnoitia spp. 
similar to what is observed in the lifecycles of other closely related apicomplexan parasites 
(Gutierrez-Exposito et al., 2013). In the same way, the relationship between B. besnoiti and 
other Besnoitia spp. isolated from ungulates (B. tarandi and B. caprae) should be 





Moreover, a sylvatic cycle involving birds as intermediate hosts should be considered, since 
some endemic regions of besnoitiosis (e.g., Pyrenees, southern Portugal, Israel, South 
Africa, Nigeria, Kenya) correspond to important staging spots and funnels of migratory birds 
in the African Eurasian flyway. Whether birds can become infected by Besnoitia species as 
final or intermediate hosts and play a role as long distance vectors similar to T. gondii 
remains to be shown and warrants further investigation (Olias et al., 2011) 
In endemic areas, infection is widespread within cattle populations, but the proportion of 
infected cattle that develop the disease is low (Pols, 1960; Bigalke, 1968; Legrand, 2003; 
Bourdeau et al., 2004; Cortes et al., 2006b; Alzieu et al., 2007). The prevalence of clinical 
cases varies from 1 to 10% and the incidence between 2% and 5% (Jacquiet et al., 2010) 
Three clinical scenarios can be considered after the initial contamination of a herd with B. 
besnoiti: (1) a small proportion of animals with typical clinical signs; (2) a larger subset of 
seropositive individuals with sclero-conjunctival cysts; (3) the largest subset of asymptomatic, 
seropositive individuals (Jacquiet et al., 2010; Lienard et al., 2011). In areas where the 
disease is emerging, up to 20% of newly contaminated cattle show typical signs (Jacquiet et 
al., 2010). In endemic areas most clinical cases are reported in two to four-year old cattle, 
even though younger animals (from six months upwards) may present clinical signs (Alzieu 
et al., 2007; Jacquiet et al., 2010). It was found a positive correlation between the prevalence 
of the disease and the age of the animal (Ashmawy & Abu-Akkada, 2014; Fernandez-Garcia 
et al., 2010; Gutierrez-Exposito et al., 2014; Waap, Nunes, Cortes, Leitão & Vaz, 2014). All 
cattle breeds seem to be susceptible to besnoitiosis (Alvarez-Garcia et al., 2014b; EFSA, 
2010; Jacquiet et al., 2010; Lienard et al., 2011), and no gender predisposition was 
established (Alvarez-Garcia et al., 2014a; Goldman & Pipano, 1983; Gutierrez-Exposito et 
al., 2014; Waap et al., 2014), despite Jacquiet et al. (2010) has suggested that males are 
more susceptible than females, showing more acute clinical manifestations with a higher 
mortality rate. Bovine besnoitiosis occurs preferentially from spring to autumn with maximum 
clinical expression in summer (Ferrié, 1984; Legrand, 2003). This is coincident with the 
period of higher activity of hematophagous insects and some authors use this observation to 
rationalize the occurrence of mechanically transmission of B. besnoiti in nature (Alvarez-
Garcia et al., 2013; Alvarez-Garcia et al., 2014b; Cortes et al., 2014). While agreeing that it 
might play a role in the epidemics of besnoitiosis, one has to consider that infection might be 
constant throughout the year, and that it is the climatic/environmental factors, like higher UV 
exposition and higher temperatures for example, that determine the severity of clinical signs 
in this time of year (Bigalke, 1968). In a recent longitudinal study of besnoitiosis 
seroprevalence that combined entomological survey of hematophagous flies in an endemic 
area, no clear relationship between peaks of positive seroconversions or antibody levels and 





The first serological studies looking into the prevalence of B. besnoiti infection were done 
in Israel and South Africa and reported seroprevalences of around 50 to 60% for the first 
(Frank, Pipano & Rosenberg, 1977; Goldman & Pipano, 1983; Neuman, 1972) and around 
50% for the latter (Janitschke, De Vos & Bigalke, 1984). Recently in Egypt animal 
prevalences of 13.7% were found (Ashmawy & Abu-Akkada, 2014), while in Jordan values of 
6.0% individual animal prevalence and 26.7% herd prevalence were reported (Talafha, Al-
Majali, Ababneh & Abutarbush, 2015). In Europe, cross-sectional studies investigating the 
prevalence and incidence of the disease are still sparse. Recent studies in endemic regions 
of Spain, determined individual animal prevalences of 16% in Navarra (Alvarez-Garcia et al., 
2014a) and herd prevalences of 87.3%, with within-herd prevalences ranging from 15.1% to 
95.7%, with a mean of approximately 50 % in the province of Huesca, Aragon (Gutierrez-
Exposito et al., 2014). Similarly, another report from the Basilicata region of southern Italy 
(recently considered an endemic region) found a herd prevalence of 83.0% and an individual 
animal prevalence of 44.1% (Rinaldi et al., 2013). In Northern Greece, considered a non-
endemic region, a prevalence of 22% of infected animals was found (Papadopoulos et al., 
2014). In a wide survey in Portugal, covering the all continental country (i.e. extending far 
beyond the endemic region of Alentejo), Waap et al. (2014), determined a herd prevalence of 
5.1 % in Portugal, while the prevalence of seropositive animals within infected herds ranged 
from less than 10.3% up to 72.4 %, with a mean of 33.0%. The lower intra-herd values may 
be explained by the recent introduction of infection in the herd or, considering an older 
introduction of infection, by a slower transmission of disease in herds through unknown 
epidemiological constrains. The high within-herd prevalence could be the result of a more 
successful transmission cycle or a long-year cohabitation with infection. Nevertheless, after 
the initial herd infection with B. besnoiti, the individual animal prevalence can rise from initial 
values of around 30-40% up to 70-90% in a matter of few months (Cortes et al., 2006b; 
Fernandez-Garcia et al., 2010; Lienard et al., 2011). 
1.1.3 Clinical signs and pathogenesis 
Bovine besnoitiosis is clinically characterized has having an acute stage, that starts with 
an initial febrile syndrome and usually evolves to the characteristic generalized edema or 
anasarca, and a chronic stage, that is characterized by the formation of numerous tissue 
cysts containing bradyzoites, leading to the typical scleroderma (Alvarez-Garcia et al., 
2014b; Bigalke & Prozesky, 2004; Jacquiet et al., 2010; Lienard et al., 2011; Radostits, Gay, 
Hinchcliff & Constable, 2006). Jacquiet et al. (2010) and Pols (1960) refer an incubation 





days, depending on the method of parasite inoculation (Basson, McCully & Bigalke, 1970; 
Bigalke, 1968; Bigalke & Prozesky, 2004). The mean incubation period of the experimental 
mechanical transmission of B. besnoiti by hematophagous flies accomplished by Bigalke 
(1968), was 13 days. In a recent study about the chronology of disease progression in 
naturally infected cattle (Gollnick et al., 2015), the authors proposed the assignment of 
specific clinical features to differentiate bovine besnoitiosis stages. Animals in the acute 
stage had to show fever (body temperature > 39.0 °C) or at least two of the following clinical 
signs/diagnoses: depression, conjunctivitis, subcutaneous edema, lymphadenitis or 
lameness. Cattle were classified as chronically infected when first parasitic cysts were visible 
in the scleral conjunctivae or mucous membranes. The time period between the acute and 
chronic stage is referred to as subacute stage of disease.  
Hyperthermia is the first clinical sign and, as previously stated, marks the beginning of the 
acute phase. It may last for 3 to 10 days, can reach 42 °C (Alvarez-Garcia et al., 2014b; 
Jacquiet et al., 2010) and is accompanied by progressive inappetence, culminating in 
complete anorexia in severe cases, with consequent loss of weight, declining body condition 
and diminished milk production (Bigalke & Prozesky, 2004; Cortes et al., 2014). Affected 
animals are usually apathetic and prefer to lie down; they can show photophobia, serous 
nasal and ocular discharges, increased heart and respiratory rates, hyperemia of 
unpigmented skin and mucous membranes and swelling of superficial lymph nodes (Alvarez-
Garcia et al., 2014b; Cortes et al., 2014; Gollnick et al., 2015; Pols, 1960). In this phase, the 
fast proliferating tachyzoites start invading macrophages, fibroblasts and endothelial cells 
within blood vessels, causing necrotic vascular lesions, vasculitis, and thrombosis, specially 
of capillaries and small veins in the dermis, subcutis fascia, testicles and upper respiratory 
mucosa (Alvarez-Garcia et al., 2014b; Cortes et al., 2014). They multiply by endodyogeny in 
the host cell cytoplasm and the released tachyzoites disseminate trough the blood stream 
(Pols, 1960) to infect new cells and repeat the parasite lytic cycle. Proliferative organisms 
may be detected in blood from the 3rd up to 12th day after the beginning of the febrile reaction 
(Basson et al., 1970; Bigalke, 1968; Pols, 1960). These cumulative lesions, together with a 
possible toxic effect of the parasite, cause an increased vascular permeability, resulting in 
edema and sometimes small hemorrhages and foci of necrosis in the afore-mentioned sites 
(Bigalke & Prozesky, 2004). The evolving anasarca may vary from a slight swelling of the 
face and thickening of the skin fold of the neck, back or chest regions, to a generalized 
subcutaneous edema covering the entire body. The anasarca often goes unnoticed and its 
presence is only revealed when fluid accumulates along the ventral part of the body, such as 
brisket, sternum, legs, udder, prepuce and scrotum. Animals may recover by the third week 
of the reaction, with the disappearance of the mentioned signs, or progress sequentially to 





movements that may lead to permanent posterior lameness. In severe cases, edemas in 
alveolar and interstitial tissues in the lungs may also cause severe respiratory disorders and 
be accompanied by pneumonitis and emphysema (Alvarez-Garcia et al., 2014b). In males, 
an acute orchitis develops, with painful testes and transient or definitive infertility (Cortes et 
al., 2005; Dubey et al., 2013). In pregnant animals, this pathophysiological condition can lead 
to abortion (Alvarez-Garcia et al., 2014b; Cortes et al., 2014). Death may occur sometimes in 
the acute stage, usually by secondary complications like pneumonia or septicemia (Bigalke & 
Prozesky, 2004; Pols, 1960). In that matter, Dubey et al. (2013), reported the death of a bull 
in the acute stage of the disease due to a protein-losing nephrotic syndrome and posed the 
question of the role of protein-losing glomerulophaty in the pathogenesis of acute 
besnoitiosis anasarca.  
The subsequent chronic stage is characterized by the formation of myriads of tissue cysts 
containing the slow replicating bradyzoites. These cyst can grow up to 0.6 mm (Pols, 1960) 
and are formed in the same tissues where the initial proliferation occurred, namely dermis, 
subcutis, upper respiratory tract, scleral conjunctiva, vestibulum vaginae and vagina, testis, 
connective tissues, muscles and sometimes spleen, liver, lung and heart (Basson et al., 
1970; Olias et al., 2011). Recently, Frey et al. (2013) assessed the intra-organ parasite 
distribution in naturally infected cattle, in a subclinical stage (i.e., seropositive animals, that 
were clinically symptomatic in the acute stage, that had visible tissue cysts in the past that 
cleared by the time of slaughter and did not show evident chronic clinical signs). They 
showed that, in the six cows studied, the most frequent cyst locations were the upper 
respiratory tract (rhinarium, larynx/pharynx), followed by the distal genital tract (vulva/vagina) 
and the skin of the neck. Cyst formation occurs almost synchronously throughout different 
tissues (Bigalke, 1968) with the first ones being noticed in skin biopsies around the second 
week after the beginning of the acute stage (Dubey et al., 2013). At 4 to 5 weeks post-
infection, tissue cysts measuring more than 100 μm can be found, and cyst development 
apparently reaches completion at 10 weeks post-infection (Basson et al., 1970). The small 
cysts visible by the naked eye in the scleral conjunctiva, vulvar region and nasal mucous 
tissues may be detected upon close visual inspection as early as 8 weeks post-infection 
(Alvarez-Garcia et al., 2014b; Cortes et al., 2014). The multifocal whitish pinpoint tissue cysts 
in the scleral conjunctiva are considered pathognomonic, representing a feature with 
considerable value in clinical diagnosis (Jacquiet et al., 2010; Rostaher et al., 2010; Sannusi, 
1991). It is not certain if new tissue cysts are formed during the chronic stage and how long 
the cysts persist in cattle (Bigalke and Prozesky, 2004), but it is accepted that they last for 
years, probably the all lifespan of the animal (Cortes et al., 2014) Although some tissue cysts 
do degenerate and cause inflammation, there is no evidence that besnoitiosis can be 





The skin lesions that arouse in the chronic stage may be explained by the presence of 
numerous tissue cysts in the dermal and stratum papillare, accompanied by a granulomatous 
reaction and fibrosis surrounding the cysts. These events, together with vascular lesions that 
interfere with the skin blood supply, are responsible for alopecia (Bigalke, 1968). The most 
characteristic clinical sign is the scleroderma, with the progressive thickening, hardening and 
prominent folding and wrinkling of the skin, which may be widespread or more localized. 
Progressive alopecia, accompanied by dermatitis, and hyperkeratosis, hyperpigmentation 
and dermatitis crustosa also occurs (Bigalke & Prozesky, 2004; Cortes et al., 2014; Pols, 
1960). Deep, raw fissures sometimes develop between folds of the skin in sites such as leg 
joints and bonny prominences. The superficial lymph nodes are swollen and usually a low-
grade intermittent fever is present, causing further anorexia and weight loss (Bigalke & 
Prozesky, 2004). 
In the male reproductive tract, the presence of tissue cysts in different locations may lead 
to permanent sterility. Dubey et al. (2013), reported a diffuse interstitial lymphoplasmocytic 
orchitis with an absence of spermatogenesis and the presence of cysts in the epididymis, in 
the testicles (scattered between the seminiferous tubules), and in bigger amounts in the 
pampiniform plexus. Back in 1981, a study with severely and chronically affected bulls in 
Nigeria reported severe orchitis in 64% of the animals (Kumi-Diaka, Wilson, Sanusi, Njoku & 
Osori, 1981). The authors found: several cysts of varying sizes in the scrotum displacing 
normal tissues; the tunicas (dartos, vaginalis and albuginea) were infiltrated by besnoitia 
cysts, fibrosis and some inflammatory cells; also, numerous cysts of varying sizes were 
observed in the testes and epididymis (interstitial tissues and seminiferous tubules) with 
accompanying inflammatory cellular infiltration of the interstitium; the testes and the testicular 
germinal epithelium were displaced and degenerated in many cases, with partial or complete 
arrest of spermatogenic activity. Cortes et al. (2005) also described severe anatomic and 
histological alteration on the teste of a chronically infected bull. The severity of lesions 
observed in testes and the consequent oligospermia/aspermia are the result of a 
combination of events: (1) reduced blood supply to the testes as the result of the 
development of cysts in the pampiniform plexus; (2) displacement and direct pressure on the 
germinal epithelial cells originated by the Besnoitia cysts that develop in the interstitial 
spaces and under the epithelial cells of the seminiferous tubules; this interferes with normal 
spermatogenesis and causes atrophy and necrosis of epididymal and/or testicular tissues; 
(3) poor heat exchange through the thickened acanthotic scrotum or partially devitalized 
scrotum (Alvarez-Garcia et al., 2014b; Kumi-Diaka et al., 1981). 
Concerning the female reproductive tract, despite cysts have been found in the genital 
tract (Basso et al., 2013; Frey et al., 2013; Nobel et al., 1981), it is assumed that they do not 





become pregnant and successfully give birth to healthy calves that develop normally (Shkap, 
Pipano, Marcus & Krigel, 1994). 
Death may also occur in the chronic stage of the disease regardless of the gender, and 
animals may be culled due to poor body condition (Pols, 1960). Some affected animals, 
however, seem to recover from these clinical manifestations, at least partially (Jacquiet et al., 
2010), but they retain the large number of cysts (Cortes et al., 2014). 
1.1.4 Diagnosis 
Diagnosis of bovine besnoitiosis can be easily made when the animal presents the typical 
skin lesions of the chronic phase by demonstrating the presence of the parasite. The 
characteristic tissue cysts, may be observed macroscopically and can be confirmed by direct 
tests such as microscopy smears (scleral conjunctival cysts scraping) to identify bradyzoites 
(Sannusi, 1991), by histological/histopathological examination of skin biopsies to identify the 
typical cysts (Bigalke, 1968; Dubey et al., 2013; Pols, 1960; Sannusi, 1991) or by molecular 
techniques (PCR) to demonstrate the parasite DNA in tissue samples (Cortes et al., 2007b; 
Schares et al., 2011b). However, typical clinical signs are not always present neither are 
skins cysts. At the acute, short lasting stage, clinical signs are very unspecific and can be 
easily confused with other diseases, such as blue tongue or malignant catarrhal fever (EFSA, 
2010; Jacquiet et al., 2010); there are no detectable parasite stages in tissues and anti-B. 
besnoiti antibodies will only be present around 2 weeks after the onset of clinical signs 
(Jacquiet et al., 2010; Schares et al., 2011b). Passing the acute stage, not all animal evolve 
to the typical chronic stage, but maintain a sub-clinical infection (Bigalke, 1968; Pols, 1960). 
These animals may play an important role in the epidemiology of the disease, as previously 
discussed, and represent the bigger challenge for diagnostic. For sub-clinically infected 
animals, histopathology is not suitable, and more sensitive methods such as PCR are 
required (Cortes et al., 2014). Nevertheless, sub-clinically infected animals with a low 
number of cysts in the skin may still not present B. besnoiti DNA in the sample and might be 
PCR negative (Schares et al., 2011b). Despite this limitation, PCR was shown to be 
appropriate for the diagnosis of bovine besnoitiosis in the acute stage of the disease, during 
which no anti-B. besnoiti antibodies are found yet (Cortes et al., 2014; Schares et al., 2013). 
Assessment of antibodies against B. besnoiti in sera of infected animals is an appropriate 
approach for the diagnosis of clinical and subclinical disease. A number of tests have been 
developed so far, including indirect fluorescence antibody test (IFAT) (Cortes et al., 2006a; 
Goldman & Pipano, 1983; Janitschke et al., 1984; Schares et al., 2010; Shkap et al., 2002), 





France; PrioCHECK® Besnoitia Ab, Prionics, Switzerland), in-house ELISAs (Cortes et al., 
2006a; Fernandez-Garcia et al., 2010; Janitschke et al., 1984; Shkap, Ungar-Waron, Pipano 
& Greenblatt, 1984), western blot (Cortes et al., 2006a; Fernandez-Garcia et al., 2009a; 
Schares et al., 2010) and modified agglutination test (MAT) (Waap et al., 2011). Although all 
tests available perform well during the chronic phase of the disease, they show low 
sensitivity during the acute stage, since detectable antibody levels have not yet developed. 
Additionally serological tests may yield a low percentage of chronically infected animals 
undiagnosed as a result of a low level of circulating antibodies and the possible presence of 
seronegative animals with tissue cysts (Fernandez-Garcia et al., 2010; Garcia-Lunar et al., 
2013a; Schares et al., 2010). Furthermore, specificity of this tests, especially ELISA, have 
been questioned when used routinely in diagnostics with field samples. Recently in Italy, 
Gazzonis et al. (2014), detected 712 animals (22.7%) with a positive reaction in ELISA, but 
only 10 of them (0.3%) were confirmed by WB, while in Australia, testing with the 
PrioCHECK® initially revealed 160 (18,4%) positive animals, with none being confirmed by 
immunoblot and IFAT (Nasir, Lanyon, Schares, Anderson & Reichel, 2012). 
The IFAT, when performed with the appropriate expertise, shows no cross-reaction with 
N. caninum or T. gondii antibodies. The cut-off dilution for Besnoitia IFAT ranges from 1/200 
to 1/256. Western blotting is clearly more expensive and time consuming compared with 
IFAT. It may show cross-reactions with related protozoans, especially N. caninum, but at a 
lower extent than ELISA and is usually recommended as a confirmation test in combination 
with other methods (Cortes et al., 2006a; Garcia-Lunar et al., 2013a; Millan et al., 2012; 
Schares et al., 2010; Schares et al., 2011a). The ELISA is more suitable for analyzing larger 
numbers of samples, but, for the serological diagnosis of individual cases at least one other 
confirmation test, IFAT or western blot, should be used (Garcia-Lunar et al., 2013a; Jacquiet 
et al., 2010). Recently, Schares et al. (2013) described an ELISA (using immune affinity 
chromatography purified B. besnoiti antigens), with 100% sensitivity for sera of chronically 
infected animals, and 99.8% specificity when tested with positive N. caninum sera. False 
positive results can thus be avoided and the time consuming and expensive confirmatory 
tests are no longer necessary, but the added usefulness of this test, compared to existing 
ones, still has to be proven with routine field samples. Nevertheless, the author was able to 
identify acute cases of bovine besnoitiosis by the detection of low avidity IgG in this ELISA. 
The direct agglutination test, based on the complex formation of formalin-treated parasites in 
the presence specific IgG antibodies, is also very suitable for the screening of large amounts 
of samples and is relatively inexpensive. It offers the major advantage of avoiding the use of 
secondary specie-specific antibodies, which turns this technique particularly attractive for 
epidemiological purposes, by allowing testing a large variety of species that may be 





1.1.5 Treatment, vaccines and control measures 
Presently there is no specific treatment for bovine besnoitiosis (Alvarez-Garcia et al., 
2013; Cortes et al., 2014; EFSA, 2010; Jacquiet et al., 2010). No suitable drug is available, 
despite the testing of several compounds in experimentally infected rabbits, gerbils and cattle 
(Pols, 1960; Shkap, De Waal & Potgieter, 1985; Shkap, Pipano & Ungar-Waron, 1987a). 
Affected animals should receive supportive therapy and be treated symptomatically (Bigalke 
& Prozesky, 2004; Radostits et al., 2006). 
A live vaccine against bovine besnoitiosis was developed in the Onderstepoort Veterinary 
Institute, South Africa (Bigalke, Basson, McCully, Bosman & Schoeman, 1974a; Bigalke, 
Schoeman & McCully, 1974b), and has been in use there since 1974. It is administered 
subcutaneously to weaners or older animals and each dose contains approximately 106 
organisms of a blue wildebeest strain of B. besnoiti grown in cell culture. A single dose was 
shown to protect cattle from the clinical form of the disease for observation periods of up to 4 
years, but did not entirely prevent subclinical infection from taking place. Annual re-
vaccination for 2 to 3 years is recommended (Bigalke, 1981). Israel also uses a live vaccine 
derived from attenuated cell cultured parasites (Pipano, 1997), but no information regarding 
its safety or efficacy is found in scientific literature. However, the use of any of these 
vaccines is geographically limited, because live attenuated vaccines pose a risk of 
introducing the parasite into uninfected herds and of inducing carriers among the vaccinated 
animals. This is of particular concern when, as in the case of B. besnoiti, the knowledge 
about the biology, transmission and life cycle of the parasite is scarce (Cortes et al., 2014). 
In this way, with the lack of treatment and effective vaccine, this Europe’s reemerging 
disease can only be battled, at least for now, with the implementation of sanitary control 
measures, summarized by Jacquiet et al. (2010). First, to prevent introduction of B. besnoiti 
to non-endemic areas, all purchased/imported cattle from endemic areas should be tested 
serologically before or at purchase and ideally, the analysis should be repeated after 3 to 4 
weeks to discard false negative results due to very recent infections (Basso et al., 2013). 
Second, in the case of an outbreak in a previously Besnoitia-free herd, infected animals 
should be separated from non-infected ones, and skin and stable insecticides and/or traps 
should be used to minimize the fly population around the herd (Mehlhorn et al., 2009); a 
rapid and systematic evaluation of individual infection status should be done in order to cull 
all seropositive animals as soon as possible. Third, in endemic areas, herds should adopt 
regular programs to control fly population (for example with regular application of pyrethroid 
insecticides) and also evaluate individual infection status to be able to systematically 
eliminate positive ones. With several years of systematic elimination of chronically infected 





campaign is necessary for veterinarians and for cattle breeders, especially in the regions of 
recent emergence. 
In this way, the gap of knowledge around B. besnoiti, not only in some fundamental 
aspects of its biology, but also in the possible means to address the disease it causes 
prompted us to focus our studies in this parasite. In particular, considering recent reports on 
other Apicomplexa that refer protein disulfide isomerase (PDI) as a potential target for drug 
or vaccine formulation, we concentrated our studies in this protein, hoping to understand its 
role in the biology of B. besnoiti and if it can be addressed for besnoitiosis therapy. 
1.2 Protein disulfide isomerase  
Protein disulfide isomerase (PDI) is a multifunctional protein that acts as a thiol–disulfide 
oxidoreductase, being able to catalyze disulfide bond formation, breakage and 
rearrangement in all non-native protein and peptide substrates reported to date, depending 
on the redox state of its cysteine containing active sites (Hatahet & Ruddock, 2009; Wang et 
al., 2015). Independently of its redox activity, PDI can also act as a chaperone, catalyzing the 
correct folding of newly synthesized or denatured proteins into their native conformations 
(Kozlov, Määttänen, Thomas & Gehring, 2010). The sulfhydryl (-SH) side group (thiol) of 
cysteine is unique among amino acids, because when two cysteines are within close 
proximity, a disulfide bond can form. Disulfide bond is a covalent linkage that requires the 
deprotonation of one cysteine thiol and donation of two electrons to an acceptor such as 
oxygen. Disulfide bond formation is oxidation, breaking of a disulfide bond is reduction, and 
rearrangement (simultaneous reduction and oxidation) of a bond within a protein is 
isomerization; these processes are dictated by the local redox conditions (Sevier & Kaiser, 
2002) (Figure 6). Disulfide bonds serve important functions during protein folding and in 
stabilizing protein structures (both intra or intermolecular) and have the capacity to work as 





The first description of PDI-like activity was simultaneously published by two independent 
groups in the early sixties of the twentieth century, one working with pigeon and chicken 
pancreatic extracts (Venetianer & Straub, 1963b) and the other with rat and bovine liver 
microssomes (Goldberger, Epstein & Anfinsen, 1963). It was the first folding catalyst to be 
reported half a century ago, back then in studies with the reactivation of reduced enzymes, 
mainly ribonuclease (RNase) and lysozyme (Givol, Goldberger & Anfinsen, 1964; Goldberger 
et al., 1963; Goldberger, Epstein & Anfinsen, 1964; Venetianer & Straub, 1963a, 1963b). PDI 
was first purified in 1966 from bovine liver microssomes, and described as “an enzyme which 
catalyzes sulfhydryl-disulfide interchange in proteins” (De Lorenzo, Goldberger, Steers, Givol 
& Anfinsen, 1966). It was given the enzyme classification number EC 5.3.4.1 in 1972, along 
with its subsequent officially accepted name – protein disulfide isomerase, a name that was 
mentioned for the first time in a publication of Hawkins and Freedman in 1975. However, 
Figure 6. Schematic representation of thiol–disulfide interchange reactions catalyzed by PDI. 
PDI-catalyzed disulfide formation occurs when oxidizing equivalents are transferred from the 
active site of oxidized PDI to reduced substrate, resulting in either a native disulfide (a) or a 
nonnative disulfide (b) in the substrate and reduced PDI. The mispaired disulfide can be 
isomerized by reduced PDI through direct intramolecular disulfide rearrangement (c). 
Alternatively, the nonnative disulfide can be converted to the native one via the pathway of 
reduction (d) and reoxidation (a). In some cases, the disulfide inactive substrate can be reduced 
by reduced PDI (e) to facilitate substrate unfolding. Note that in all the thiol–disulfide 
interchange reactions, a mixed disulfide is formed between the N-terminal cysteine in the PDI 
active site and a cysteine in the substrate. Only one catalytic domain of PDI is shown for 





despite the concurrent identification of other substrates of PDI in vitro, including soybean 
trypsin inhibitor (Steiner, De Lorenzo & Anfinsen, 1965), immunoglobulins (De Lorenzo et al., 
1966; Murkofsky & Lamm, 1979; Roth & Koshland, 1981), vasopressin and oxytocin 
(Varandani, Nafz & Chandler, 1975), insulin (Varandani & Nafz, 1970; Varandani et al., 
1975), bovine serum albumin (Teale & Benjamin, 1976), cholera toxin (Moss, Stanley, Morin 
& Dixon, 1980), bovine pancreatic trypsin inhibitor (Creighton, 1992), ricin (Barbieri, Battelli & 
Stirpe, 1982), and procollagen (Forster & Freedman, 1984; Wilson, Lees & Bulleid, 1998), 
the importance of this enzyme only started to be recognized about 20 years later, in the mid-
eighties, with the publication of the first highly cited review specifically on PDI (Freedman, 
1984) and the sequence of rat PDI (Edman, Ellis, Blacher, Roth & Rutter, 1985). In addition, 
the subcellular localization of PDI to the ER was confirmed (Lambert & Freedman, 1985) and 
its detailed action in catalyzing a specific folding pathway was defined (Creighton, Hillson & 
Freedman, 1980). However, the accurate identification of the domain boundaries took almost 
another 20 years. The domain structure of PDI has been determined by theoretical (Ferrari & 
Soling, 1999) and experimental (Alanen et al., 2003; Denisov et al., 2009; Dong, Wearsch, 
Peaper, Cresswell & Reinisch, 2009; Freedman et al., 1998; Kemmink, Darby, Dijkstra, 
Nilges & Creighton, 1997; Kemmink, Darby, Dijkstra, Scheek & Creighton, 1995; Kemmink, 
Darby, Dijkstra, Nilges & Creighton, 1996; Kemmink et al., 1999; Kozlov et al., 2006; Nguyen 
et al., 2008; Tian, Xiang, Noiva, Lennarz & Schindelin, 2006) procedures and it is now known 
to comprise four thioredoxin-like domains in the order of a, b, b’, and a’, with a C-terminal 
acidic extension c and an x-linker between domains b’ and a’ (Alanen et al., 2003; Hatahet & 
Ruddock, 2009; Pirneskoski et al., 2004; Wang et al., 2015) (Figure 7). The thioredoxin-like 
domains can be catalytic or noncatalytic and are identified as either a or b-type domains 
based on the presence or absence of a catalytic motif, with use of the prime symbol to 
indicate their position in the protein. The a-type domains functionally resemble thioredoxin 
and usually contain two cysteines in a CXXC tetrapeptide active-site motif with an 
intermediate GH sequence being the most common in the PDIs. The b-type domains, 
although structurally similar to thioredoxin, do not contain catalytically active cysteines and 
therefore are not redox active (Appenzeller-Herzog & Ellgaard, 2008; Kozlov et al., 2010). 
Instead, the b-type domains appear to act as spacers, and are likely responsible for 
substrate binding and specificity (Byrne et al., 2009; Denisov et al., 2009; Klappa, Ruddock, 
Darby & Freedman, 1998a; Pirneskoski et al., 2004). Generally, the sequence identity is 
much higher for catalytic a-type domains than for non-catalytic b-type domains since the 
latter are missing a number of residues important for catalysis that are conserved among the 










PDI is found in all multicellular organisms, including higher plants, and is expressed in 
yeast but not bacteria. Instead, bacteria have homologous Dsb proteins to facilitate oxidative 
protein folding and isomerization in the periplasmic space (Arts et al., 2013; Inaba, 2009). It 
is regarded that all eukaryotes possess a species-dependent PDI family of enzymes 
(Pirneskoski et al., 2004), that share a common structural feature of having at least one 
thioredoxin-like domain (Kozlov et al., 2010; Wang et al., 2015). For example, in 
Saccharomyces cerevisiae there are five PDI family members (Pdi1p, Mpd1p, Mpd2p, 
Eug1p, and Eps1p) (Xiao et al., 2004), while in humans more than 20 members have been 
characterized so far (Appenzeller-Herzog & Ellgaard, 2008; Benham, 2012; Kozlov et al., 
2010). It is the modular combinations of thioredoxin-like catalytic and noncatalytic domains 
that give rise to structural and functional differences of PDI family members (Benham, 2012). 
A thioredoxin-like domain has been loosely defined as anything with a predicted thioredoxin-
like structure. However, we could define it more specifically as a domain capable of reacting 
with cysteines. This definition appears to make the most sense, as members of the disulfide 
isomerase family should be capable of reacting with cysteine side chains. Nevertheless, the 
founding member of this family, PDI, also exhibits non-specific polypeptide-binding 
chaperone activity, and thus, a more inclusive definition of PDI family members would 
comprise proteins that contain non-thiol-reactive thioredoxin-like domains with chaperone-
like activities for ER folding and secretion of proteins (Kozlov et al., 2010).  
Thioredoxin is a small, ubiquitous protein of approximately 12 kDa involved in several 
cellular activities (Holmgren, 1985, 1989). In addition to being the founding member of the 
thioredoxin superfamily of proteins, the structure of thioredoxin forms the foundation of a 
protein fold known as the thioredoxin fold, that is found in a wide range of proteins including 
thioredoxin, DsbA, PDI, glutathione peroxidase, glutathione S-transferase, arsenate 
reductase, calsequestrin, and circadian oscillation regulator, many of which are involved in 
Figure 7. Domain organization of rat PDI.  
Domain boundaries are shown in brackets below each domain. Endoplasmic reticulum 
retention signal KDEL is identified as well as the active sites (CGHC) in the a-type 





thiol metabolism or use thiol-based chemistry (Hatahet & Ruddock, 2009). The thioredoxin 
fold is characterized by the following sequence of α-helices and β-strands: β1 – α1 – β2 – α2 
– β3 – β4 –α3. It forms a three-layer α – β – α structure with two α-helices packing onto one 
side of a four stranded β-sheet, of which strand three is antiparallel to the others, and with an 
additional α-helix packing onto the other side of the β-sheet (Ferrari & Soling, 1999; Hatahet 
& Ruddock, 2009). Nevertheless, although the thioredoxin fold is defined by these three α -
helices and four β-strands core, this is not the structure of thioredoxins, which have an 
additional β – α before the thioredoxin fold and thus a β0 – α0 – β1 – α1 – β2 – α2 – β3 – β4 
– α3 structure (Figure 8) (Forman-Kay, Clore, Wingfield & Gronenborn, 1991; Holmgren, 
Soderberg, Eklund & Branden, 1975; Katti, LeMaster & Eklund, 1990). 
Crystallization studies of full-length S. cerevisiae PDI provided the first direct evidence of 
the long suspected PDI flexibility, since in yeast PDI, crystals grown at different temperatures 
exhibits two opposite forms: (1) at 4 °C, the four thioredoxin domains are arranged in the 
shape of a twisted ‘‘U’’, with the active sites facing each other (a-type domains) across the 
long sides of the ‘‘U’’, the inside surface of the ‘‘U’’ (b-type domains) acts as a rigid base and 
is enriched in hydrophobic residues, that facilitate interactions with misfolded proteins (Tian 
et al., 2006); (2) at 22 °C, yeast PDI shows a “boat-shaped” form, as the result of the drastic 
rotation and translation of the a domain, preventing the two active sites from facing each 
other (Tian et al., 2008). This extended conformation was already previously suggested by 
Solovyov and Gilbert (2004) for the rat PDI. PDI must be a highly flexible enzyme in order to 
accommodate its structurally diverse substrates, of varied sizes and conformations (e.g. 
procollagen and insulin), in a way that permits the access of the active sites to the critical 
substrate thiols (Laurindo, Pescatore & Fernandes, 2012). An analysis of the inter-domain 
contacts in the two crystal structures suggests that PDI is a molecule with two flexible arms, 
represented by the a-type domains, that are connected to a relatively rigid base formed by 
the b-type domains module (Tian et al., 2008; Tian et al., 2006). Tian et al. (2008) showed 
that restricting the flexibility of the a domain results in a 60% decrease in enzymatic activity, 
whereas restricting the flexibility of the a’ domain results in only 24% reduction. They 
identified the junction between domains a and b as a major site of flexibility and suggested 
that the loops connecting the a and a’ domains to the b-b’ base enable the yeast PDI to 
facilitate these conformational changes. Nevertheless, a recent work about the plasticity of 
human PDI, indicated that, in contrast to the situation reported in yeast PDI, the C-terminal 
half (b’ and a’ domains and x-linker region) is more flexible than the N-terminal half (a and b 
domains) of the protein (Wang et al., 2010a). The x-linker region, allows the human PDI to 
partially swing into and out of the binding site on the b’ domain, originating capped and 
uncapped conformers of PDI, which respectively restrict or allow substrate accessibility and 





PDI is ubiquitously expressed in most tissues and cell types of mammals, especially in 
tissues active in the synthesis and secretion of disulfide-bonded proteins, namely liver and 
pancreas (Hillson, Lambert & Freedman, 1984). It is retained in the ER by a C-terminal ER 
retention signal, usually the KDEL sequence in mammalian cell or the HDEL sequence in S. 
cerevisiae, but other closely related sequences can occur (Alanen, Raykhel, Luukas, Salo & 
Ruddock, 2011; Pelham, 1990). In this way, PDI is primarily located in the ER lumen where 
its concentration can approach the millimolar range, although it has also been found in other 
intracellular compartments, such as mitochondria, nucleus, cytosol, and even at the cell 
surface and extracellular space (Noiva, 1999; Turano, Coppari, Altieri & Ferraro, 2002). 
There are increasingly evidences of the importance of chaperones and protein folding 
catalysts in cell signaling (Ellis, 2006; Henderson & Pockley, 2010; Lee, Park, Kang & Ahn, 
2009). Although it is unclear how PDI escapes the ER, the role of PDI in cell surface has 
been documented in several biological functions (Jordan & Gibbins, 2006; Turano et al., 
2002) such as platelet activation and aggregation (Essex, 2009; Essex & Li, 2003), thrombus 
formation (Cho, Furie, Coughlin & Furie, 2008; Jasuja, Furie & Furie, 2010; Popescu, Lupu & 
Figure 8. Schematic representation of the organization of the thioredoxin fold and PDI domains. 
(A) The thioredoxin fold incorporates an N-terminal βαβ motif, β1-α1-β2, that is connected to a C-
terminal ββα motif, β3-β4-α3, by a loop containing a third α-helix, α2. (B) Thioredoxin structure is 
represented by a thioredoxin-fold organization that includes an extra N-terminal βα motif, β0-α0 (gray); 
A a-type domain is represented here with the position of the active site motif CxxC indicated by the 
yellow sphere. α Helices are shown in green and  β sheets in orange. (adapted from Gruber, 






Lupu, 2010; Reinhardt et al., 2008), thyroid hormone synthesis (Delom, Mallet, Carayon & 
Lejeune, 2001), leukocytes adhesion (Bennett, Edwards, Sklar & Rogelj, 2000) and 
lymphocyte migration (Bi, Hong, Lee & Baum, 2011). In addition, PDI and PDI family 
members are directly and indirectly involved with the immune system function. Indirectly, 
because they are responsible by the ER quality control of proteins that are involved in 
immune defense, like the major histocompatibility complex (MHC) molecule (Kang, Park, Oh, 
Cho & Ahn, 2009; Kim et al., 2009; Lee et al., 2009; Peaper & Cresswell, 2008; Raghavan, 
Del Cid, Rizvi & Peters, 2008) or immunoglobulins (Ig) (Anelli et al., 2002; Anelli et al., 2007). 
Directly, since PDI has been ascribed a role in internalization of pathogens such as viruses, 
as was documented for the in vitro, cell cultured, infection of polyomavirus (Gilbert, Ou, Silver 
& Benjamin, 2006), Newcastle disease virus (Jain, McGinnes & Morrison, 2007, 2008, 2009), 
Dengue Virus (Diwaker, Mishra, Ganju & Singh, 2015) and HIV (Bi et al., 2011; Gallina et al., 
2002; Markovic et al., 2004; Ryser, Levy, Mandel & DiSciullo, 1994), or chlamydia, where 
native PDI on the cell surface was proven to be required for the effective attachment of this 
obligate intracellular bacterial pathogen of eukaryotic cells (Abromaitis & Stephens, 2009; 
Conant & Stephens, 2007; Davis, Raulston & Wyrick, 2002). Moreover, PDI family enzymes 
are emerging as important players in other processes that require changes in cell adhesion 
or migration, such as cancer (Benham, 2012). PDI has been implicated in the survival and 
progression of some cancer cells, such as malignant glioma (Goplen et al., 2006), breast 
cancer (Lee, Lim, Cheong, Singh & Gam, 2012), ovarian cancer (Xu et al., 2012; Zhao et al., 
2015) and prostate cancer (Welsh et al., 2001) by compensating for endoplasmic reticulum 
stress with the upregulation of the protein-folding capacity (Yu et al., 2014). It has been 
suggested as a potential drug target for chemotherapy in several tumors (Xu, Sankar & 
Neamati, 2014), including melanomas (Lovat et al., 2008), lung adenocarcinomas (Tufo et 
al., 2014) and breast cancer (Chen, Chang, Wu, Kung & Wu, 2015). 
Also, PDI family enzymes are being implicated in the pathogenesis of many 
neurodegenerative diseases that are collectively classified as protein misfolding disorders 
(PMDs), including Parkinson’s and Alzheimer’s disease, Huntington’s disease, prion related 
disorders and amyotrophic lateral sclerosis (Andreu, Woehlbier, Torres & Hetz, 2012; 
Benham, 2012; Conway & Harris, 2015). PMDs are diseases where at least one protein or 
peptide has been shown to misfold, aggregate, and accumulate in tissues where the 
disease-specific damage occurs (Mukherjee, Morales-Scheihing, Butler & Soto, 2015; Soto, 
2003), and, besides the neurodegenerative disorders, include other systemic ones such as 
the highly prevalent type II diabetes (Mukherjee et al., 2015). These diseases are generally 
related with aging and a progressive decline and failure of cellular protein folding and quality 
control systems (Andreu et al., 2012; Cuanalo-Contreras, Mukherjee & Soto, 2013). 





interfere with cell function, result in inherent cytotoxicity and may originate tissue 
inflammation (Soto, 2003; Wilkinson & Gilbert, 2004). 
1.2.1 Protein disulfide isomerase in apicomplexan parasites 
Although much as been learned about PDIs in higher eukaryotes, limited information is 
available regarding PDIs in protozoa parasites. Nevertheless, growing interest in this family 
of proteins has led to significant advances recently. Hitherto, several PDIs and PDI-like 
enzymes were identified in protozoan parasites, specifically in N. caninum (Lee et al., 2003; 
Liao et al., 2006; Liao et al., 2005; Naguleswaran et al., 2005), T. gondii (Meek, Back, 
Klaren, Speijer & Peek, 2002a; Meek, Back, Klaren, Speijer & Peek, 2002b), P. falciparum 
(Florenta et al., 2000; Mahajan et al., 2006; Mouray et al., 2007), P. chabaudi (Novo, Martins, 
Prata, Lopes & Armada, 2009), P. vivax, P. knowlesi and P. berghei (Mahajan et al., 2006), 
P. yoelli (Carlton et al., 2002), L. donovani (Padilla et al., 2003), L. major (Achour, Chenik, 
Louzir & Dellagi, 2002), L. amazonensis (Hong & Soong, 2008), Theileria parva (Ebel, 
Bender, Bocskor, Binder & Lipp, 2002), Cryptosporidium parvum (Blunt, Montelone, Upton & 
Khramtsov, 1996), Eimeria tenella (Han et al., 2014), Giardia lamblia (Gillin et al., 1990; 
Knodler et al., 1999), Trypanosoma brucei (Rubotham, Woods, Garcia-Salcedo, Pays & 
Nolan, 2005) and Babesia caballi (Ikadai et al., 2005). The functional importance of PDI 
should be the same for these parasites as previously described for other eukaryotes, as well 
as the primary ER localization. Nevertheless, it was shown that PDI is also present at the 
surface of N. caninum (Naguleswaran et al., 2005), T. gondii (Meek et al., 2002a), P. 
falciparum (Florenta et al., 2000), L. donovani (Padilla et al., 2003) and T. parva (Ebel et al., 
2002) and that it is present in the excretory-secretory compartment of N. caninum (Liao et al., 
2006), T. gondii (Zhou et al., 2005) and P. berghei (Lal et al., 2009). In apicomplexans the 
secretory products have been implicated in parasite host cell entry, intracellular survival, and 
interaction with the host (Carruthers, 1999, 2002; Zhou et al., 2005) and several studies 
demonstrate that inhibition of PDI has a negative correlation with parasite in vitro 
proliferation. This was shown for N. caninum by Naguleswaran et al. (2005) and Liao et al. 
(2006), as the preincubation of N. caninum tachyzoites with PDI inhibitors (5,5’-dithiobis(2-
nitrobenzoic acid) (DTNB), p-chloromercuribenzoic acid (pCMBA), tocinoic acid and 
bacitracin) and anti-PDI antibodies resulted in decreased adhesion of tachyzoites to the host 
cell, with consequence inhibitory effect on the growth of the parasite. In L. amazonensis 
promastigotes, incubation of parasites with bacitracin and pCMBA lead to a decreased 
number of viable parasites, where pCMBA concentrations above 0.5 mM were able to kill all 





L. major (Achour et al., 2002). Also, the action of the broad spectrum anti-parasitic (and anti-
viral) drug nitazoxanide (NTZ), and some derivatives lacking the nitro group, was linked to 
PDI inhibition, since affinity chromatography with thiazolide-coupled-resin binds N. caninum 
PDI and these compounds also inhibited the enzymatic activity of recombinant N. caninum 
PDI (Muller, Naguleswaran, Muller & Hemphill, 2008). NTZ and some non-nitro-thiazolides 
compounds efficiently inhibit the in vitro propagation of N. caninum (Esposito et al., 2005), B. 
besnoiti (Cortes et al., 2007a), T. gondii (Galvan-Ramirez Mde et al., 2013), G. lamblia 
(Adagu, Nolder, Warhurst & Rossignol, 2002; Muller, Ruhle, Muller, Rossignol & Hemphill, 
2006) and Cryptosporidium parvum (Gargala et al., 2000; Giacometti, Cirioni, Barchiesi, 
Ancarani & Scalise, 2000; Theodos, Griffiths, D'Onfro, Fairfield & Tzipori, 1998). Similarly, 
affinity chromatography showed that the antiplasmodial compound DS61 (1,4-bis(3-[N-
(cyclohexylmethyl) amino]propyl)piperazine) targets P. falciparum PDI (Florenta et al., 2000).  
The relevance of PDI was further strengthened with the description of T. gondii PDI as a 
major target for naturally occurring human IgA antibodies secreted at mucosal sites (Meek et 
al., 2002a). Secretory IgA (sIgA) antibodies, represent the humoral component of the 
mucosal immune system (MIS) and serve as the first line of defense against pathogens, by 
preventing adhesion and entry into the epithelium, and facilitating their clearance by 
peristaltic or mucociliary movements (Corthesy, 2009; Mantis & Forbes, 2010), in a process 
called immune exclusion. By recognizing polyvalent antigens on the surfaces of pathogens, 
sIgA are able to agglutinate them and retard or abolish the ability of the pathogen to adhere 
to and/or penetrate the epithelium (Strugnell & Wijburg, 2010). Meek, Klaren, van Haeringen, 
Kijlstra and Peek (2000), showed that there is an anti-T. gondii IgA response in human tears 
against this ubiquitous parasite, with 81 % of the tear samples tested recognizing T. gondii 
antigens. The authors found no relation between the presence of anti-T. gondii IgA in tears 
and chronic infection, since only 23% of individuals had evidence of systemic immunity 
against the parasite and suggested that these antibodies might belong to the natural 
antibody repertoire. In subsequent studies, Meek et al. (2002a) identified the major 49 kDa 
antigen as PDI and determined that the IgA epitopes recognize conserved regions of this 
enzyme and are able to cross react with other apicomplexan PDIs, namely P. falciparum 
(Meek et al., 2002b). Also, they demonstrated the presence of anti-T. gondii-PDI sIgA in 
human milk and in tears of, very likely, T. gondii naïve infants, facts that further support the 
notion that anti-PDI sIgA form part of the natural immune memory (Meek et al., 2002b). 
Likewise, N. caninum-PDI is also targeted by sIgA in bovine tears, suggesting that PDI-
specific antibodies constitute part of the mucosal antibody repertoire possibly involved in the 
defense against protozoan parasites (Liao et al., 2006). In addition, works on the analysis of 
N. caninum and T. gondii antigenic proteins recognized several immunodominant antigens 





parasites, being PDI one of the constantly identified antigens (Ma et al., 2009; Shin et al., 
2004; Shin et al., 2005; Zhou et al., 2014). A recent Portuguese study in patients with acute 
malaria (P. falciparum), also detected PDI as one of the major immunogenic proteins (Costa, 
Nogueira, de Sousa, Vitorino & Silva, 2013). In Leishmania species, PDI is suspected to 
have an important role in the virulence of these parasites (Achour et al., 2002; Amit et al., 
2014). Furthermore, recent works on neosporosis, applying the acute disease mouse model, 
determined 90% protection against disease and a significant reduction of cerebral parasite 
burden and numbers of viable tachyzoites in brain tissue, when mice were intranasally 
vaccinated with recombinant N. caninum PDI (Debache, Guionaud, Alaeddine & Hemphill, 
2010). Interestingly, intraperitoneal vaccination was ineffective (Debache et al., 2010; 
Debache et al., 2011), suggesting that the profile and/or homing of the immune response 
elicited are critical for this protective effect (Hemphill et al., 2013). 
In conclusion, all these evidences together further support the importance of PDI in 
apicomplexan parasites and in the host immune response against them. First, because of 
PDI fundamental role in the ER quality control by assuring the correct folding of proteins; 
Misfolded protein can lose their function, form aggregates and interfere with cell function. 
The obligate intracellular apicomplexan parasites depend on their ability to interact with the 
host cell for survival and this interaction is in a major part achieved by the sequentially 
discharge of their secretory organelles, which contain a vast set of proteins that are, 
obviously, essential for this process. One point that differentiates apicomplexan parasites 
from other intracellular pathogens, is that invasion of the host cell is a parasite driven and not 
a host cell driven process, fact that puts more pressure on the parasite for quality control of 
essential proteins and renders it more vulnerable for aiming these proteins as drug targets. 
Second, because of PDI explicit engagement in the host cell adhesion/invasion process, 
either directly, through an undescribed direct interaction with the host cell, or indirectly, by 
guarantee the adequate redox state of extracellular environment and correct folding of 
secreted proteins. Third, because PDI seems to be an immunodominant antigen that plays 
an important role in host immune response 
In this way, and since the disruption of PDI function (either through drug inhibition or anti-
PDI antibodies) was shown to negatively affect parasite growth, this protein has been 
proposed as a suitable target for anti-protozoan drugs and for protozoa vaccine development 
(Achour et al., 2002; Amit et al., 2014; Florenta et al., 2000; Han et al., 2014; Hemphill et al., 
2013; Hong & Soong, 2008; Liao et al., 2006; Mouray et al., 2007; Naguleswaran et al., 






1.3 Aim of the work 
Currently, it is generally accepted that PDI is present at the surface of apicomplexan 
parasites, where it participates in the host cell adhesion/invasion process. In addition, PDI 
has been identified as a major immunogenic protein in several parasitic diseases and also as 
a target of the natural antibody repertoire. Moreover it was shown that interference with PDI 
function has a negative impact in the growth of several apicomplexan parasites, especially in 
the closely related N. caninum and T. gondii. In this way, we hypothesize that B. besnoiti PDI 
plays a crucial role on host cell invasion and in bovine response to infection and that it can 
be, in agreement with what was proposed by several authors, a promissory drug target. The 
main purpose of this work was to characterize the enzymatic activity of B. besnoiti PDI and to 
evaluate its role in parasite-host cell interaction and in the bovine immune response. For this 
we identify the following objectives: 
 Isolation and sequencing of B. besnoiti PDI cDNA. 
 Cloning and heterologous expression of recombinant B. besnoiti PDI (recBbPDI) and 
truncated versions of PDI. 
 Development of specific monoclonal anti-recBbPDI antibodies by means of cellular 
fusion (hybridoma technology). 
 Characterization of the enzymatic activity of recBbPDI and its sensitivity to drug 
inhibitors and specific antibodies. 
 Immunolocalization of PDI in B. besnoiti bradyzoites and tachyzoites and evaluation 
of the role of PDI in host cell invasion. 







Chapter 2  | 
Besnoitia besnoiti protein disulfide isomerase (BbPDI): 
















Besnoitia besnoiti is a cyst-forming apicomplexan parasite of cattle with high veterinary 
relevance in many tropical and subtropical regions, with particular emphasis for sub-Saharan 
Africa (Bigalke & Prozesky, 2004). In Europe, besnoitiosis has been recently reported in 
Portugal (Cortes et al., 2006c; Cortes et al., 2005), Spain (Castillo et al., 2009; Fernandez-
Garcia et al., 2010; Fernandez-Garcia et al., 2009a; Fernandez-Garcia et al., 2009b; Irigoien 
et al., 2000)., France (Alzieu et al., 2007; Bourdeau et al., 2004; Jacquiet et al., 2010), Italy 
(Agosti et al., 1994; Gentile et al., 2012b; Gollnick et al., 2010; Mangili et al., 2012; Manuali 
et al., 2011; Mutinelli et al., 2011), Greece (Papadopoulos et al., 2014), Hungary (Hornok et 
al., 2014), Croatia (Beck et al., 2013), Switzerland (Basso et al., 2013; Lesser et al., 2012) 
and Germany (Mehlhorn et al., 2009; Schares et al., 2009). There is no treatment against 
this infection despite the efforts to identify and develop effective agents (Cortes et al., 2007a; 
Shkap et al., 1987a). Live-attenuated vaccines have been used in Israel and South Africa 
(Basson et al., 1970; Bigalke et al., 1974a) but they do not prevent subclinical infection and 
their use is geographically limited. Therefore, there is an urgent need for studying potential 
drug targets and vaccine candidates. Protein disulfide isomerase (PDI) is a key enzyme that 
enables proteins to acquire their correct three dimensional structure (Appenzeller-Herzog & 
Ellgaard, 2008; Hatahet & Ruddock, 2009; Wilkinson & Gilbert, 2004). This enzyme, one of 
the most abundant in the endoplasmic reticulum (ER) and classically described as an ER-
resident protein (Lambert & Freedman, 1985), is a member of the thioredoxin superfamily 
(Ferrari & Soling, 1999) and consists of two homologous catalytic domains, a and a’ , 
comprising each an active site with a CxxC motif, separated by two homologous non-
catalytic domains, b and b’ , and a highly acidic C-terminal extension c (Byrne et al., 2009; 
Edman et al., 1985; Kemmink et al., 1999; Kozlov et al., 2010). PDI catalyzes disulfide 
formation and the rearrangement of incorrect disulfide pairing during the oxidative protein 
folding process (Schwaller, Wilkinson & Gilbert, 2003; Wilkinson & Gilbert, 2004). Misfolded 
proteins can lose their functionality and accumulate as large, insoluble aggregates that might 
interfere with cell viability (Wilkinson & Gilbert, 2004). Current evidence suggests that PDIs 
are also involved in a wide range of other biological functions in many cellular compartments 
including the cell surface, where they may participate in the reducing exterior environment 
and/or may be involved in cell adhesion (Turano et al., 2002). Parasite PDI-like enzymes 
were identified in Neospora caninum (Naguleswaran et al., 2005), Toxoplasma gondii (Meek 
et al., 2002a; Meek et al., 2002b), Theileria parva (Ebel et al., 2002), different Leishmania 
species (Achour et al., 2002; Hong & Soong, 2008; Padilla et al., 2003), Cryptosporidium 





Mahajan et al., 2006; Mouray et al., 2007; Novo et al., 2009). T. gondii and N. caninum, both 
closely related to B. besnoiti (Ellis et al., 2000), have been shown to express highly 
homologous molecules, which could indicate that PDI plays a key role in the biology of 
neosporosis and toxoplasmosis (Ma et al., 2009; Meek et al., 2002b; Naguleswaran et al., 
2005). In this way, the important role of PDI in these two species and presumably in other 
apicomplexan parasites as well, might not allow for the accumulation of a large number of 
mutations in the protein sequence, rendering this molecule an interesting drug target. In fact, 
bacitracin and anti-PDI antibodies are effective at inhibiting the enzymatic activity of PDI in 
CHO cells (Mandel, Ryser, Ghani, Wu & Peak, 1993), and allowed the demonstration of the 
fundamental role of PDI in N. caninum host cell invasion (Naguleswaran et al., 2005). 
Furthermore, T. gondii PDI is targeted by mucosal IgA in humans (Meek et al., 2002b) and N. 
caninum PDI by IgA in cattle (Liao et al., 2006), suggesting that PDI specific antibodies may 
be involved in the host defense against these parasites. In addition, the analysis of N. 
caninum antigenic proteins identified PDI as one of the immunodominant proteins associated 
with the processes of invasion, proliferation and egress of apicomplexan parasites (Shin et 
al., 2004; Shin et al., 2005). The inhibitory effect of N. caninum PDI antiserum on the growth 
of this parasite was also demonstrated (Liao et al., 2006). Recently, intranasal vaccination of 
mice with recombinant N. caninum PDI conferred 90% protection against disease and 
significantly reduced the cerebral parasite burden and the numbers of viable tachyzoites in 
brain tissue (Debache et al., 2010). All the evidence obtained so far points towards the 
importance of PDI in the host immune response and cell invasion process, and prompted us 






2.2 Materials and methods  
2.2.1 Tissue culture and parasite purification 
The B. besnoiti Bb1Evora03 strain (Cortes et al., 2006c) was maintained by serial 
passages in confluent monolayers of Vero cells grown in DMEM with Glutamax (Invitrogen) 
supplemented with 10% heat-inactivated fetal bovine serum and 20mM HEPES, at pH 7.2–
7.5 as previously described (Cortes et al., 2006c; Reis et al., 2006). For parasite purification, 
freshly egressed tachyzoites were collected from the cell cultures supernatants, centrifuged 
at 800 g for 10 min, passed three times through a 25 G needle, washed three times with 
PBS, and passed through PD10 columns according to the manufacturer’s instructions (GE 
Healthcare). Bradyzoites were freshly obtained from mechanical disruption of cysts, collected 
from fresh skin biopsies of a chronically infected cow. Biopsies were made on an aseptically 
prepared site, with 8 mm biopsy punch, and immediately collected to PBS solution. Liberated 
bradyzoites were washed and purified as above. 
2.2.2 B. besnoiti PDI-gene sequence 
B. besnoiti tachyzoites were purified from in vitro cultures, and genomic DNA was isolated 
using DNeasy Blood and Tissue Kit (Qiagen). Primers for the initial PCR amplifications were 
designed based on conserved regions of the aligned PDI nucleotide sequences from N. 
caninum (AY751081) and T. gondii (AJ312317). PCR amplification was carried out in a 20 μl 
PCR mixture (1x reaction buffer, 1 U of Taq DNA polymerase (Fermentas), 10 pmol of each 
primer, and 0.2 mM dNTP’s), using B. besnoiti genomic DNA, primers PDIBesF2 and 
PDIBesR2 (Table 1), and running 30 cycles (90 °C for 30 s, 55 °C for 1 min, 72 °C for 1 min 
15 s). PCR products were cloned in the pTZ57R/T vector (Fermentas), and sequenced in 
both directions by dideoxy-chain termination method (Sanger, Nicklen & Coulson, 1977). 
Primers for genome walking were designed based on the sequence obtained.  
Genome walking libraries were generated and amplifications were carried out according to 
the manufacturer’s instructions (Clontech, USA). 2.5 μg of genomic DNA was digested 
separately with AluI, HaeIII, HpaI or SmaI. Subsequently, the GenomeWalker adaptors were 
ligated to the DNA. PCR amplification of DNA fragments from genomic libraries was carried 
out using Taq DNA polymerase (Fermentas) and gene-specific primers PDIBesGWF1, 
PDIBesGWF2, PDIBesGWR1 and PDIBesGWR2 (Table 1). After the first genome walking, 





primers PDIBesGWR3 and PDI BesGWR4. All clones were again sequenced in both 
directions, as above. 
 
 
Table 1. List of primers used for PCR amplification in this chapter. 
In lowercase letters is the sequence for the restriction enzyme. 








PDI BesGWR4 GAAGCGACGCTGTCTGGAGACGTTCTGCAA 
  




2.2.3 Production of recombinant B. besnoiti PDI (recBbPDI) 
2.2.3.1. Cloning and sequencing of B. besnoiti PDI cDNA 
For cDNA synthesis, B. besnoiti tachyzoites were purified from in vitro cultures and total 
RNA was extracted (High Pure RNA Isolation Kit – Roche). RNA obtained from 108 
tachyzoites was reverse transcribed by a two-step RT-PCR procedure (First Strand cDNA 
Synthesis Kit – Fermentas) for the production of cDNA. The PDI ORF was PCR-amplified 
using the forward primer PDIBesEX1 and the reverse primer PDIBesEX2 (Table 1), that 
contain EcoRI and XhoI sites respectively, and cDNA as template. Amplification was carried 
out using the conditions described above and performing 30 cycles (90 °C for 30 s, 60 °C for 
1 min, 72 °C for 1 min 15 s). PCR products were cloned into the pTZ57R/T vector 





2.2.3.2 Plasmid construction and expression 
Full-length B. besnoiti PDI cDNA was released from pTZ57R-PDI by restriction-reactions 
with EcoRI and XhoI, subcloned into pGEX-6P-1 expression vector hydrolyzed with the same 
enzymes, and sequenced for confirmation. Production and purification of recombinant 
glutathione S-transferase (GST) fusion protein was conducted according to the 
manufacturer’s recommendation (GE Healthcare). Briefly, the pGEX-6P-PDI construct was 
transformed into E. coli BL21 cells, cultures were grown in liquid broth and induced for 2 h 
with 1mM IPTG when absorbance at 600 nm was 0.8. The cell pellet was collected and lysis 
performed by sonication. The recombinant B. besnoiti PDI (recBbPDI) was purified from the 
lysate using Glutathione Sepharose 4B and following the brand indications with the exception 
that 0.1% Triton X-100 was used in binding and washing steps. Protein quantification was 
performed using a NanoDrop 2000 spectrophotometer assuming an extinction coefficient of 
93000 M-1 cm-1 and a molecular weight of 81 kDa. The extinction coefficient and molecular 
weight were calculated based on the amino acid sequence, using the ProtParam tool of the 
ExPASy Bioinformatics Resources Portal from the Swiss Institute of Bioinformatics 
(http://web.expasy.org/protparam/) (Artimo et al., 2012; Gasteiger et al., 2005) 
2.2.4 Determination of the reductase activity of recBbPDI and its inhibition by 
bacitracin 
RecBbPDI activity was measured by a turbidimetric assay based on the polymerization of 
reduced insulin (Lundstrom & Holmgren, 1990) as adapted by Smith et al. (2004). 
Commercial bovine PDI (Sigma) was used as a control. The assay was performed in 96-well 
microtiter plates and all solutions were made with assay buffer: 100mM potassium 
phosphate, 2mM EDTA, pH 7. Bacitracin, at concentrations ranging from 0.5mM to 4 mM, or 
assay buffer (5 μL) were added to respective wells; the reaction solution was made by mixing 
70 μL assay buffer with 10 μL of insulin (1.6 mM) and the enzymes or buffer (blank); 75 μL of 
reaction solution were added to each well and the reaction was started with the addition of 20 
μL of 5mM DTT. Absorbance at 650 nm was read in a SECTRAmax® 340 pc microplate 
spectrophotometer over 60 min every 5 min. Enzyme activity was calculated from the 
increase of turbidity over time accordingly to the formula:  
 






2.2.5 Antiserum production 
One mouse was intraperitoneally immunized and one rabbit subcutaneously immunized, 
both three times in intervals of three weeks, with 10 μg and 500 μg, respectively of recBbPDI 
emulsified in Freund’s incomplete adjuvant (MP Biomedicals, Inc.). The animals had free 
access to food and water and were housed and managed according to the applicable 
National and EU regulations. Four days after the last injection they were bled and the specific 
anti-recBbPDI antibody titre determined by enzyme-linked immunosorbent assay (ELISA). 
Briefly, coating was performed with 0.1 μg/well of recBbPDI and alkaline phosphatase-
conjugated secondary antibodies were used with p-nitrophenylphosphate (Sigma) (1 mg mL-
1) in 100mM glycine containing 1 mM MgCl2 and 1 mM ZnCl2, pH 10.4 as enzyme substrate. 
The plate was incubated 30 min in the dark at room temperature and the reaction stopped by 
the addition of 50 μL 3 N NaOH. Absorbance was read at 405 nm in a TIM 200 Inter Med 
plate reader. 
2.2.6 Western blotting 
Protein samples were prepared from purified tachyzoites or bradyzoites. The cellular 
pellet (108 parasites) was resuspended in Laemmli sample buffer (BioRad) and heated for 5 
min at 95 °C. Proteins were separated by SDS–PAGE (12%) under reducing conditions and 
blotted onto nitrocellulose (Millipore) at 100 Volts for 1 h in Tris–glycine buffer with 20% (v/v) 
methanol. The membranes were blocked overnight at 4 °C with 1% fish gelatin (Sigma) and 
probed with mouse anti-recBbPDI followed by incubation with alkaline phosphatase-
conjugated goat anti-mouse-IgG secondary antibody (Sigma) diluted 1:5000. The final 
enzyme reaction was developed using the BCIP/NBT kit (Bio-Rad). 
2.2.7 Immunofluorescence  
Purified tachyzoites or bradyzoites were allowed to adhere to poly-L-lysine-coated 
microscopy coverslips for 30 min, and were fixed for 10 min with cold methanol (-20 °C). 
Parasites were then probed with mouse anti-recBbPDI serum and FITC-conjugated anti-
mouse antibodies (Invitrogen). To visualize the entire cells, parasites were simultaneously 
probed with rabbit anti-B. besnoiti (Cortes et al., 2006b) and TRITC-conjugated anti-rabbit 
antibodies (Invitrogen). All these sera were used at 1:500 dilutions. DNA was stained with 
DAPI (1 μg mL-1; Sigma) for 2 min and the slides were mounted with Mowiol (Calbiochem) 





2.2.8 Database search and biocomputing approaches 
Similarity searches on the Protein databank were done using the Blast search program 
(Altschul et al., 1990). Alignment between two protein amino acid sequences was done using 
SIM (http://expasy.org/tools/sim-prot.html) (Huang & Miller, 1991). Multiple sequence 
alignment of PDI amino acid sequences was performed using MEGA 4 and ClustalW 
(Kumar, Nei, Dudley & Tamura, 2008). Search for BbPDI neighbors and phylogenic tree 
construction were performed using the web server phylogeny.fr (http://www.phy- logeny.fr) 
(Dereeper et al., 2008). Pattern search was performed using ScanProsite 
(http://expasy.org/prosite/) (Gattiker, Gasteiger & Bairoch, 2002) and Superfamily 1.69 
version (http://supfam.org/SUPER- FAMILY/) (Gough, Karplus, Hughey & Chothia, 2001). 
2.2.9 Comparative modelling and model validation  
A theoretical three-dimensional model for PDI from B. besnoiti (BbPDI) was constructed 
by comparative modelling by the Swiss-Model server v.3.7 (Arnold, Bordoli, Kopp & 
Schwede, 2006; Kiefer, Arnold, Kunzli, Bordoli & Schwede, 2009; Peitsch, 1996) 
(http://swissmodel.expasy.org/) using as template the heterodimer Tapasin-ERp57 
crystallographic deduced model (Dong et al., 2009) (PDB code: 3F8U chain C). 
Superimposition of models and calculation of the root mean square values (RMS) between 
the model and modelling template using the Carbon alpha fitting, were made by Swiss-Pdb 
Viewer v. 3.7 (Guex & Peitsch, 1997). RasMol v. 2.6 (Sayle & Milner-White, 1995) and 
Swiss- Pdb Viewer v. 3.7 were used for visualization of models. Search for structurally similar 
proteins was done using Dali server v. 2.0 (http://www.embl-ebi.ac.uk/dali/) (Holm & Sander, 
1993). Model structure validation was performed by Procheck programs (Laskowski, 
MacArthur, Moss & Thornton, 1993; Morris, MacArthur, Hutchinson & Thornton, 1992). The 
substrate pocket was predicted using the WHAT IF program (http://swift.cmbi.ru. 
nl/servers/html/index.html) (Vriend, 1990). The model was deposited in the PMDB 
(https://bioinformatics.cineca.it/PMDB/) (Castrignano, De Meo, Cozzetto, Talamo & 
Tramontano, 2006) under the identification number PM0075875. In this manuscript the 





2.3 Results and discussion  
2.3.1 Molecular characterization of the gene coding for BbPDI  
The gene sequence of B. besnoiti PDI was determined and deposited at GenBank under 
the accession number DQ490130. The sequence analysis showed an ORF of 1416 
nucleotides, comprising three exons, the first one spanning 164 bp, the second one 199 bp 
and a third one 1053 bp, which are separated by two introns of 343 bp and 97 bp 
respectively. The deduced amino acid sequence revealed a protein with 471 residues, 
presenting the characteristic catalytic thioredoxin motifs CxxC, and showing high amino acid 
conservation within the catalytic sites regions motif with other PDI entries in databases 
(Figure 9). A comparison of the BbPDI amino acid sequence with available PDI sequences 
from other species of the phylum Apicomplexa revealed identity levels as follows (Table 2): 
88.5% for N. caninum (BAD67151) (NcPDI) and 87.7% for T. gondii (CAC28361) (TgPDI); 
between 48.1% and 48.2% for Plasmodium species, P. chabaudi (AAV36000) (PcPDI) P. 
yoelli (EAA17481) (PyPDI), P. berghei (CAH95379) (PbPDI), P. falciparum (CAC15387) 
(PfPDI), and P. vivax (ABB72222) (PvPDI); 37.1% for C. parvum (AAB40710) (CpPDI); 
between 35.8% and 34.3% for Babesia and Theileria species, B. bovis (EDO05830) 





Table 2. Identity and similarity levels of PDI from B. besnoiti, N. caninum, T. gondii, P. falciparum and 
B. Taurus. 
Light gray highlights the high identity and similarity between B. besnoiti, N. caninum and T. gondii. 
Results are given in percentage based on the amino acidic sequence of B. besnoiti PDI compared to 










B. besnoiti N. caninum T. gondii P. falciparum B. taurus 
B. besnoiti –– 88,5 87,7 48,1 30,7 
N. caninum 96,2 –– 98,5 42,9 31,1 
T. gondii 96,0 94,3 ––– 44,0 30,9 
P. falciparum 69,3 68,7 68,7 –– 27,5 









Figure 9. The cDNA encoding BbPDI (GenBank accession number. DQ490130.1).  
Nucleotide sequence (above) and deduced amino acid sequence (below) are shown. Light gray 
highlights hits to the Pfam thioredoxin model (PF00085) and medium gray denotes the thioredoxin 
family active site Prosite pattern (PS00194). The characteristic catalytic thioredoxin motifs CxxC are 
boxed. The C-terminal putative ER retention signal is displayed on a black background. The stop 
codon is indicated by *. Based on the alignment with chain C of Tapasin Erp57 (PDB code 3F8U) the 
proposed delimitation of a, b, b’ and a’ and c domains is showed by brackets and underlined; x-





As expected for members of the thioredoxin superfamily, two thioredoxin domains 
(PS51352) were identified in BbPDI. These are localized between amino acids 28–134 (a 
domain) and 351– 459 (a’ domain), and contain the thioredoxin family active site pattern 
(PS00194) [LIVMF]-[LIVMSTA]-x-[LIVMFYC]-[FYWSTHE]- x(2)-[FYWGTN]-C-[GATPLVE]-
[PHYWSTA]-C-x(6)-[LIVMFYWT] between amino acids 48–66 (a domain) and amino acids 
372–390 (a’ domain). A putative thioltransferase domain is present between amino acids 
223–335. The BbPDI a domain presents the characteristic CGHC eukaryotic active site motif, 
but there is a substitution of the histidine by a tyrosine in the a’ domain active site motif 
(CGYC), similar to what was described for N. caninum (Naguleswaran et al., 2005) and T. 
gondii (Meek et al., 2002a). The putative ER retention motif GEEL is present at C terminus of 
the amino acid sequence, diverging from the classical KDEL sequence found in eukaryotic 
ER-resident proteins (PS00014), but again in agreement with N. caninum (Naguleswaran et 
al., 2005) and T. gondii (Meek et al., 2002a). 
 
2.3.2 B. besnoiti PDI and its relationship to other members of the thioredoxin-like 
superfamily 
BbPDI belongs to the thioredoxin like superfamily (cluster 00388) and is included in the 
PDI_a family (cluster defined cd02961) and the PDI_a_PDI_a’_c subfamily (cd02995). This 
sub-family includes ER-resident eukaryotic proteins involved in the oxidative protein folding 
(Marchler-Bauer et al., 2009). Structurally, PDI consists of four thioredoxin-like domains, a, b, 
b’ and a’, plus a highly acidic C-terminal extension c. Two domains contain a redox-active 
catalytic site (a and a’), and the other (b and b’) do not (Kemmink et al., 1995; Kozlov et al., 
2010; Marchler-Bauer et al., 2009). Catalytic domains usually contain two cysteines in a 
CxxC active-site motif (Appenzeller-Herzog & Ellgaard, 2008).  
The search for protein neighbors through the web server phylogeny.fr on non-redundant 
databases, identified orthologues in the Muridae family (Rattus norvegicus, Mus musculus), 
Hominidae family (Homo sapiens, Pan troglodytes), Bovidae family (Bos taurus), Nematoda 
phylum (Caenorhabitis elegans), in the Phaniasidae family (Gallus gallus), the Amphibia 
(Xenopus laevis) and Insecta class (Culex quinqiuefasciatus), in the Branchistomidae family 
(Branchiostoma floridae); Viridiplantae (Arabidopsis thaliana, Medicago sativa), in the phyla 
Apicomplexa (P. falciparum), Platyhelminthes (Schistosoma mansoni), Dinoflagellata 
(Perkinsus marinus) and in the Tetraodontidae family (Tetraodon nigroviridis). No orthologue 







Figure 10. Multiple sequence alignment between the catalytic a and a' domains of Apicomplexa PDI 
family and predicted Secondary Structure Elements for the BbPDI model. 
Conserved residues in all sequences are in bold and marked (*). Residues with >90% identity are in 
bold and marked (♣). Residues with conserved properties are in bold and marked: hydrophobic (λ) and 





), β-strand (). Residues numbering according entries in database were used except for PyPDI 
(starting at mature enzyme). P. chabaudi (Pc), P. yoelli (Py), P. berghei (Pb), P. falciparum (Pf), B. 
besnoiti (Bb), T. gondii (Tg), N. caninum (Nc), C. parvum (Cp), B. bovis (Bbo), B. caballi (Bc), T. 





The multiple alignment between the a and a’ domains of the PDI amino acid sequences 
from apicomplexan parasites (Figure 10) showed that from the 20 residues around the active 
site motif, VlVkfYAPWCgHCKrmaPeY (B. besnoiti sequence) 12 are identical or their 
chemical properties are conserved. Also the P103-T104 and R120 residues (a domain) and 
P426 and R445 (a’ domain) (B. besnoiti numbering) are conserved. The aligned residues to 
T104 in the a0 domain are also conserved in all the apicomplexan PDIs except for the 
Sarcocystidae in which the Threonine residue was changed to a Serine residue (similar 
chemical properties), S427 (B. besnoiti, T. gondii) and S429 for N. caninum. This residue 
conservation is similar to the one described for the human PDI family (Lappi et al., 2004) and 
indicates similar functional activities as reported for the equivalent residues in the human PDI 
family.  
Analysis of the phylogenetic tree (Figure 11) showed that at the first divergent node the 
Apicomplexa are divided into two branches, the first one comprising the Plasmodium 
(orthologue) and the Toxoplasma, Neospora, Besnoitia, Babesia and Theileria species 
homologues and the second one comprising the Cryptosporidiidae members. The first 
branch diverges again into one containing Toxoplasma, Besnoitia and Neospora PDI 
homologues and one containing the Babesia and Theileria homologues as expected. 
Orthologues from P. marinus are phylogenically closer to the Cryptosporidiidae than to B. 
besnoiti. Phylogenetically, B. besnoiti PDI is relatively divergent from B. taurus PDI, the 
target host for B. besnoiti infection, with an amino acid sequence identity of only 30.7% in 







Figure 11. Mid-point rooting cladogram tree for PDI amino acid sequence. 
Branch support values are presented. Accession numbers and parasite source were provided for 
PDI from Apicomplexa from the Plasmodiidae, Theileriidae, Babesiidae and Sarcoscystidae 
families. The polypeptide sequences from the crystallographic deduced model used as a template 
for in silico modelling of BbPDI were also introduced (Homo sapiens, 3FU8_C). Orthologues from 
different species are shown. Some orthologues from M. musculus, P. troglodytes, P. marinus, C. 
quinquefasciatus, S. mansoni, B. floridae and X. laevis were omitted due to their similarities to other 
entries already included. Light gray highlights phylum Apicomplexa and medium gray denotes 





2.3.3 Analysis of an in silico model of B. besnoiti PDI 
The catalytic sites exhibit a structure that is reminiscent for thioredoxin domains. Both a 
and a’ domains have a double-wound alternating α/β fold, consisting of a 5-stranded β-sheet 
core, enclosed by 4 α-helices. The active site disulfide is located in a short segment at the N-
terminus of helix 2, as described (Kemmink et al., 1996), after a kink caused by the 
conserved Proline residue P64, (a domain) and P388 (a’ domain). The view of the model 
(Figure 12A) shows the four thioredoxin domains. Domains a, a’, b and b’ are, as expected, 
presenting the five β-strands characteristic of the fold.  
The stereochemical quality of the model, checked by Procheck program, showed that 
95.6% of residues are in the core plus allowed regions of the Ramachandran plot. The model 
presents 99.3% of M/c bond lengths, 95.1% of M/c bond angles and 88.1% of planar groups 
within the expected limits and an overall G factor of -0.04. The structural alignment obtained 
from the superimposition of the model with the 3F8U_C template model showed a RMS of 
0.33 Å on 407 Ca atoms and a RMS of 1.15 Å on 119 Ca atoms from the superimposition 
with the S. cerevisiae PDI crystallographic deduced model 2B5E. Search for structurally 
similar proteins using Dali reveals a very high structural similarity with the used template 
3F8U chain C (Z score 42.6) against a Z score 27.1 for 2B5E chain A. The phylogenetical 
distance of the H. sapiens Tapasin-ERp57 (PDB code 3F8U_C) and the S. cerevisiae PDI 
(PDB code 2B5E_A) to B. besnoiti PDI is similar for both cases. As the comparative 
modelling is highly dependent on the degree of amino acid sequence identity, the 
discrepancies observed on the structural alignment could be due essentially to the low amino 
acid sequence identity, 28.7% in 456 amino acid overlap for 2B5E protein and 33.6% in 446 
amino acid overlap for 3F8U_C sequence. 
2.3.4 Analysis of catalytic domains 
In each catalytic site, Cys residues are placed on a and a’ domains face to face. On 
domain a, Cys residues are in a reduced state, in contrast to the oxidized state on a’ domain, 
as occurs in Humicola insolens (Serve et al., 2010). It was shown (Lappi et al., 2004) that the 
movement of the side chain of the Arg residues in human PDI, equivalent to B. besnoiti R120 
and R445 residues, are used by the enzyme to maintain a high pKa value for the Cys 
residue, while allowing the reaction which requires a thiolate to proceed at an appropriate 
rate. Similar to what was described for human PDI, the side chains of R120 and R445 
residues in BbPDI are also distant from the Cys residues of the active site suggesting an 









Figure 12. B. besnoiti PDI model and binding pocket. 
(A) View of the B. besnoiti PDI model. Cartoon representation generated by Rasmol: α-
helices (red), β-strand (yellow), turns (blue) and aperiodic structures (grey). Residues of 
the active center (CxxC) are spacefill displayed in grey in both domains a and a'. The β 
sheet, characteristic of each domain (in yellow), is visible from left to right, respectively 
domains a, b, b' and a'; (B) View of the binding pocket of B. besnoiti PDI. Representation 
generated by Swiss-Pdb Viewer v 3.7 by superimposition of the BbPDI model and the 
residues belonging to the pocket predicted by WHAT IF docking program. Residues 
belonging to the pocket are displayed in red. The pocket residues belonging to the 





Several studies showed that all domains of PDI act synergistically during catalysis. The 
experimental results from disulfide- bond isomerase (DsbC) from E. coli (Banaszak, Mechin, 
Frost & Rypniewski, 2004; McCarthy et al., 2000) and Haemophilus influenza (Zhang, 
Monzingo, Segatori, Georgiou & Robertus, 2004) crystal structures, suggest hinge-flexibility 
within the proteins, which allows movements of the active sites, in order to accommodate the 
substrate in the cleft between the catalytic domains, and also differences in the orientation of 
the catalytic domains (Banaszak et al., 2004; McCarthy et al., 2000). This flexibility, 
essentially due to the x-linker region between b’ and a’ domains, agrees with the 
experimental data (Nguyen et al., 2008; Wang et al., 2010b) and is fundamental for 
interaction with folding substrates. 
In the BbPDI model the distance of Cys residues of a and a’ catalytic domains is 
approximately 35 Å. In addition to the predicted movement of the R120 and R445 residues, 
these facts agree with the hypothesis that substrate binding induces domain-movements, 
leading to a different orientation and distance between a and a’ catalytic domains Cys 
residues. 
Substrate pocket prediction on BbPDI by WHAT IF program (Figure 12B), detected one 
pocket comprising residues belonging to a, b and b’ domains. The inclusion in the pocket of 
residues from b and b’ domains is in agreement with the described participation of several 
domains in the binding activities of PDI suggesting that b and b’ domains act to fix substrates 
for further catalytic chain action of the a and a’ domains. 
2.3.5 RecBbPDI catalytic activity and bacitracin inhibition  
The activity of recombinant GST-tagged B. besnoiti PDI expressed in E. coli, was tested 
by following the aggregation of insulin at 650 nm, as a consequence of disulfide bond 
reduction (catalyzed by PDI). RecBbPDI is functionally active and shows a dose dependent 
cross-linking activity in the range of 0.05 mM to 1.75 mM (Figure 13A). The profile of activity 
is similar to that observed for bovine PDI (bPDI) (Figure 13B), although at lower enzyme 
concentrations recBbPDI exhibited higher activity levels and at higher concentrations (0.88 
mM and 1.75 mM) recBbPDI activity levels are lower compared to bPDI. 
Recombinant BbPDI activities were sensitive to bacitracin, a classic PDI inhibitor, in a 
dose-dependent manner at enzyme concentrations ranging from 0.05 mM to 0.22 mM 
(Figure 13C, D and E). At higher enzyme concentrations, however, PDI activity was not 
inhibited in the range of bacitracin concentrations tested (0.5–4 mM) (data not shown). 
Bovine PDI used as control showed a dose dependent inhibition by bacitracin in the above-








In an attempt to understand differences in sensitivity of recBbPDI and bPDI to bacitracin in 
silico docking studies were performed. The data suggests that bacitracin makes hydrogen 
bonds within the substrate pocket residues Glu123 (a domain), Glu151 and Ser 152 (b 
domain) in the BbPDI model, and with Glu123, Glu153 and Ser154 in a B. taurus PDI model 
constructed by threading (data not shown). The comparative analysis suggests that 
Figure 13. B. besnoiti PDI (BbPDI) enzymatic activity. 
Reductase activity was tested by measuring the aggregation of insulin. (A) A dose dependent activity 
of BbPDI was observed in the range of 0.05 mM to 1.75 mM. (B) Bovine PDI (bPDI), used as control, 
shows also a dose dependent activity in the range of 0.22 mM to 1.75 mM. Decrease of activity 
observed when bacitracin, tested at concentrations ranging from 0.5 mM to 4 mM, was used with a 






bacitracin, due to a different orientation in the substrate pocket, interacts more extensively 
with the b’ domain in bPDI than in BbPDI 
2.3.6 Western blotting analysis and immunolocalization of PDI  
In Western blots of B. besnoiti tachyzoites and bradyzoites extracts, the anti-recBbPDI 
serum revealed a band of 53 kDa, as expected (Figure 14A and B). The antiserum also 
reacted with a band of similar molecular mass in N. caninum and T. gondii tachyzoite 
extracts (Figure 14C and D). This is not surprising, considering the high amino acid 
sequence homology of PDIs in the three species. Western blots of recBbPDI labeled with 
anti-recBbPDI antiserum revealed two bands, one corresponding to the GST-PDI-fusion 
protein (~81 kDa) and the other corresponding to free PDI devoid of the GST tag (~53 kDa) 






Figure 14. Western blot analysis using mouse serum. 
(1) anti-recBbPDI hyper immune serum (diluted 1:1000); (2) pre-immune serum 
(diluted 1:1000); (A) B. besnoiti tachyzoite total protein extract, (B) B. besnoiti 
bradyzoite total protein extract, (C) N. caninum tachyzoite total protein extract, (D) 





The anti-recBbPDI serum, tested by immunofluorescence on B. besnoiti tachyzoites and 
bradyzoites smears, showed a scattered and uneven intracellular staining, with higher 
intensity in the perinuclear area, a pattern that is compatible with ER labeling (Figure 15). B. 
besnoiti PDI staining is similar in both parasite stages, but tachyzoites seems to show a more 
scattered distribution whereas bradyzoites a more spotted and condensed one with a clear 




In conclusion, we showed that B. besnoiti expresses a PDI with 471 amino acid residues, 
presenting the two thioredoxin domains and the catalytic motif CxxC as expected for the 
members of the thioredoxin superfamily. Within the region of the catalytic sites there is a high 
amino acid sequence identity with PDIs from other apicomplexans, most notably with N. 
caninum and T. gondii. Phylogenetic analysis confirms that BbPDI belongs to a cluster 
comprising the PDIs from these two species. Using the SwissModel server it was possible to 
construct an in silico model by comparative modelling covering the four domains a, b, b’ and 
a’. The results obtained by Procheck programs analysis, gave us confidence to use this 
model as a working hypothesis and the model presents the expected fold for all domains. As 
described in PDIs from other sources, the distance between catalytic domains and between 
Cys residues from each domain suggest the presence of the x region linking b’ and a’ 
Figure 15. Indirect immunolocalization of B. besnoiti PDI 
IFAT in purified tachyzoites (top panel) and bradyzoites (bottom panel), using mouse anti-recBbPDI 
serum and FITC conjugated secondary antibodies (PDI-green), rabbit anti-B. besnoiti and TRICT 
conjugated secondary antibodies (Bb-red) and DAPI to label the cell nuclei (blue). Merged image is 





domain, and agree with the hypothesis that substrate binding induces domain movements, 
leading to different orientations and distances between a and a’ catalytic domains and Cys 
residues during the catalytic reaction. This confirms what has been found earlier for other 
PDI models.  
Recombinant BbPDI shows a dose dependent catalytic activity and is inhibited by 
bacitracin. Western blotting results confirm the specificity of produced antiserum against PDI 
in B. besnoiti tachyzoite and bradyzoite extracts, and cross-reactive activity with PDIs from 
other apicomplexans confirms the close phylogenetic relationship between these species. 
Immunofluorescence-based localization studies show that this protein is largely associated 
with the ER in both tachyzoites and bradyzoites. These studies form the basis for future 
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One important function of the immune system is the production of soluble proteins that 
exhibit properties that contribute specifically to immunity and protection against foreign 
material and potentially damaging entities, such as bacteria, virus or parasites. These soluble 
proteins are known as antibodies or immunoglobulins and share a common structure that 
allows them to bind to a nearly unlimited number of specific antigens, including proteins, 
carbohydrates, glycoproteins, polysaccharides, nucleic acids and lipids (Abbas et al., 2014; 
Actor, 2014). Immunoglobulins can be secreted or membrane-bound. Secreted antibodies 
are produced by a terminally differentiated B-lymphocyte (or B-cell), called plasma cell, and 
circulate freely in extracellular fluids. Membrane-bound antibodies are present on the surface 
of B-cells where they serve as antigen-specific receptors and participate in the formation of 
the B-cell receptor (BCR) (Coico & Sunshine, 2015a). All immunoglobulin molecules consist 
of a basic unit (monomer) with a molecular weight of approximately 150 kDa, that comprises 
a symmetrical core structure composed of two identical light chains (25 kDa) and two 
identical heavy chains (55 kDa), held together by one or more interchain disulfide bonds 
(Nunez-Prado et al., 2015) (Figure 16). Both the light chains and heavy chains contain a 
series of repeated homologous units, each about 110 amino acid residues in length, that fold 
independently in a globular motif that is called an Ig domain. Also, all chains contain an 
amino-terminal variable region (V) and a carboxyl-terminal constant region (C). In the heavy 
chains, the V region is composed of one Ig domain, and the C region is composed of three or 
four Ig domains. Each light chain is composed of one V region Ig domain and one C region Ig 
domain. Like the name implies, variable regions vary in their amino acid sequences among 
antibodies made by different B cell clones. The V region of one heavy chain (VH) and the 
adjacent V region of one light chain (VL) form the antigen-binding site (see Figure 16). The C 
region Ig domains are distant from the antigen-binding site and do not participate in antigen 
recognition. The heavy chain C regions (CH) are responsible for most of the biologic functions 
of antibodies, since this is where the interaction with other effector molecules and cells of the 






The analysis of the structural characteristics and biological activity of immunoglobulins 
really began in 1959 with the distinct works of Edelman (1959) and Porter (1959). They 
decided to address this issue by splitting the immunoglobulins and, despite previous 
attempts (Porter, 1950), for the first time they were able to separated them into analyzable 
parts suitable for further study. Edelman showed that reduction of the disulfide bonds of 
antibodies in the presence of denaturizing agents led to dissociation of the molecule into four 
fragments: two identical chains with a molecular weight of about 22 kDa each and two others 
of about 53 kDa each. They were named light chain and heavy chain and it was first 
proposed that IgG molecule consisted of two heavy and two light chains linked by disulfide 
bonds and noncovalent interactions (Edelman, 1959). Porter’s (1959) experiments focused 
on a specific IgG of rabbit serum that he cleaved with papain. This enzyme hydrolyzed 
peptide bonds and produced three fragments of similar molecular weight (50kDa). Two of 
these fragments were found to retain ability to bind antigen specifically, although, unlike the 
intact molecule, they could no longer precipitate the antigen from solution. These two 
fragments are referred to as Fab (fragment, antigen-binding), are identical to each other and 
consist of the complete light chain (VL and CL) associated with a VH-CH1 fragment of the 
heavy chain. The third fragment is composed of two identical disulfide-linked peptides, that 
Figure 16. Structure of an antibody molecule.  
Schematic diagram of a secreted IgG molecule (on the left) and a membrane-bound 






correspond to the heavy chain CH2 and CH3 domains and is called Fc (fragment, 
crystallizable), because it has a propensity to aggregate and to crystalize into lattice. The 
crystals of the Fc fragments coming from antibodies with different specificities were 
practically homogeneous. It should be noted that if pepsin is used instead of papain to cleave 
rabbit IgG, proteolysis occurs C-terminally to the disulfide bridge between the heavy chains 
at the hinge region, generating a divalent fragment of IgG, referred as F(ab’)2 (Figure 17). In 
this situation the inter-chain disulfide bonds are kept intact and only two fragments are 






Figure 17. Proteolytic digestion of IgG by papain (left) and pepsin (right). 
Cleavage occurs at the sites indicated by arrows. Papain digestion allows 
separation of two antigen-binding regions (Fab fragments) from the portion of 
the IgG molecule that binds to complement and Fc receptors (Fc fragment). 
Pepsin generates a single bivalent antigen-binding fragment, the F(ab’)2. 





Each clone of a B-cell produces an antigen receptor (immunoglobulin) with a unique 
antigen-binding structure, that is determined during the process of lymphocyte maturation, 
through complex process of gene rearrangement and genetic recombination. Briefly, the 
genes that encode diverse antigen receptors are generated by the rearrangement of different 
variable (V) region gene segments with diversity (D) and joining (J) gene segments. This 
process, named V(D)J recombination, involves selection of one V gene, one D segment 
(when present), and one J segment in each lymphocyte and rearrangement of these 
segments to form a single V(D)J exon that will code for the carboxyl-terminal ends of an 
immunoglobulin variable region. It is this random use of different V, D and J segments that 
contributes to the diversity of the antigen receptor repertoire. Early in the maturation of 
lymphocytes, low-affinity antibodies are produced and it is the process of affinity maturation, 
where somatic mutation of Ig V genes and selection of B-cells with high-affinity antigen 
receptors occurs, that will latter generate antibodies with high affinity for antigen (Abbas et 
al., 2014). 
Quite apart from the structure and the function in the immune response, antibodies have 
long been an important tool for investigators, who capitalize on their specificity to identify or 
label particular molecules or cells and to separate them from a mixture. The physiological 
response to a specific antigen, i.e. the antibody production, is highly heterogeneous. There is 
a huge diversity of B lymphocytes, the precursors of plasma cells, in the spleen of a mouse 
or a man. All are derived from a common stem cell, but each line develops, as briefly 
mentioned, an independent capacity to make an antibody that recognizes a different 
antigenic determinant. When an animal is injected with an immunizing agent, it responds by 
making diverse antibodies directed against different antigen molecules on the injected 
substance and/or different determinants on a single antigen, and even different antibodies 
that recognize, more or less well, a single determinant. So conventional antiserums contain 
mixtures of antibodies, that vary from animal to animal, making it very difficult or even 
impossible to make reproducible reagents (sera) against a specific antigen (Milstein, 1980). 
Each antibody is made, however, by a different line of lymphocytes and their derived plasma 
cells. If we could harvest one such cell (making a single specific antibody) and grow it in 
culture, this single cell's progeny, or clone, would be a source of large amounts of identical 
antibody against a single antigenic determinant: a monoclonal antibody (mAb). Unfortunately 
antibody-secreting cells cannot be maintained in in vitro culture. There are however 
malignant tumors of the immune system called myelomas that are immortal and able to 
secrete large amounts of immunoglobulins. They can be cultured in vitro, but it is impossible 
to determine to what antigen is the secreted antibody directed or to induce myelomas that 





breakthrough was achieved in 1975, when Georges Köhler and César Milstein described for 
the first time a method for immortalizing individual antibody-secreting cells from an animal 
immunized with a known antigen by fusing them with a myeloma cell line and growing them 
in a way that unfused normal and tumor cells cannot survive (Köhler & Milstein, 1975). The 
resultant fused cells that grow out are called hybridomas and each hybridoma makes only 
one antibody, derived from one B-cell from the immunized animal. The antibodies secreted 
by many hybridoma clones are screened for binding to the antigen of interest, and this single 
clone with the desired specificity is selected and expanded. The products of these individual 
clones are monoclonal antibodies, each specific for a single epitope on the antigen used to 
immunize the animal and to identify the immortalized antibody-secreting clones (Goding, 
1996). With this technique, antibodies could be transformed in a well-defined chemical 
reagent that can be reproduced at will, making it a valuable tool for scientific research and 
clinical medicine. Monoclonal antibodies have not only fueled breakthrough discoveries in 
basic research, but have also been developed as clinical diagnostics, reagents for high 
throughput drug screening, and more importantly, life-saving medicines (Abbas et al., 2014; 
An, 2010).  
In apicomplexan parasites, references to the use and development of monoclonal 
antibodies started early in the 1980’s, especially in Plasmodium spp. and Toxoplasma. Many 
of these early studies were already directed to different purposes like diagnostics (Araujo, 
Handman & Remington, 1980; Erlich, Rodgers, Vaillancourt, Araujo & Remington, 1983) or 
treatment (Cox, 1980; Freeman, Trejdosiewicz & Cross, 1980; Johnson, McDonald & Neoh, 
1983b), but most of them were descriptive of a specific mAb developed and it’s 
characterization, in terms of antigen recognition and/or the effect in experimental parasite 
growth (for example: Handman, Goding & Remington, 1980; Handman & Remington, 1980; 
Johnson, Haynes, Leppard, McDonald & Neoh, 1983a; Perrin, Ramirez, Er-Hsiang & 
Lambert, 1980; Pinder & Hewett, 1980; Potocnjak, Yoshida, Nussenzweig & Nussenzweig, 
1980; Sethi, Endo & Brandis, 1980; Yoshida, Nussenzweig, Potocnjak, Nussenzweig & 
Aikawa, 1980). Consequently, the first studies started to report the inhibitory effect of specific 
antibodies on the invasion of apicomplexan parasites and their intracellular replication, 
especially in Toxoplasma gondii (Hauser & Remington, 1981; Johnson et al., 1983b; 
Schwartzman, 1986; Sethi, Endo & Brandis, 1981), Plasmodium falciparum and P. vivax 
(Hollingdale, Nardin, Tharavanij, Schwartz & Nussenzweig, 1984), Cryptosporidium parvum 
(Perryman, Riggs, Mason & Fayer, 1990) and Eimeria bovis (Whitmire, Kyle, Speer & 
Burgess, 1988). In these early times however, hyper-immunization of mice was most 
frequent accomplished by using mixed antigenic molecules, like the parasite itself or parasite 
protein extracts whose contents were far from defined, originating a blind monoclonal 





was in fact the case for the only two published studies concerning mAb development for B. 
besnoiti. One study fused spleen cells of mice immunized with total protein extracts of 
purified tachyzoites (Shkap, Pipano & Zwernemann, 1995) whereas the other of mice 
immunized with purified live tachyzoites (Njagi, Entzeroth, Nyaga & Musoke, 2004). Shkap et 
al. (1995), reported one mAb with a strong immunofluorescence labelling of the polar 
organelle complex, that recognized a 70 kDa polypeptide on immunoblots, while Njagi et al. 
(2004) reported three mAb recognizing antigens of >200 kDa and one with 75 kDa, with 
different fluorescence patterns against B. besnoiti tachyzoites. However, both studies could 
not ascribe the specific location of the reactive epitope to a particular organelle or specifically 
identify the target proteins. Nowadays, in this post-genomic era, the means to address a 
more specific production of mAb are present, not only because we can immunize mice with 
purified and specific peptides but also because screening of epitope recognition is much 
more sensitive. In this way, since PDI has been recognized as an important player in host 
cell invasion process and host immune response, we proceeded with the production of anti-
PDI mAb, to acquire a powerful tool for further studies addressing these issues. 
3.2 Materials and methods 
3.2.1 Production of recombinant B. besnoiti PDI (recBbPDI) and truncated 
versions. 
For cDNA synthesis, B. besnoiti tachyzoites (108) were purified from in vitro cultures, RNA 
was extracted (High Pure RNA Isolation Kit – Roche) and reverse transcribed by a two-step 
RT-PCR procedure (First Strand cDNA Synthesis Kit – Fermentas). For the full length B. 
besnoiti PDI the cDNA was PCR-amplified using the forward primer PDI_F_Nde and the 
reverse primer PDI_R_Xho, that contain Nde and XhoI recognition sites respectively (primer 
sequences are shown in Table 3). Truncated versions of BbPDI were produced 
corresponding to the domains a, b, b’ and a’c using the primers presented in Table 3 
containing the mentioned recognition sites, as follows: domain a, forward primer PDI_F_Nde 
and reverse primer PDI_a_R_Xho; domain b, forward primer PDI_b_F_Nde and reverse 
primer PDI_b_R_Xho; domain b’, forward primer PDI_b’_F_Nde and reverse primer 
PDI_b’_R_Xho; and domain a’c, forward primer PDI_a’c_F_Nde and reverse primer 
PDI_R_Xho. Schematic representation of the truncated version is depicted in Figure 18. PCR 
amplification was carried out in a 25 µl PCR mixture (1x reaction buffer, 1 U of Taq DNA 





cycles (90 °C for 30 s, 60 °C for 1 min, 72 °C for 1 min 15 s). PCR products were cloned into 
the pGEM-T Easy Vector, its nucleotide sequence was confirmed and then subcloned in the 
pET28a vector using the Xho I and Nde I restriction sites of the polylinker. The strain 
Rosetta(DE3)pLysS was used for expression purposes; Protein expression was induced by 
the addition of isopropyl-D-thiogalactopyranoside to a final concentration of 1 mM when 
bacterial cultures attained an OD of 0.6 to 0.9 (measured at 600 nm wavelength), followed by 
incubation for 2 hours. The domains were purified by affinity chromatography using Ni 




Table 3. List of primers used for PCR amplification of the full length recBbPDI and the 
truncated versions a, b, b’ and a’c. 
Underlined is the sequence for the restriction enzyme together with the necessary added 
nucleotides for efficient cleavage in lowercase letters. 
Primers’ name Sequence (5’- 3’) 
PDI_F_Nde  ggaattccatatgCGGGCTGGGGTCTGCTACCTT 
PDI_R_Xho   ccgctcgagttaCAATTCCTCGCCCTTGTCGT 
PDI_a_R_Xho   ccgctcgagttaCAACGCTGCCCTCGACCTC 
PDI_b_F_Nde  ggaattccatatgGACGACAAGGTTACCAAGGAG 
PDI_b_R_Xho   ccgctcgagttaTAGAGTCGTCGAAGTCCTTTTC 
PDI_b’_F_Nde  ggaattccatatgACCGAAAAGGACTTCGACGAC 












As domain a and domain b were present in the insoluble fraction of the bacteria lysate 
they were purified in denaturing conditions, by the addition of 8M urea. All fractions were 
analyzed by SDS-PAGE and elution fractions were pooled and concentrated using a 
ultrafiltration centrifugal device (Amicon, Millipore) with the appropriate nominal molecular 
weight limit, accordingly with the manufacture’s recommendations and instructions. Protein 
quantification was performed using a NanoDrop 2000 spectrophotometer assuming the 
extinction coefficient and the molecular weights presented in Table 4. The extinction 
coefficients and molecular weights were calculated based on the amino acid sequence, using 
the ProtParam tool of the ExPASy Bioinformatics Resources Portal from the Swiss Institute 




Figure 18. Schematic representation of the truncated version of recombinant BbPDI produced. 
Recombinant BbPDI is shown on the top. Domain boundaries are illustrated and labeled, with 
the a-type domains in red and the b-type and c domain in blue. Location of the active sites 





Table 4. Recombinant proteins produced in this chapter. 
Expected molecular weight (MW) and extinction coefficient (ε) was calculated by ProtParam tool  
based on the amino acidic sequence of the protein and includes the initiating N-terminal methionine 
residue and the histidine tag from pET-28a. Molecular weights assuming that cysteines from active 
sites form disulfide bonds 








RecBbPDI 491 55039.7 5.57 49890 
Domain a 164 17804.4 6.5 17210 
Domain b 135 15402.1 5.44 9970 
Domain b' 125 13965.7 7.11 5500 
Domain a'c 145 16526.7 5.98 17085 
 
 
3.2.2 Production of monoclonal antibodies against B. besnoiti PDI 
3.2.2.1 Mice immunization 
Four weeks old, female BALB/c mice were intraperitoneally immunized three times, every 
2 weeks, with 10 µg of recBbPDI emulsified in incomplete Freund’s adjuvant (Sigma). After 
the third injection the mouse was bled and the anti-PDI antibody titre determined by enzyme 
linked immunosorbent assay (ELISA). Three days after the last immunization the mice were 
sacrificed and the spleen aseptically collected to harvest cells for cell fusion. 
3.2.2.2 Anti-recBbPDI antibody titre determination 
A blood sample was collected and serum titre determined by ELISA using as antigen to 
sensitize the plates recBbPDI, at 0.2 μg/well in carbonate buffer 0.5 M (pH 9.5), overnight at 
4ºC. As secondary antibody a goat anti-mouse alkaline phosphatase-conjugated IgG (heavy 
and light chain) (Sigma) diluted at 1:5000. Incubations with antibodies were carried out at 37 
ºC in the dark. p-Nitrophenylphosphate (Sigma) (1 mg ml−1) in 100mM glycine containing 1 
mM MgCl2 and 1 mM ZnCl2, pH 10.4 was used as enzyme substrate and the plate incubated 
30 minutes in the dark at room temperature. The absorbance was read at 405nm in a TIM 






3.2.2.3 Cell fusion and HAT selection 
Myeloma cells Sp2/0 Ag14 were maintained in vitro in exponential growth in Dulbeco’s 
Minimal Essential Medium (DMEM) supplemented with 10% fetal calf serum at 37 °C, 5% 
CO2 and 95% of relative humidity. They were collected by centrifugation (300 g for 5 min.), 
washed twice in serum-free medium and counted by trypan blue exclusion in a Neubauer 
chamber. 
In a laminar flow hood, the spleen was transferred to a petri dish and then repeatedly 
injected with serum-free DMEM using a 25 gauge needle to drive the spleen cells free into 
the medium. The cells are harvested by centrifugation (300 g for 5 min.), washed twice in 
medium and counted as above. 
A third and final wash in serum-free DMEM was made while combining splenocytes (108) 
and myeloma cells (5×107) in the same tube and centrifuging at 300g for 5 min. The 
supernatant was discarded and care was taken to assure that the cell pellet is dry. Cell were 
fused in the presence of 50% polyethylene glycol (PEG, Hybri-Max™ Sigma): while gently 
stirring, 0.8 mL PEG was gradually added over a period of 1 min; then, one milliliter of 
serum-free DMEM was added slowly with gentle agitation over one minute, and the PEG 
further diluted with new addition of 20 mL of DMEM over a 4 minute period with gentle 
agitation. The cells were centrifuged and resuspended in 50 mL of selection medium (DMEM 
supplemented with 1×10−4M Hypoxanthine, 4×10−7 M Aminopterin, 1.6×10−5 M Thymidine 
(HAT, Sigma) and with 10% (v/v) inactivated fetal calf serum), 100 µL distributed through 8 
microculture plates wells and incubated at 37 °C, 5% CO2 and 95% of relative humidity. On 
day one 100 µL of selection medium was added to each well and, every 2 to 3 days after, 
half the medium of each well was replaced with fresh medium. When hybrids start to grow 
and be visible under the inverted microscope, the supernatants were tested by ELISA for 
antibody presence. 
3.2.2.4 Cell expansion and cloning 
Positive wells for anti-recBbPDI antibody presence were expanded gradually to 24 wells 
plates, T25 and T75 culture flasks. When semi-confluent monolayers were achieved cells 
were frozen in liquid nitrogen and the supernatant stored for testing antibody presence. For 
cloning, selected flasks were scrapped, the hybrid cells centrifuged at 300 g for 10 minutes 
and then resuspended in culture medium (DMEM supplemented with 10% heat-inactivated 
fetal bovine serum, 20 mM HEPES, 250 g/mL amphotericin B, 100 U/mL penicillin and 100 
g/mL streptomycin). The number of hybrid cells was determined by counting with trypan 
blue exclusion in a Neubauer chamber, and the concentration of cells adjusted to 5 cells/mL. 





microculture plates and incubated as previously described. On day one 100 μL of culture 
medium was added to each well and, every 2 to 3 days after, half the medium of each well 
was replaced with fresh medium. When cells started to grow and be visible under the 
inverted microscope, the supernatants were again tested by ELISA for antibody presence. 
Positive wells were gradually expanded to 24, 12 and 6 wells plates. At this stage 
supernatants were also tested by western blot (WB), over recBbPDI and its truncated 
versions, and indirect immunofluorescence (IFAT), over fixed B. besnoiti tachyzoites, in order 
to distinguish different antibodies. Desired flasks were selected to proceed once more with 
cloning as just described. Again, positive wells for antibody production were expanded and 
the cell clones supernatants were tested by ELISA, WB and IFAT. 
3.2.2.5 Enzyme-linked immunosorbent assay (ELISA) 
Soluble protein extracts were prepared from purified tachyzoites of B. besnoiti, N. 
caninum and T. gondii by sonication. RecBbPDI (0.2 μg/well) or soluble protein extracts (2 
μg/well) coated plates were incubated with mAb (1μg/mL), for 1 hour at 37 °C. As secondary 
antibodies, AP-conjugated anti-mouse polyvalent immunoglobulins (G,A,M) (Sigma) were 
used in a 1:10.000 dilution. p- Nitrophenylphosphate (Sigma) (1 mg ml−1) in 100mM glycine 
containing 1 mM MgCl2 and 1 mM ZnCl2, pH 10.4 was used as enzyme substrate. The plate 
was incubated 30 minutes in the dark at room temperature and the absorbance was read at 
405 nm in a TIM 200 Inter Med plate reader. 
3.2.2.6 Western blot (WB) 
Protein samples prepared from purified tachyzoites of B. besnoiti, N. caninum and T. 
gondii, and purified recBbPDI and domains a, b, b’ and a’c were separated by SDS–PAGE 
(12%) and blotted onto nitrocellulose membrane. For ease of operations, a Prep/2D comb 
was used, so that small strips from the nitrocellulose membrane could be cut for batch 
analysis. Also, considering the different molecular weights, recBbPDI, domain a and domain 
b’ were pooled together in the same membrane. Membranes were blocked with 1% fish 
gelatin solution, probed with the mAb (hybrid cell culture supernatant or 2 μg/mL of purified 
mAb) and then incubated with an AP-conjugated secondary antibody (Sigma). Enzyme 







Purified parasite tachyzoites were allowed to adhere to poly-L-lysine-coated microscopy 
coverslips for 30 min, and were fixed for 10 min with cold (-20°C) methanol. Parasites were 
then probed with mAb supernatant and FITC-conjugated anti-mouse antibodies (Invitrogen). 
To visualize the entire cells, parasites were simultaneously probed with rabbit anti-B. besnoiti 
(Cortes et al., 2006b) and TRITC-conjugated anti-rabbit antibodies (Invitrogen). All these 
sera were used at 1:500 dilutions; supernatants were used undiluted. DNA was stained with 
DAPI (1 μg mL; Sigma) for 2 min and the slides were mounted with Mowiol (Calbiochem) and 
examined under a UV light microscope. 
3.2.2.8 Monoclonal antibody purification and isotype determination. 
The clones selected for purification were gradually adapted to serum free medium (EX-
CELL®, Sigma) and expanded to 175cm2 tissue culture flasks. Secreted antibodies from the 
cell culture medium were collected by centrifuging at 300g for 10 minutes to sediment cells 
and filtering through a 0.45 μm PVDF membrane. The antibody was purified by affinity 
chromatography using HiTrap Protein G HP columns (GE Healthcare), accordingly to the 
manufacturer instructions. All fractions were collected and analyzed by SDS-PAGE. 
Fractions of purified mAb were pooled and concentrated using an Amicon Ultra 15 with a 
nominal molecular weight cut off of 50 kDa. Antibody concentration was determined using a 
NanoDrop 2000 spectrophotometer with the pre-configured IgG reference (extinction 
coefficient of 13.7 M-1cm-1 at 280 nm for a 1% (10 mg/mL) IgG solution) 
The isotype of the antibodies obtained was determined by ELISA, using a commercial kit 
accordingly to the manufacturer’s instructions (Mouse Mono Ab-ID Kit, Zymed). 
3.2.2.9 Storage of hybrid cells 
Throughout the process of mAb production, hybrid cells were frequently frozen in liquid 
nitrogen. For that, cells were scraped from the tissue culture flasks, centrifuged at 300 g for 
10 min, resuspended in plain DMEM and placed on ice. Cells were counted in a Neubauer 
chamber by trypan blue exclusion and the concentration adjusted to approximately 2x107 
cells/mL. Ice cold frozen medium (DMEM with 40% FBS and 20% DMSO) was then slowly 
added to the cell suspension while gently stirring, yielding a final suspension of 
approximately 107 cells in DMEM with 20% FBS and 10% DMSO. Cell suspension was 





Thawing of cells was done rapidly in a 37 °C water bath. The cells were transferred to a 
culture flask already with 37 °C heated culture medium and left in the incubator for 12 hours. 
Cells were then washed twice with PBS and fresh culture medium added. 
3.2.3 Epitope prediction 
Prediction of mAb epitope recognition in BbPDI was made combining in silico prevision 
based in the amino acidic sequence and the three-dimensional protein structure with the 
results obtained with WB and ELISA. Linear prediction of epitopes was done with BepiPred 
(http://www.cbs.dtu.dk/services/BepiPred/) (Larsen, Lund & Nielsen, 2006), based on the 
deduced amino acid sequence encoding BbPDI (GenBank accession No. DQ490130). The 
prediction based on the 3D structure was performed by ElliPro 
(http://tools.immuneepitope.org/ellipro/) (Ponomarenko et al., 2008) based on the theoretical 
three-dimensional model developed in Chapter 2, and deposited in the PMDB 
(https://bioinformatics.cineca.it/PMDB/, (Castrignano et al., 2006)) under the identification 
number PM0075875. Multisequence alignment was executed by Clustal Omega from the 
European Molecular Biology Institute (http://www.ebi.ac.uk/Tools/msa/clustalo/) (Li et al., 
2015; Sievers et al., 2011), using the deduced amino acid sequence encoding B. besnoiti 
PDI (GenBank accession No. DQ490130), N. caninum PDI (AAV34741) and T. gondi PDI 
(AJ306291). 
3.3 Results and discussion 
For the successful production of novel monoclonal antibodies based on hybridoma 
technology there are three critical points. The first point is immunization to facilitate 
differentiation of B-lymphocytes into more matured forms. The second point is the fusion of 
targeted antigen-sensitized B-lymphocytes with myeloma cells and the in vitro selection of 
the hybridoma. The third point is the initial screening assay to access the desired mAb 
production (Shepherd & Dean, 2000; Tomita & Tsumoto, 2011). If these critical points are 
achieved, hybridoma technology allows generation of monoclonal antibodies with high affinity 
and specificity. 
Mice immunization followed the standard protocol of three antigen inoculations, two weeks 
apart, with recBbPDI emulsified in incomplete Freund’s adjuvant to slow down the otherwise 





neutrophils and macrophages at the site of injection, stimulating the proliferation of specific 
antibody-producing B cells and their precursors in the local lymph nodes and spleen. As 
mature antibody-secreting cells fuse poorly with myelomas and it is the committed precursors 
that are required for hybridoma production, the animals were given a final boost with antigen 
three days before the spleen was harvested, accordingly the protocol described by Shepherd 
and Dean (2000). With this protocol high antibody titers are usually obtained but these were 
confirmed by ELISA at the time of the third inoculation. In fact, all mice had titers higher that 
1:50000 two weeks after the second inoculation, as assessed by ELISA using recBbPDI 
sensitized plates, and were used to proceed to the cell fusion process as scheduled.  
The introduction of PEG for somatic cell fusion and its commercial (ready-to-use) 
availability resulted in standardization of the hybridoma technology (Davidson & Gerald, 
1976, 1977; Lane, 1985; Maggio, Ahkong & Lucy, 1976). Nevertheless, the fusion process 
itself is random and poorly controlled and hybrid cells will result from the desired fusion of 
myeloma cells with splenocytes, but also from the unwanted fusion between two splenocytes 
or two myeloma cells. Thus, a key point in this technique is the selection of the desired long-
term hybrid cell line (Goding, 1996), that was accomplished by using an enzyme-deficient 
myeloma cell line, unable to grow in hypoxanthine-aminopterin-thymidine (HAT) selective 
medium, a procedure first described by Littlefield (1964). The myeloma cell line Sp2/0 Ag14, 
was engineered to be deficient in the enzyme hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT). When the main biosynthetic pathway for guanosine is blocked by the 
aminopterin added to the medium, HGPRT becomes essential in the salvage pathway for 
DNA synthesis, by converting the hypoxanthine to guanosine monophosphate. In this way, 
HGPRT-negative cells (i.e. immortal myeloma cells) will die when cultured in HAT medium, 
but they can survive if they are made HGPRT-positive my fusing with and HGPRT-positive 
cell such as a splenocyte. Every cell not immortalized by fusing with a myeloma cell will die 
within days of in vitro culture (Goding, 1996; Hope & Graves, 1978; Shepherd & Dean, 
2000).  
The initial screening of the hybridoma culture supernatants for specific antibody 
production also represents a key step for the success of the technique, since it is on the 
basis of these results that a hybridoma colony is picked, expanded and cloned. Initial testing 
was done by indirect ELISA and started when considerable cell growth was visible under the 
inverted microscope, usually around the 10th to 15th day post-fusion. At this time testing has 
to be quick and specific considering the large number of supernatants to test and so, it relied 
solely on the recognition of recBbPDI in ELISA. A polyvalent and polyclonal affinity purified 
secondary antibody was used in order to guarantee that we could detect all the expected 
classes of antibodies (IgG, IgM and IgA). Best performing positive wells were gradually 





supernatants available initial screening was diversified in an attempt to perceive differences 
in the mAbs secreted. In this way, selection for native B. besnoiti PDI was accomplished by 
labeling B. besnoiti tachyzoites by IFAT and soluble B. besnoiti tachyzoites protein extracts 
by ELISA as well as total parasite protein extracts by WB. For differences in epitope 
recognition truncated versions of BbPDI were used for screening, both by ELISA and WB. 
The screening results for the fusions performed were always consensual in the way that no 
differences were observed when testing by ELISA (where conformational epitopes are 
recognized) or by WB (where linear epitopes are labeled), i.e., independently of the antigen 
used for labeling (soluble extracts, purified protein or domains) either we obtained positive 
supernatants in both techniques or negative ones for both. Regarding PDI domain 
recognition, we noticed that the vast majority of antibodies produced recognized domain a’c, 
since around 90% of positive supernatant hybridomas tested labeled this domain. No 
labeling, in either WB or ELISA, was achieved for domains a and b and the remaining 10% 
were divided in supernatants that recognized the domain b’ and supernatants that labeled 
only the full length PDI and not any domain. Considering that mice were immunized with full 
length recBbPDI, that was functionally active, we can consider domain a’c as more 
immunogenic than the others domains. 
After the screening process, 5 hybridoma cell lines were selected from the panel of hybrid 
cells produced. Differences in the labeling of recBbPDI and truncated versions produced by 
WB and ELISA were the basis for picking different hybridomas, since the IFAT never 
produced differences in the labelling of B. besnoiti tachyzoites among the antibodies tested. 
However, we could never achieve the labeling of domain a or domain b by ELISA or WB. 
The selected cells were cloned by the limiting dilution method, following standard protocols 
(Coller & Coller, 1983; Lefkovits & Waldmann, 1984; Waldmann & Lefkovits, 1984). After 
cloning, hybridomas were again tested for the production of mAb by the methods just 
described and expanded. It is not uncommon that hybridomas suffer chromosome lost and 
sometimes the ability to produce antibodies, which warrants the need for continuous 
screening along all processes of mAb production (Goding, 1996). In fact, this happened with 
one of the cell lines picked for cloning. Hybridoma selection was once more based on the 
screening results but care was taken to pick up a hybrid cell line derived from a single 
colony. Nevertheless, to be absolutely sure that we ended up with a true clone, a second 





For purification, with the loss of mAb production ability of one of the cell lines, we ended 
up with 4 different hybrid cell lines, each producing a different mAb. At this time, a chemically 
defined serum free medium was used to expand cells, in order to guarantee that no 
interference from proteins in the FBS would hamper the purification method or the purity of 
obtained mAbs. Adaptation to serum free medium was previously tested, as well as the mAb 
production ability in the new medium. Initially, crescent amounts of serum free medium were 
gradually used, while reducing the normal medium. Later, we could assess that medium 
change could be made immediately without prejudice to cell viability or mAb production 
capability. Purification was performed using a peristaltic pump and HiTrap Protein G HP 
columns in aseptic conditions (Figure 19). 
Figure 19. Coomassie stained SDS-PAGE (10%) of 
purified mAb (only elution fractions are shown). Under  






Characterization of the purified mAbs was confirmed by defining the immunoglobulin 
isotype, using a commercial kit, and repeating the screening assays. Also cross reactivity 
with N. caninum and T. gondii was evaluated by ELISA and WB, since there is a high level of 
identity (88%) and similarity (96%) between PDI protein sequences of these apicomplexan. A 
resume of mAb characterization is presented in Table 5. All four mAb obtained are IgG1, with 
a Kappa light chain and can label both recBbPDI and B. besnoiti tachyzoite PDI by ELISA, 
WB and IFAT. Concerning domain recognition, mAb T8a and S4a label the domain a’c, while 
mAb R60b recognizes domain b’. Monoclonal antibody S16p was unable to recognize any of 
the produced truncated PDI fragments and is probably directed to a junction region of these 
fragments (Figure 20). Regarding PDI recognition of the above mentioned closely related 
Figure 20. Western blot analysis of monoclonal antibodies T8a, S4a, 
S16p and R60b over recBbPDI and truncated version produced, 
corresponding to domains a, a’c, b and b’. 
Schematic representation of probed nitrocellulose membrane is 
presented in the legend on the right. Considering  the molecular weight of 
antigens, membrane had only domain b (1), only domain a’c (2) or 
recBbPDI with domain a and b’ (3). Mouse Anti-PDI polyclonal serum 
was used as a positive control. All mAbs recognize the full length 
recBbPDI. Mab T8a and S4a labels domain a’c. Mab R60b labels domain 





apicomplexan parasites, mAb T8a labels only B. besnoiti PDI; mAb S4a and S16p cross 
reacts with N. caninum PDI and labels it in both techniques; likewise, mAb R60b recognizes 
N. caninum PDI in both the ELISA and WB but is also able to recognize T. gondii PDI, but 
only by WB (Figure 21). In this way, mAb T8a is probably directed to a non-conserved region 
of domain a’c, since it only labels B. besnoiti PDI, while mAb S4a is probably directed to a 
conserved region of a’c. To better elucidate mAb epitope recognition and understand 
differences in specificity, the alignment of the amino-acidic PDI sequences of B. besnoiti 
(GenBank accession No. DQ490130), N. caninum (AAV34741) and T. gondi (AJ306291) was 
done, as well as the in silico prediction of epitopes, in an attempt to suggest probable sites 
for epitope recognition. Two in silico methods were used, one based on the amino acidic of 
PDI and the other based on the three-dimensional structure of the protein and the prediction 
output was compared with the results obtained in antigen recognition (Figure 22). 
 
 
Table 5. Resume of monoclonal antibody characterization.  
Labeling of antigens, either recBbPDI and truncated versions corresponding to domains a, b, b’ 
and a’c or total protein extracts of B. besnoiti, N. caninum and T. gondii, is marked with +. 
 Monoclonal antibody 
 T8a S4a R60b S16p 
   
Immunizing antigen GST-PDI His-PDI 
Isotype IgG1, Kappa light chain 
Antigen recognition     
Full length recBbPDI + + + + 
Domain a     
Domain b     
Domain b’   +  
Domain a’c + +   
Specificity     
B. besnoiti 
ELISA + + +  
WB + + + + 
N. caninum 
ELISA  + + + 
WB  + + + 
T. gondii 
ELISA     








Figure 21. Evaluation of cross reactivity of monoclonal antibodies T8a, S4a, R60b 
and S16p with PDI of N. caninum and T. gondii tachyzoites. 
Total protein extracts of B. besnoiti (1), N. caninum (2) and T. gondi (3) were 
separated by SDS-PAGE and blotted into nitrocellulose membrane, as well as 
recBbPDI (4). Polyclonal anti-PDI serum was used as positive control and a naïve 





                                     ºººººººººººººººººº   ººººººººººº 
                                            ***** 
BbPDI    MRAGVCYLALAVGLLAGASVCCAAEDEVVTVLTASNFDDTLKKHEIVLVKFYAPWCGHCK 60 
NcPDI    ....FSFVL.......T...Y....E.A..............NT................ 
TgPDI    ....FSFAL.......T.V.YS...E.A..............NN................ 
 
 
                     ººººººººººººººººººººººººººººººº    ººººº 
           ******      *           ****************       *********** 
BbPDI    RMAPEYEKAAKMLKEKGSSVLLAKVDATAETDIADKQGVREYPTVTLFRNEKPEKFTGGR 120 
NcPDI    ...........I......KIM.......S...............L.....Q......... 
TgPDI    ...........T......KIV.......S...............L....K.....Y.... 
 
 
                           ººººººººº          ºººººººººººººººº 
         ***                  ***********       *******        ***** 
BbPDI    TAEAIVEWIEKMTGPALIEVEGSVDDKVTKESPIAFVGEVKSKDSEMAKLFEEVANESRQ 180 
NcPDI    ................VT....KPEEQ..........A.LS....D......D....... 
TgPDI    ................VT.....AE......A.....A.LA....D.............. 
 
 
              ºººººººººº         ºººººººººº 
                 *****      ***************                 * 
BbPDI    LGKFFVKYDAPAEKIYSLRYEEGTDDFSGKTKDELKKFVETESFPLLGPINAENFRKHID 240 
NcPDI    ....LA..GVSD............EP.T...........D.................Y.. 
TgPDI    ..R.LA..G.SD............EA.T...........D.................Y.. 
 
 
                    ººººººº     ººººººººº                     ºººº 
                    *************  ****           ***** 
BbPDI    RDLDLVWLCGTEKDFDDSKAAVREAAKKLRDTRSFVWLDTDQFKAHAENALGITEFPGLV 300 
NcPDI    ................EA..........................G............... 
TgPDI    ................EA.T................. .......G............... 
 
 
                   ººººººººººººººº  ºººººººº       ººººººººººº 
                      *****            ***** *************** 
BbPDI    FQGKKGRFVLPEATTSLKDASKIIKFFEDVDAGKIERSLKSEPVPEKQEEAVKVVVGKNF 360 
NcPDI    ..S...........S.....A..S........................D........... 
TgPDI    ..S.................A..SQ..D..E....D............D........... 
 
 
             ºººººººº    ººººººººººººººººººººººººººººº 
                                           ****          ************ 
BbPDI    EEMVIQKDKEVLLEIYAPWCGYCKSFEPIYKEFAEKYKDVDHLVVAKMDGTANETPLDEF 420 
NcPDI    .........D.M..........................................A..E.. 
TgPDI    .........D.M.............................................E.. 
 
 
                  ºººººººººººººººººººººººººººººººº 
          *           ***************       **************** 
BbPDI    NWSSFPSIFFVKAGEKTPMKFEGSRTVEGLTEFINKHGSKPLKKDDKGEEL* 471 
NcPDI    S.................................................. 
TgPDI    S................................V................. 
 
Figure 22. Epitope prediction of monoclonal antibodies produced in B.besnoiti PDI. 
Alignment (Clustal Omega) of the deduced amino acid sequence encoding B. besnoiti (BbPDI; 
GenBank accession No. DQ490130), N. caninum PDI (NcPDI; AAV34741) and T. gondi PDI (TgPDI; 
AJ306291). Light gray highlights hits to the Pfam thioredoxin model (PF00085) and medium gray 
denotes the thioredoxin family active site Prosite pattern (PS00194). The characteristic catalytic 
thioredoxin motifs CxxC are boxed. The C-terminal putative ER retention signal is displayed on a black 
background. The stop codon is indicated by *. Delimitation of a, b, b’ and a’c truncated versions of 
recBbPDI (as they were cloned and expressed) is showed by brackets and underlined; Epitope 
prediction by BepiPred (*) and ElliPro (º) for BbPDI is shown above its sequence. Arrows point 
hypothetical mAb epitope recognition considering results obtained for the labelling of total protein 
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Through hybridoma technology we were able to obtain four monoclonal antibodies from 
mice immunized with recBbPDI. These were all able to recognize recBbPDI in WB and 
ELISA as well as natural B. besnoiti PDI in IFAT, WB and ELISA. Two mAbs (T8a and S4a) 
are directed to antigenic determinants in domain a’c, one (R60b) to antigenic determinants in 
domain b’, while the other is probably directed to a junction between the truncated versions 
produced. The ability to recognize PDI from the closely related parasites N. caninum and T. 
gondii was evaluated, and mAb T8a was found to be specific for BbPDI. These mAb may 
represent a valuable tool for research in the biology of this apicomplexan parasite and will 
allow for further studies about the role of PDI in B. besnoiti host cell invasion and host 
immune response. 
The production of monoclonal antibodies through the hybridoma technology although 
relatively simple in the procedures is a very laborious and time consuming task. When 
expanding the hybrid cells, both after the fusion and cloning process, we are also increasing, 
almost exponentially, the amount of cell culture plates or flasks in the laboratory. These need 
to be taken care and frequently tested for mAb production and early on, as soon as possible, 
stored in liquid nitrogen. The mAbs here described and characterized are in fact the result of 
three distinct fusions of mice spleens with hybrid cells and may represent the tip of the 
iceberg of the potentially different antibodies that the obtained hybridomas can produce. In 












Chapter 4  | 
Kinetic characterization of B. besnoiti PDI and its 












Protein disulfide isomerase (PDI) is one of the most abundant proteins of the eukaryotic 
cell, found primarily in the endoplasmic reticulum but also in other intracellular compartments 
and at cell surface (Hillson et al., 1984; Turano et al., 2002). It was the first folding catalyst to 
be reported half a century ago and the first enzyme known to possess disulfide isomerase 
activity (Givol et al., 1964; Goldberger et al., 1963; Goldberger et al., 1964; Venetianer & 
Straub, 1963a, 1963b). PDI is a member of the thioredoxin superfamily (Ferrari & Soling, 
1999), that is characterized by one or more domains with sequence similarity to thioredoxin 
(a ubiquitous 12 kDa α-β protein), and an active site with two cysteines in a CxxC motif 
(Wilkinson & Gilbert, 2004). PDI has four structural thioredoxin-like domains, a, b, b’, and a’, 
a linker region x between the b’ and a’ domains, and a C-terminal acidic extension c. The 
enzyme catalyzes a variety of thiol-disulfide exchange reactions, including the formation and 
rearrangement of disulfide bonds during oxidative protein folding (Puig et al., 1997), and can 
also act as a chaperone, even for substrate proteins that do not form disulfide bonds (Cai, 
Wang & Tsou, 1994; Primm, Walker & Gilbert, 1996; Puig & Gilbert, 1994b; Wang & Tsou, 
1993). The a-type domains contain the active site, and are sufficient alone to perform thiol–
disulfide exchange reactions in simple substrates (Darby & Creighton, 1995; Darby, Penka & 
Vincentelli, 1998; Westphal, Darby & Winther, 1999). The b-type domains form a rigid base, 
providing a spacer for the attachment of more mobile active site domains that can access 
substrates from opposite sides simultaneously (Kozlov et al., 2010). They jointly contribute to 
the binding site, but the b’ domain is the principal peptide and nonnative protein-binding site, 
and is required for isomerization reactions (Byrne et al., 2009; Darby et al., 1998; Denisov et 
al., 2009; Hatahet & Ruddock, 2009; Klappa, Ruddock, darby & Freedman, 1998b; 
Pirneskoski et al., 2004). 
Several assays have been used to determine the activities of PDI and the reactions it 
catalyzes, which are all thiol-disulfide exchange reactions. We should distinguish at least 
three overall reactions that PDI can catalyze (Hatahet & Ruddock, 2009; Hawkins, Blackburn 
& Freedman, 1991): 1) Oxidation reactions, where, as the name suggest, the substrate 
attains a higher state of oxidation through the gain of electrons or a loss of oxygen. Thus, the 
protein or peptide substrate dithiol is oxidized to the disulfide state, with the simultaneous 
loss of a disulfide from the PDI active site, that must be reoxidized to complete the catalytic 
cycle. In vitro, oxidized glutathione (GSSG) is usually used as the terminal electron acceptor. 
This generates reduced glutathione (GSH) and results in a change in the reduction potential 
and redox-buffering capacity of the buffer. Care must be taken to ensure that sufficient 





the reaction does not significantly affect the folding efficiency or yield. If no GSSG or 
equivalent electron acceptor is present, PDI is also able to reduce a disulfide bond in one 
nonnative protein molecule to form a disulfide in another nonnative protein. 2) Reduction 
reactions, where the substrate is driven to a lower oxidation state, through the gain of 
electrons or the loss of oxygen. Here, a protein or peptide substrate disulfide is reduced to 
the dithiol state, with the concomitant gain of a disulfide in the PDI active site. PDI must be 
reduced as well to complete the catalytic cycle. In vitro, GSH or DTT is often used as the 
electron donor. Again, this results in a change in the reduction potential and redox-buffering 
capacity of the buffer. 3) Isomerization reactions in which the disulfides and thiols in a protein 
or peptide substrate are rearranged to give a different disulfide-bonding pattern. In direct 
isomerization, no net change exists in the redox state of the active site of PDI, and so no 
other redox reagents are required.  
The various in vitro assays hitherto described, despite the richness of variations between 
them, can be grouped in three major categories, according to Hatahet and Ruddock (2009): 
those based on the gain of activity of a substrate protein, widely used, in part because of 
their sensitivity and relative simplicity. They can detect activity after only a very small 
percentage of the refolding protein has reached the active state. Here the classic example is 
the use of ribonuclease A (RNase A), a one-domain protein that contains four disulfide bonds 
in the native state. The starting state of RNase can be: (a) reduced RNase (Creighton et al., 
1980; Lyles & Gilbert, 1991; Xiao et al., 2004), to give an assay that looks primarily at 
oxidation; (b) ‘‘scrambled’’ RNase (Ibbetson & Freedman, 1976; Lambert & Freedman, 1983; 
Walker & Gilbert, 1997), where the protein has been reduced and allowed to oxidize under 
denaturing conditions, which produces a set of proteins in which the disulfide bonds are 
predominantly nonnative, to give an assay that looks primarily at isomerization, or (c) 
glutathionylated RNase T1 (Ruoppolo & Freedman, 1994, 1995), in which all of the cysteines 
in the protein are glutathionylated at the start, in an assay that looks at isomerization. One 
problem associated with these assays is that they do not directly measure disulfide-bond 
formation in the substrate protein and a gain of activity does not always directly correlate with 
disulfide-bond formation, since many folding intermediates may present biological activity. In 
addition, the biophysical conditions of the system are often varied, and care must be taken to 
assure that any changes observed relate to changes in the activity of PDI and not changes in 
activity or stability of the folded substrate, its folding intermediates or the reaction buffer. The 
second problem relates to the complexity of the substrate, since 764 different disulfide-
bonded states are theoretically possible for RNase A. Certainly, only a small fraction of these 
may be experienced during refolding, but each intermediate is in fact a different substrate for 
PDI with different requirements for catalysis, and a global assay, such as the regain of 





in that the starting material itself is not homogeneous (and shows considerable batch-to-
batch variation). The third problem is related to assaying the activity of RNase, where 
essentially two different assays are used: (a) the hydrolysis of RNA (Goldberger et al., 1964; 
Ibbetson & Freedman, 1976; Janiszewski et al., 2005; Laboissière, Sturley & Raines, 1995; 
Laboissière, Chivers & Raines, 1995), which is the natural substrate for this enzyme, but 
which requires very small changes in absorbance to be accurately measured with time, 
imposing the use of a good double-beam spectrophotometer. This method was first 
described by Anfinsen, Redfield, Choate, Page and Carroll (1954); or (b) the hydrolysis of 
cCMP (Lyles & Gilbert, 1991; Walker & Gilbert, 1997; Walker, Lyles & Gilbert, 1996; Xiao et 
al., 2004), an assay that, for detailed kinetics, requires the accurate measurement of very 
high absorbance values. In this way, although these methods can be used to measure the 
relative order of activity and compare different proteins, they are poor methods to determine 
PDI activity quantitatively, given the complexity of the system and the heterogeneity of the 
starting material in the ‘‘scrambled’’ RNase assay. Among other examples of assays that fall 
in this category we point out the use of denatured and reduced lysozyme (Goldberger et al., 
1964; Puig, Lyles, Noiva & Gilbert, 1994) and the use of riboflavin-binding protein (Rancy & 
Thorpe, 2008). The first is based on the regain of lysozyme activity, that is measured by 
following the decrease in absorbance at 450 nm of a Micrococcus lysodeicticus cell wall 
suspension. The refolding of lysozyme has been widely studied and served as an important 
model for the understanding of protein folding mechanisms (Chaffotte, Guillou & Goldberg, 
1992; Dobson, Evans & Radford, 1994; Eyles, Radford, Robinson & Dobson, 1994; Hooke, 
Radford & Dobson, 1994; Lin, Ruaan & Hsieh, 2007; Matagne, Radford & Dobson, 1997; 
Mizuguchi, Arai, Ke, Nitta & Kuwajima, 1998; Radford, Buck, Topping, Dobson & Evans, 
1992; van den Berg, Chung, Robinson & Dobson, 1999; van den Berg, Chung, Robinson, 
Mateo & Dobson, 1999).  
A second category of assays is based on changes in the biological/physical properties of 
a substrate. The insulin-reduction assay is the most used assay and was first described in 
works with thioredoxin by Holmgren (1979). It was latter adapted by Luthman and Holmgren 
(1982), Lundstrom and Holmgren (1990) and more recently by Smith et al. (2004), that 
suggested it as a good high-throughput turbidimetric assay for screening inhibitors of PDI 
activity. In this assay, PDI facilitates the reduction of insulin by GSH or DTT with the 
consequent aggregation of the β-chains of insulin. This aggregation results in turbidity and 
changes in light scattering, that are monitored by the increasing in absorbance at 650 nm. 
Again, this assay is very useful to determine the relative order of activity of different catalysts, 
but it is a poor method for quantification. Because the assay measures aggregation 
properties of the product, it is also very sensitive to changes in biophysical conditions. A 





reaction proceeds in glutathione redox system in conjunction with glutathione reductase 
(GR). In this way, the GSSG formed by the reduction of insulin by GSH is reduced by GR, 
with the concomitant oxidation of nicotinamide adenine dinucleotide phosphate (NADPH) and 
a decrease in absorbance at 340 nm (Maeda, Ado, Takeda & Taniguchi, 2007). This assay is 
quantitative, but only up to the time point at which turbidity starts to contribute to the apparent 
changes in absorbance at 340 nm due to light scattering (Hatahet & Ruddock, 2009). Other 
assays that fall into this category are peptide-based thiol-disulfide exchange assays in which 
an associated change in substrate fluorescence occurs (Christiansen, St Hilaire & Winther, 
2004; Raturi, Vacratsis, Seslija, Lee & Mutus, 2005; Westphal, Spetzler, Meldal, Christensen 
& Winther, 1998). 
A third grouping of assays is based on quenching dithiol-disulfide exchange reactions and 
then subsequently monitoring the disulfide bond state of the substrate. These quenching-
based assays are considerably more time consuming and are always discontinuous, 
representing snapshots of the overall reaction at different time points. However, they have 
the potential to provide much more detailed kinetic analysis of even complex systems 
(Hatahet & Ruddock, 2009). Although various peptides and proteins have been used, the 
classic substrate in this type of assay is the bovine pancreatic trypsin inhibitor (BPTI) 
(Creighton et al., 1980). 
PDI and PDI-like enzymes were identified in numerous apicomplexan parasites, as 
previously described (see Introduction, Chapter 1), but for only a few their corresponding 
enzymatic activity was demonstrated in vitro, namely Giardia lamblia (Knodler et al., 1999), 
Leishmania major (Achour et al., 2002), L. donovani (Amit et al., 2014; Padilla et al., 2003), 
L. amazonensis (Hong & Soong, 2008), Neospora caninum (Liao et al., 2006; Muller et al., 
2008), Plasmodium falciparum (Mahajan et al., 2006; Mouray et al., 2007), and 
Trypanosoma brucei (Rubotham et al., 2005). There is a growing interest in this enzyme, 
since it has been described as a immunodominant antigen (Costa et al., 2013; Ma et al., 
2009; Shin et al., 2004; Shin et al., 2005; Zhou et al., 2014), an important virulent factor 
(Achour et al., 2002; Amit et al., 2014) and a target for naturally occurring secretory IgA (Liao 
et al., 2006; Meek et al., 2002a; Meek et al., 2002b; Meek et al., 2000). Furthermore, PDI is 
believed to play an important role in host cell interaction and parasite survival, since several 
studies demonstrate that inhibition of PDI has a negative correlation with parasite in vitro 
proliferation. For N. caninum, preincubation of tachyzoites with PDI inhibitors, both drugs 
(5,5’-dithiobis(2-nitrobenzoic acid) (DTNB), p-chloromercuribenzoic acid (pCMBA), tocinoic 
acid and bacitracin) and anti-PDI antibodies resulted in decreased adhesion of tachyzoites to 
the host cell, with a consequent inhibitory effect on the growth of the parasite (Liao et al., 
2006; Naguleswaran et al., 2005). Also, in L. amazonensis and L. major promastigotes, 





parasites (Achour et al., 2002; Hong & Soong, 2008), with higher concentrations of bacitracin 
and pCMBA halting parasite growth. In addition, nitazoxanide (NTZ) and some non-nitro-
thiazolides compounds efficiently inhibited the in vitro propagation of N. caninum (Esposito et 
al., 2005), B. besnoiti (Cortes et al., 2007a), T. gondii (Galvan-Ramirez Mde et al., 2013), G. 
lamblia (Adagu et al., 2002; Muller et al., 2006) and Cryptosporidium parvum (Gargala et al., 
2000; Giacometti et al., 2000; Theodos et al., 1998). Thiazolides are a promising broad 
spectrum anti-parasitic and anti-viral family of drugs, that are also inhibitors of the enzymatic 
activity of PDI, with high affinity for this enzyme (Muller et al., 2008). Furthermore, recent 
works in neosporosis, applying the acute disease mouse model, determined 90% protection 
against disease and significantly reduction of cerebral parasite burden and numbers of viable 
tachyzoites in brain tissue, when mice were intranasal vaccinated with recombinant N. 
caninum PDI (Debache et al., 2010). Intraperitoneal vaccination was ineffective (Debache et 
al., 2010; Debache et al., 2011). However, this only shows that a protective effect of 
vaccination depends not only on the antigen but also on the route of antigen delivery 
(Hemphill et al., 2013). Altogether these are strong evidences that support the importance of 
PDI in apicomplexan parasites and host immune response, targeting this protein as a good 
candidate for anti-protozoan drugs and vaccine development, which warrants the need for 
further studies. 
Here we intend to evaluate the kinetic activity of recombinant PDI and active site 
truncated versions and test the sensitivity to known PDI drug inhibitors (bacitracin, tocinoic 
acid, DTNB and pCMBA) and anti-PDI monoclonal antibodies developed in this work and 
presented in Chapter 3. The assay of choice for measuring PDI activity was the assay based 
in the insulin aggregation as described by Lundstrom and Holmgren (1990) and adapted by 
Smith et al. (2004), since it allows for further large scale screening of drug inhibitors. The 







4.2 Materials and methods 
4.2.1 Catalytic activity of recBbPDI and truncated versions, corresponding to the 
active domains a and a’c 
PDI activity was measured by a turbidimetric assay based on the polymerization of 
reduced insulin (Lundstrom & Holmgren, 1990) as adapted by Smith et al. (2004). The assay 
was performed in 96-well microtiter plates and all solutions were made freshly with assay 
buffer (AB): 100 mM potassium phosphate, 2 mM EDTA, pH 7. Reaction solution (RS) was 
made by diluting the enzyme in AB and adding 11 μL of Insulin (1.6 mM or 10 mg/mL; 
Sigma) to a total volume of 75 μL per well. For that, twice of the necessary volume of AB with 
enzyme was first prepared and then serially diluted 1:1 in separated tubes. To each tube the 
corresponding amount of insulin (i.e., 11 μL x no. of wells) was added and carefully agitated. 
Inhibitors or AB (10μL) were added to respective wells and then 70 μL of RS distributed 
through wells. The reaction was started by the addition of 20 μL of a 5 mM DTT solution. 
Absorvance at 650 nm was read at room temperature in a SPECTRAmax 340 pc microplate 
spectrophotometer, every 5 min, with a period of 30 sec agitation before each reading, for 60 
to 90 min. 
Enzyme activity was calculated from the increase in turbidity over time according to the 
formula:  
(EnzymeABS650 t – EnzymeABS650 t0) – (BlankABS650 t – BlankABS650 t0) 
 
Where “t” represents time and “blank” the reaction without enzyme. This formula allows 
the correction for the uncatalyzed rate of insulin aggregation observed in a parallel control, in 
the absence of PDI. 
 
4.2.2 PDI in the excretory-secretory compartment of B. besnoiti tachyzoites 
Freshly egressed B. besnoiti tachyzoites were collected and purified as previously 
described. For the preparation of excretory-secretory antigen (ESA) purified tachyzoites (108) 
were incubated in PBS and PBS with 1% ethanol at 37 °C for 15 minutes. Parasites were 
removed from supernatant by centrifuging at 800 g for 10 minutes at 4 °C. Supernatant was 
collected and a protease inhibitor cocktail (Roche) added. Pellet was resuspended in PBS 





Samples were separated by SDS-PAGE (12%) and transferred to nitrocellulose membranes. 
These were blocked overnight at 4 °C with 1% fish gelatin (Sigma) and probed with mouse 
anti-recBbPDI followed by incubation with alkaline phosphatase-conjugated goat anti-mouse-
IgG secondary antibody (Sigma) diluted 1:5000. The final enzyme reaction was developed 
using the BCIP/NBT kit (Bio-Rad). 
4.2.3 In vitro invasion assay 
Vero cells were grown to confluence in 12 mm glass coverslips. Freshly lysed out 
tachyzoites were collected and purified as previously described and 3.5x108 tachyzoites/mL 
were incubated at room temperature for 10 min with drugs in microtubes. Drops of 300 μl 
containing 108 tachyzoites were placed over the coverslips and incubated for 1 hour at 37°C 
with 5% CO2 and relative humidity over 95%. Coverslips were then washed and transferred 
to a new cell culture plate with fresh medium and incubated for 11 hours. Finally, coverslips 
were collected, prepared for IFAT and the number of parasitophorous vacuoles were counted 
in 40 different fields under a UV light microscope. 
4.2.4 Immunofluorescence 
Coverslips were washed with PBS, fixed with 4% paraformaldehyde at room temperature 
for 30 min and then permeabilized with cold methanol (-20°C) for 10 min. Unspecific binding 
sites were blocked with 3% BSA in PBS, for 30 min at room temperature. Parasites were 
then probed with rabbit anti-B. besnoiti (Cortes et al., 2006b) and FITC-conjugated anti-
mouse antibodies (Invitrogen). All sera were used at 1:500 dilutions. DNA was stained with 
DAPI (1 μg/mL; Sigma) for 2 min and the slides were mounted with Mowiol (Calbiochem) and 





4.3 Results and discussion 
4.3.1 Catalytic activity of recBbPDI and active domains. 
Initial activity assays were performed with a GST-tagged recBbPDI. While the recBbPDI 
produced in the Glutathione S-transferase (GST) Gene Fusion System was active and 
inhibited by bacitracin the activity levels were lower than the bovine PDI used as control (see 
Figure 13 on page 56). We were concerned that the relatively large size of the GST tag could 
difficult the PDI activity and since the purification of recBbPDI by cleavage of the GST tag 
was proven to be difficult and fastidious we changed the cloning strategy to produce a His-
tagged recombinant protein. A new full length B. besnoiti PDI, as well as the truncated 
versions corresponding to the domains a, b, b’ and a’c, were cloned, expressed and purified 
as described in chapter 3.  
The activity of recombinant His-tagged proteins expressed in E. coli, was tested by 
following the aggregation of insulin at 650 nm, as described by Smith et al. (2004). This 
assay looks only at the reduction of the insulin disulfide catalyzed by PDI but it was chosen 
because of its relatively simplicity and the possibility of being used for rapid screening of PDI 
inhibitors, as validated in the above mentioned work. We tested the recBbPDI activity, as well 
as that of the truncated versions corresponding to the active domains a (recBb-a) and a’c 
(recBb-a’c) and observed that increasing concentrations of enzyme, either the full length 
recBbPDI (Figure 23A) or the truncated version recBb-a’c (Figure 23B), results in a faster 
aggregation of insulin, measured by solution turbidity. Using the truncated version recBb-a in 
these experiments no enzymatic activity was detected (data not shown). 
  
Figure 22. Reductase activity measured by the aggregation of insulin of (A) recombinant B. besnoiti 
PDI (recBbPDI) and (B) truncated version corresponding to domain a’c (recBb-a’c). 
Results show that both recBbPDI (A) and recBb-a’c (B) are functionally active, in a dose dependent 
manner in the range of concentrations tested. The profile of activity is similar between the full length 
enzyme and the domain, but recBbPDI exhibited considerable higher activity levels, and a shorter lag 





The full length recombinant PDI and the domain a’c show a dose dependent cross-linking 
activity in the range of concentrations tested, from 0.05 mM to 1.75 mM and from 0.22 mM to 
14 mM, respectively. The profile of activity is similar and both enzymes present a decrease in 
the lag time with the increase in enzyme concentration, similar to what Maeda et al. (2007) 
has observed. Nevertheless, full protein presents a shorter lag time in all concentrations, 
since it starts the cross-linking activity of insulin earlier than the truncated version. For 
example, at 1.75 mM turbidity starts to be noticed at around 5 min for recBbPDI and at about 
40 min. for domain a’c. The higher concentration of a’c tested (14mM) starts to aggregate 
insulin and increase turbidity at the 25 min only. When comparing equimolar quantities, 
recBb-a’c exhibits considerable lower activity levels than the full length enzyme: only 10% of 
the recBbPDI activity at 0.22 mM and 0.44 mM and around 20 % at 0.88 and 1.75 mM. The 
multi-domain structure of PDI is known to be essential for high catalytic efficiency. Single a-
type domains (or mixtures of these) have poor activity toward protein substrates, but they 
can still be able to catalyze oxidation, reduction, and isomerization. Nevertheless, for more 
complex isomerization reactions, the entire molecule is required for full activity (Darby & 
Creighton, 1995; Darby et al., 1998; Hatahet & Ruddock, 2009). In a functional study with 
multi-domain constructs, Darby et al. (1998) demonstrated that reconstruction of the PDI 
molecule from the isolated a and a’ domains results in a progressive increase in catalytic 
efficiency as further domains are added. For more than 30% of expected activity, the minimal 
constructs required for the catalysis were either abb’ or b’a’c. Constructs without the b’ 
domain were less efficient catalysts in nearly all the reactions examined. The decrease to 
10% to 20% in the reductase capabilities of domain a’c is in agreement with what was 
described by Sun, Dai, Liu, Chen and Wang (2000) for human a’c PDI domain. However, 
Puig et al. (1997) reported for a 21-kDa C-terminal fragment of rat PDI (corresponding to 
domains a’c with 37 amino acid from b’ domain) an activity of 30% of that of PDI. Regarding 
the a domain, the lack of activity found agrees with what was described for yeast PDI, but not 
for human PDI. Katiyar, Till and Lennarz (2001), working with yeast PDI constructs also 
found no activity for a construct lacking 218 amino acids from the C-terminus (corresponding 
to the a domain with part of the b domain), but 30% activity for a construct lacking only 152 
amino acids from the C-terminus. For human PDI, a domain is reported to retain 50% of the 
activity of normal PDI (Darby & Creighton, 1995; Darby, Kemmink & Creighton, 1996), while 
the construct of ab together preserves from 13% to 22%, depending on the assay used (Sun 
et al., 2000). 
Comparing to previous results with GST-tagged recBbPDI, the His-tagged protein shows 
higher activity levels, attaining ABS values of 0.2 (at 1.75 mM) compared to the maximum of 
0.079 of the GST-tagged enzyme. The His-tagged PDI also shows higher amplitude of 





lower enzyme concentration to the higher, while GST-recBbPDI only shows a 1.8 fold 
increase. Interestingly, in these assays, GST-recBbPDI seems to show a ceiling effect above 
the 0.44 mM concentration, meaning that higher enzyme concentrations are not able to attain 
higher turbidity or ABS values. Comparing to bovine PDI (see Figure 13 on page 56), His-
recBbPDI shows about twice the activity levels, with a very similar profile of activity. Looking 
into equimolar quantities of enzyme, it is interesting to notice that the GST-recBbPDI shows 
higher aggregation of insulin at lower enzyme concentrations (0.05 to 0.22 mM) comparing to 
the His-recBbPDI, similar to what was described in chapter 2 for bovine-PDI used then as 
control. At enzyme concentration of 0.05 mM GST-recBbPDI shows twice the activity of His-
recBbPDI, at 0.11 mM shows 1.6 fold, at 0.22 both show similar activity, and beyond this 
concentration the situation is inverted, with His-recBbPDI at 0.44 mM showing around 1.6 
fold the activity of GST-recBbPDI, at 0.88 mM showing twice the activity and at 1.75 mM 
showing 2.6 fold more activity. Several studies showed that at substoichiometric 
concentrations PDI can have an anti-chaperone activity, facilitating the aggregation of the 
substrate protein (Puig & Gilbert, 1994a, 1994b; Puig et al., 1994; Puig et al., 1997; Song, 
Quan & Wang, 1997). However, an explanation for the different behavior of the GST-tagged 
and the His-Tagged enzyme is not clear for us. 
4.3.2. Drug inhibition. 
The activity of His-recBbPDI and recBb-a’c was tested in the presence of the known 
membrane impermeant PDI inhibitors bacitracin, tocinoic acid, 5,5′-dithiobis(2-nitrobenzoic 
acid) (DTNB) and 4-chloromercuribenzoic acid (pCMBA). Bacitracin is a potent 
metallopeptide antibiotic of narrow spectrum directed primarily against Gram positive cocci 
and bacilli that requires a divalent metal ion such as Zn2+ for its biological activity (Ming & 
Epperson, 2002). It is produced by Bacillus subtilis and Bacillus licheniformis as a mixture of 
closely related dodecapeptides, being bacitracin A the most abundant congener (Economou, 
Cocklin & Loll, 2013). Bacitracin was reported to be a PDI inhibitor in 1981 (Roth, 1981) and 
has been since widely used as a PDI specific inhibitor. More recently tough, this specificity 
was questioned by Karala and Ruddock (2010). Tocinoic acid, a cyclic hexapeptide (Cys-Tyr-
Ile-Gln-Asn-Cys) with a disulfide bridge between the terminal cysteines, DTNB and pCMBA 
are not specific for PDI. They react nonspecifically with free thiols and covalently modify 
surface sulfhydryl to prevent disulfide bond formation (Davis et al., 2002; Mandel et al., 1993; 







All drugs tested showed a dose dependent inhibition of enzyme activity, manifested in 
general by a longer lag phase and an attenuated increase in turbidity in the presence of 
inhibitor. Tested enzyme concentration ranged from 0.05 mM to 1.75 mM, for His-recBbPDI, 
and from 0.22mM to 7 mM, for recBb-a’c. Nevertheless, we noticed that for 0.22 mM of 
recBb-a’c we could not obtain consistency in the inhibition since the amplitude of the reaction 
was, by itself, very low and this concentration was disregarded. 
  
Figure 23. Reductase activity, measured by the aggregation of insulin, of recombinant B. besnoiti PDI 
(recBbPDI) in the presence of bacitracin. 
 Enzyme activity was tested in concentrations of 0.05 mM (A), 0.11 mM (B), 0.22 mM (C), 0.44 mM 
(D), 0.88 mM (E) and 1.75 mM (F) in the presence of 0.25 mM, 0.5 mM, 1 mM, 2 mM and 4 mM of 
drug. There is a dose dependent inhibition of reductase activity of recBbPDI in all enzyme 





Enzyme sensitivity to bacitracin was tested at concentrations ranging from 0.25 mM to 4 
mM of drug and a clear dose dependent inhibition was observed for both His-recBbPDI 
(Figure 24) and recBb-a’c (Figure 25). Inhibition varied from 5% to 80% in his-recBbPDI and 
from 1% to 50% in recBb-a’c depending on the molar ratio considered. The full length 
enzyme seems to be more sensitive than the domain a’c, since the higher drug concentration 
tested (4 mM) was able to inhibit enzyme activity in 80% for His-recBbPDI and only 50% in 
recBb-a’c in all enzyme concentrations tested. The mechanism of the inhibitory action of 
bacitracin on PDI is not clear yet. The only study addressing this issue hitherto published 
proposed the involvement of covalent binding of an open thiol form of bacitracin to free 
Figure 24. Reductase activity, measured by the aggregation of insulin, of truncated version 
corresponding to domain a’c (recBb-a’c) in the presence of bacitracin. 
Enzyme activity was tested in concentrations of 0.44 mM (A), 0.88 mM (B), 1.75 mM (C), 3.5 mM (D) 
and 7 mM (E) in the presence of 0.25 mM, 0.5 mM, 1 mM, 2 mM and 4 mM of drug. There is a dose 
dependent inhibition of reductase activity of recBb-a’c in all enzyme concentrations tested. Control 





cysteines in the substrate binding domain of PDI (Dickerhof, Kleffmann, Jack & McCormick, 
2011). The authors proposed that the interaction of bacitracin with the hydrophobic surface of 
the substrate-binding site of PDI lead to the opening of the bacitracin ring with subsequent 
disulfide bond formation with free PDI cysteines. They showed by MALDI-TOF⁄ TOF MS 
disulfide bond formation between an open thiol form of bacitracin and Cys314 and Cys345 of 
PDI, that are present in the b’-domain and x-linker region respectively. However, BbPDI does 
not present these mentioned cysteines and has only one in the substrate binding pocket, 
located in the b domain (Cys249). Analysis of the in silico structural model of BbPDI 
developed in chapter 2 shows that Cys249 is free, but whether it participates or not in a 
Figure 25. Reductase activity, measured by the aggregation of insulin, of recombinant B. besnoiti PDI 
(recBbPDI) in the presence of tocinoic acid. 
Enzyme activity was tested in concentrations of 0.05 mM (A), 0.11 mM (B), 0.22 mM (C), 0.44 mM (D), 
0.88 mM (E) and 1.75 mM (F) in the presence of 0.25 mM, 0.5 mM, 1 mM, 2 mM and 4 mM of drug. 
There is a dose dependent inhibition of reductase activity of recBbPDI, with drug concentrations 



































disulfide bond with bacitracin needs further assessment. Although to a lower extend than the 
full enzyme, bacitracin could also inhibit domain a’c, that presents only the two active site 
cysteines. Taking in account Dickerhof’s et al (2011) observation, we can speculate that 
bacitracin may interact directly with PDI active sites with the differences in inhibition being 
justified by having only one active site to interact in recBb-a’c and two in the complete 
protein. Against this hypothesis, Karala and Ruddock (2010)  state that the active site is 
probably not the target of inhibition of bacitracin, since they found no bacitracin inhibition with 
domain a and bacterial DsbA. Yet, as a measure of PDI reductase activity, the authors 
Figure 26. Reductase activity, measured by the aggregation of insulin, of truncated version 
corresponding to domain a’c (recBb-a’c) in the presence of tocinoic acid. 
Enzyme activity was tested in concentrations of 0.44 mM (A), 0.88 mM (B), 1.75 mM (C), 3.5 mM (D) 
and 7 mM (E) in the presence of 0.25 mM, 0.5 mM, 1 mM, 2 mM and 4 mM of drug. There is a dose 
dependent inhibition of reductase activity of recBb-a’c. Drug concentrations above 2 mM can impair 
activity in all enzyme concentrations except 7 mM (G). Control represents recBb-a’c activity without 





considered only the lag phase, measuring merely the time before an apparent increase in 
absorbance of 0.1 was recorded. Despite the differences in calculating PDI activity, our 
results also show that, for recBb-a’c (but not recBbPDI), there is no increase in the lag phase 
with the addition of bacitracin to the reaction, but there is an attenuated increase in turbidity. 
Tocinoic acid was tested in concentrations ranging from 0.25 to 4 mM and was also able 
to inhibit both enzymes but, unlike bacitracin, no significant differences in sensitivity were 
found between His-recBbPDI (Figure 26) and recBb-a’c (Figure 27). The lower tocinoic acid 
concentrations tested (from 0.25 mM to 1 mM) can reduce enzyme activity from 8% to 100% 
Figure 27. Reductase activity, measured by the aggregation of insulin, of recombinant B. besnoiti PDI 
(recBbPDI) in the presence of DTNB.  
Enzyme activity was tested in concentrations of 0.05 mM (A), 0.11 mM (B), 0.22 mM (C), 0.44 mM (D), 
0.88 mM (E) and 1.75 mM (F) in the presence of 0.0625 mM, 0.125 mM, 0.25 mM, 0.5 mM and 1 mM 
of drug. There is a dose dependent inhibition of reductase activity of recBbPDI, with drug 
concentrations above 0.25 mM stopping enzyme function. Control represents recBbPDI activity 





depending on the molar ratio present. For example, at 0.05 mM His-recBbPDI, 1 mM of 
tocinoic acid completely impaired enzyme activity, while at 1.75 mM of enzyme, the same 
drug concentration only reduced activity by 65%. Higher concentrations of tocinoic acid (2 
mM and 4 mM) were able to stop enzyme activity in all enzyme concentrations tested, with 
the exception of 7 mM of recBb-a’c that can still retain 30% and 20% of activity at tocinoic 
acid concentrations of 2 mM and 4 mM, respectively. In a similar way, DTNB showed the 
same behavior than tocinoic acid, since lower drug concentrations (0.0625 mM to 0.25 mM) 
were able to inhibit enzyme activity to a greater or lesser extent (considering a lower or 
 
  
Figure 28. Reductase activity, measured by the aggregation of insulin, of truncated version 
corresponding to domain a’c (recBb-a’c) in the presence of DTNB. 
Enzyme activity was tested in concentrations of 0.44 mM (A), 0.88 mM (B), 1.75 mM (C), 3.5 mM (D) 
and 7 mM (E) in the presence of 0.0625 mM, 0.125 mM, 0.25 mM, 0.5 mM and 1 mM of drug. There is 
a dose dependent inhibition of reductase activity of recBb-a’c, with drug concentrations above 0.5 mM 





higher enzyme concentration, respectively), while higher drug concentrations (0.5 mM and 1 
mM) were able to halt the function of both enzymes (Figure 28 and Figure 29). The same 
was true for pCMBA, but only with recBb-a’c, for which higher drug concentrations (0.5 mM 
and 1 mM) could impair enzyme crosslinking of insulin, while lower drug concentrations could 
only reduce recBb-a’c activity. With the full length PDI, pCMBA showed a clear dose 
dependent reduction of enzyme activity, with the higher drug concentration (1 mM) allowing 
still 22% of enzyme activity (1.75 mM recBbPDI), but only around 5% at lower enzyme 
concentrations (0.05 mM and 0.11 mM recBbPDI) (Figure 30 and Figure 31).  
  
Figure 29. Reductase activity, measured by the aggregation of insulin, of recombinant B. besnoiti PDI 
(recBbPDI) in the presence of pCMBA.  
Enzyme activity was tested in concentrations of 0.05 mM (A), 0.11 mM (B), 0.22 mM (C), 0.44 mM (D), 
0.88 mM (E) and 1.75 mM (F) in the presence of 0.0625 mM, 0.125 mM, 0.25 mM, 0.5 mM and 1 mM 
of drug. There is a dose dependent inhibition of reductase activity of recBbPDI. Control represents 


































Overall, tocinoic acid, DTNB and pCMBA showed a very similar pattern of inhibition for both 
enzymes tested, with the two to three lower drug concentrations gradually decreasing 
enzyme activity and the tree to five higher drug concentration causing 100% enzyme 
inhibition. Concentrations above 2mM of tocinoic acid and 0.5 mM of DTNB and pCMBA can 
cause 100% inhibition in both enzymes, with the mentioned exception of His-recBbPDI and 
pCMBA, that seem to be less sensitive to this drug. Mandel et al. (1993), reported 100% 
inhibition for concentrations above 1 mM for DTNB and p-chloromercuribenzenesulfonic acid 
(pCMBS). Tocinoic acid, DTNB and pCMBA are thiol scavengers that covalently modify 
Figure 30. Reductase activity, measured by the aggregation of insulin, of truncated version 
corresponding to domain a’c (recBb-a’c) in the presence of pCMBA. 
Enzyme activity was tested in concentrations of 0.44 mM (A), 0.88 mM (B), 1.75 mM (C), 3.5 mM (D) 
and 7 mM (E) in the presence of 0.0625 mM, 0.125 mM, 0.25 mM, 0.5 mM and 1 mM of drug. There is 
a dose dependent inhibition of reductase activity of recBb-a’c. Control represents recBb-a’c activity 





surface sulfhydryl to prevent disulfide bond formation. Tocinoic acid presents a disulfide bond 
between its N-terminal and C-terminal cysteines, that might, similarly to what was described 
for bacitracin (Dickerhof et al., 2011), be involved in disulfide bond formation with PDI 
cysteines. DTNB, also known as Ellman’s reagent, is composed of 2 molecules of 2-nitro-5-
thiobenzoate linked by a disulfide bond that is easily reduced by thiols. As for pCMBA, an 
organic mercurial compound, it can react via mercury-sulfur affinity with free sulfhydryl 
groups. The fact that these drugs can inhibit the activity of domain a’c, that only possesses 
two sulfhydryl groups in the active site cysteines, leaves us to conclude that these molecules 
might interact directly with the active site. On the other hand, if that is the case, we should 
expect that full PDI expressed lower levels of inhibition with these molecules, since DTNB 
and pCMBA react stoichiometrically with thiols and the drug molar ratio to free cysteines is at 
least half of that of recBb-a’c (if we consider the two active sites in the complete protein). The 
result obtained however, show no significant differences in inhibition between recBbPDI and 
recBb-a’c.  
4.3.3 Monoclonal antibody inhibition. 
The activity of His-recBbPDI was tested in the presence of the four monoclonal antibodies 
described in chapter 3. Enzyme sensitivity was evaluated with mAb concentrations ranging 
from 0.05 mM to 0.4 mM. MAb T8a did not inhibited His-recBbPDI activity in any of the 
enzyme concentration tested (Figure 32). The remaining mAbs tested, S4a, S16p and R60b 
were all able to decrease in a dose dependent manner His-recBbPDI activity (Figure 33, 
Figure 34 and Figure 35). Characterization of antigen recognition, done in the previous 
chapter, showed that all mAbs can recognize the full length recBbPDI, that mAb T8a and 
S4a can also recognize the truncated version corresponding to domain a’c and that mAb 
R60b can also recognize the truncated version corresponding to domain b’. The mAb S16p 
is only able to label the full length PDI, but prediction of epitope recognition gave two 
possibilities, both in the non-catalytic b-type domains. PDIs are known for their flexibility and 
plasticity, necessary to accommodate diverse substrates, of different sizes and 
conformations (Laurindo et al., 2012; Tian et al., 2008; Tian et al., 2006). Tian et al. (2008) 
showed that restricting the flexibility of the a domain results in a 60% decrease in enzymatic 
activity, whereas restricting the flexibility of the a’ domain results in only 24% reduction. They 
identified the junction between domains a and b as a major site of flexibility and suggested 
that the loops connecting the a and a’ domains to the b-b’ base enable the yeast PDI to 
facilitate these conformational changes. However, a recent work with human PDI, indicated 





and x-linker region) is more flexible than the N-terminal half (a and b domains) of the protein 
(Wang et al., 2010a). Fine tuning of epitope recognition will be needed in order to determine 
more precisely where these mAbs attach. Nonetheless, considering the relatively large size 
of an antibody molecule, the labeling of some part of one catalytic domain can probably 
constrain its mobility and the overall PDI plasticity or even block or difficult the access of 
substrate peptides to the binding site. This will also be true for the labeling of the non-
catalytic domains, especially if epitope recognition lies within the substrate binding pocket. 
Figure 31. Reductase activity, measured by the aggregation of insulin, of recombinant B. besnoiti PDI 
(recBbPDI) in the presence of monoclonal antibody T8a (mAb T8a). 
Enzyme activity was tested in concentrations of 0.05 mM (A), 0.11 mM (B), 0.22 mM (C), 0.44 mM (D), 
0.88 mM (E) and 1.75 mM (F) in the presence of 0.05 mM, 0.1 mM, 0.2 mM and 0.4 mM of mAb T8a. 






Despite recognizing domain a’c, mAb T8a and S4a are probably directed to distinct epitopes 
since the consequences on enzyme activity were quite different, with no noticeable 
interference in the former and a clear dose dependent inhibition in the latter. These results 
also agree with the differences predicted for epitope recognition on chapter 3. 
  
Figure 32. Reductase activity, measured by the aggregation of insulin, of recombinant B. besnoiti PDI 
(recBbPDI) in the presence of monoclonal antibody S4a (mAb S4a). 
Enzyme activity was tested in concentrations of 0.05 mM (A), 0.11 mM (B), 0.22 mM (C), 0.44 mM (D), 
0.88 mM (E) and 1.75 mM (F) in the presence of 0.05 mM, 0.1 mM, 0.2 mM and 0.4 mM of mAb S4a. 
There is a dose dependent inhibition of reductase activity of recBbPDI by mAb S4a. Control 





In respect to the truncated version of BbPDI corresponding to the domain a’c (recBb-a’c) 
we tested its catalytic activity in the presence of mAb T8a, S4a and S16p. Enzyme 
concentration from 0.22 mM to 7 mM were used, and no inhibition was obtained with the 
presence of any of these mAbs (data not shown). Epitope recognition for these mAbs is 







Figure 33. Reductase activity, measured by the aggregation of insulin, of recombinant B. besnoiti PDI 
(recBbPDI) in the presence of monoclonal antibody S16p (mAb S16p). 
Enzyme activity was tested in concentrations of 0.05 mM (A), 0.11 mM (B), 0.22 mM (C), 0.44 mM (D), 
0.88 mM (E) and 1.75 mM (F) in the presence of 0.05 mM, 0.1 mM, 0.2 mM and 0.4 mM of mAb S16p. 
There is a dose dependent inhibition of reductase activity of recBbPDI by mAb S16p. Control 








Figure 34. Reductase activity, measured by the aggregation of insulin, of recombinant B. besnoiti PDI 
(recBbPDI) in the presence of monoclonal antibody R60b (mAb R60b). 
Enzyme activity was tested in concentrations of 0.05 mM (A), 0.11 mM (B), 0.22 mM (C), 0.44 mM (D), 
0.88 mM (E) and 1.75 mM (F) in the presence of 0.05 mM, 0.1 mM, 0.2 mM and 0.4 mM of mAb R60b. 
Reductase activity of rec BbPDI is inhibited by mAb R60b. Control represents recBbPDI activity 





4.3.4 Involvement of BbPDI in host cell interaction. 
B.besnoiti is an obligate intracellular parasite that must actively invade the host cell for 
survival and multiplication. Invasion is a dynamic and complex process in which the 
sequential release of proteins from micronemes, rhoptries and dense granules is 
fundamental (Binder & Kim, 2004; Katris et al., 2014; Sibley, 2011; Walker et al., 2014). 
There is a vast set of proteins involved in this process, playing different roles, but all 
essential for the successful invasion. Globally these proteins are regarded has good potential 
candidates for drug or immunogenic therapy (Darcy et al., 1988; Daryani, Hosseini & Dalimi, 
2003). PDI was already identified in the excretory-secretory (ES) compartment of N. caninum 
(Liao et al., 2006), T. gondii (Zhou et al., 2005) and P. berghei (Lal et al., 2009) and at the 
cell surface of N. caninum (Naguleswaran et al., 2005), T. gondii (Meek et al., 2002a), P. 
falciparum (Florenta et al., 2000), L. donovani (Padilla et al., 2003) and T. parva (Ebel et al., 
2002). To establish the presence of PDI in ES compartment purified tachyzoites were 
incubated in the absence and presence of ethanol. Ethanol specifically stimulates microneme 
discharge, but not rhoptry or dense granule release (Phelps, Sweeney & Blader, 2008). 
Figure 35. Detection of B. besnoiti PDI in the excretory-secretory compartment. 
Western blot of supernatants (ESC) prepared after 15 min incubation of purified B. besnoiti 
tachyzoites and soluble protein extracts (SPE) of B. besnoiti. The excretory-secretory 
compartment (ESC) was evaluated in a PBS solution (1) and a 1% ethanol PBS solution (2). 
The soluble protein fraction was applied undiluted (3) and diluted 1:50 (4). Two fold serial 
dilutions were made until 1:1600 (not shown), but no labeling of PDI was achieved beyond 
1:50 dilution. Membranes were probed with mouse anti-recBbPDI, revealing a band with the 





When probed with anti-PDI serum we were able to label a band with the expected molecular 
weight of PDI, with a slight higher intensity for the ethanol induced ESA (Figure 36). For 
control, soluble protein extracts of B. besnoiti tachyzoites were used and diluted serially. This 
represents a strong evidence that in B. besnoiti PDI is also present in the ES compartment, 
highlighting the suspected importance of this protein in host cell invasion process. 
In order to assess the importance of PDI in the process of cell invasion a simple assay 
was established, consisting in the pre-incubation of Besnoitia besnoiti tachyzoites with the 
inhibitors (drugs or mAbs), and the inoculation of host cells in the presence of inhibitors. For 
that, B. besnoiti tachyzoites were incubated for 10 min with the inhibitors and then 
transferred to a Vero cell monolayer where they were left to invade for 1 hour. To maximize 
the interaction between the Vero cells and tachyzoites and, in this way, the invasion process, 
only a small drop (300 μL) of medium containing the parasites was placed over the Vero 
cells. Vero cells were then washed to remove inhibitors and free tachyzoites and fresh 
medium (without inhibitors) was added. Intracellular tachyzoites were allowed to grow for a 
total of twelve hours. In this way, the effect of inhibitors was evaluated only during the 
invasion process, with minimal impact on host cell metabolism, that could subsequently 
influence parasite growth. Nevertheless, the viability of both tachyzoites and Vero cells in the 
presence of drug inhibitors was previously evaluated, by counting viable cells in a trypan blue 
exclusion test. A two hour incubation of Vero cells and tachyzoites did not increased cell 
death. Also, after this period of incubation, the viability of B. besnoiti tachyzoites was 
accessed by inoculating cell culture monolayers and performing routine serial passages. In 
the same way, viability of Vero cell was accessed in the subsequent days after the incubation 
with drugs. The two hour incubation period with the inhibitor drugs did not affect subsequent 
viability of tachyzoites or Vero cells. 
The involvement of BbPDI in B. besnoiti-host cell interaction was in this way investigated 
by incubating tachyzoites with known PDI inhibitors, namely bacitracin, tocinoic acid, DTNB 
and pCMBA as well as with anti-PDI monoclonal antibodies. Results obtained showed a 
reduction on the host cell invasion rate of B. besnoiti tachyzoites for all drugs and mAbs 
tested (Figure 37 and Figure 38). On a molar basis, the most efficient inhibition was obtained 
with pCMBA, that with 5 μM can inhibit tachyzoite invasion in 20%, result that is only attained 
with 4 mM of Bacitracin (800 times pCMBA concentration) and 3 mM of tocinoic acid (600 
times pCMBA concentration). Best overall result was obtained with DTNB, that can inhibit in 
75% the parasite invasion rate, nevertheless, with a concentration of 2,5 mM. The 
concentration of drugs used for the invasion assay was adapted from the available literature. 
Comparable results were obtained in a similar study, but where N. caninum tachyzoites were 
only pre-incubated for 15 min. with inhibitors: 45% inhibition with 2.5 mM DTNB, 32% 





Similarly, the presence of anti-PDI mAbs during the invasion process of B. besnoiti also 
had a negative impact in tachyzoite invasion rates with reduction ranging from 4% to 35%, 
depending on the mAb and the molar ratio considered. Curiously, mAb T8a, that could not 
inhibit in vitro reductase activity of recBbPDI, was one of the best performing mAb, along with 
S16p. In the invasion assay, conditions are very different from the ones established for 
measuring the catalytic activity of the recombinant protein. One key point that certainly 
changes, for example, is the enzyme substrate, that is not the same. The way mAb T8a 
binds to recBbPDI does not seem to interfere with activity of the recombinant enzyme over 
insulin, but appears to interfere with function of natural BbPDI, in a similar way as mAbs 
could not inhibit the catalytic activity of the truncated version recBb-a’c but could do so in the 
complete protein. When in the invasion process, B. besnoiti PDI function will probably go 
beyond the reductase activity performed over insulin, with the isomerase or chaperone 
functions being possibly the major tasks. It was shown for other PDIs, that the b’ domain is 
essential for the isomerase function (Darby et al., 1998; Hatahet & Ruddock, 2009) since it 
represents the principal substrate binding site, and we can theorize that mAb T8a, despite 
recognizing an epitope on domain a’c, might interfere in a bigger extent with the binding of 
substrate peptides and in this way affect significantly the in vivo activity of BbPDI. 
  
Figure 36. In vitro invasion of Vero cells by B. besnoiti tachyzoites in the presence of drug inhibitors. 
Different concentrations of bacitracin (A), tocinoic acid (B), DTNB (C) and pCMBA (D) result in a 






In general terms, these result agree with others that also show a negative impact of anti-
PDI polyclonal sera and inhibitors in the growth of N. caninum (Liao et al., 2006; 
Naguleswaran et al., 2005), L. amazonensis (Hong & Soong, 2008) and L. major (Achour et 
al., 2002). In this assay, by using membrane impermeant PDI inhibitors, that can only act at 
the parasite surface, we show that interference with PDI function reduces B. besnoiti 
capacity to interact with the host cell, affecting ultimately its growth. Therefore, these results 
also point PDI as a potential target for drug therapy or vaccine development. 
  
Figure 37. In vitro invasion of Vero cells by B. besnoiti tachyzoites in the presence of mAbs. 
 Different concentrations of monoclonal antibody T8a (A), S4a (B), S16p (C) and R60b (D) result in 






PDI is a ubiquitous multifunctional enzyme that is well characterized in mammals and 
yeast. We showed that recombinant BbPDI produced is functionally active, presenting the 
expected reductase activity over the reduced insulin. The truncated version corresponding to 
active site domain a’c is also active, but less than the full length protein, while active site 
domain a showed no reductase activity. In the presence of the drug inhibitors bacitracin, 
tocinoic acid, DTNB and pCMBA both recBbPDI and recBb-a’c were sensitive and showed a 
reduction in the catalytic activity. With mAbs, differences were observed between recBbPDI, 
that was sensitive to all mAbs except T8a, and recBb-a’c, whose reductase activity was not 
influenced by the presence of mAbs. The proposed method for high-throughput screening of 
PDI activity validated by Smith et al. (2004) was implemented for these initial assays and will 
allow for future screening of potential inhibitors.  
We showed that B. besnoiti PDI is part of the excretory-secretory compartment in 
tachyzoites. Targeting surface associated PDI function with membrane impermeant inhibitors 
and anti-BbPDI mAbs in B. besnoiti tachyzoites invading Vero cells resulted in lower invasion 
rates which shows that this protein is probably involved in the host cell adhesion/invasion 
process. Although the exact role of this molecule at the parasite surface is not clarified, and 
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Bovine besnoitiosis is a disease known for more than a century. It’s mostly sub-Saharan 
location, with only a few pinpointed cases reported in Europe until the late 1990s, left it 
regarded as a tropical disease and fairly unnoticed for the veterinary and scientific 
community worldwide. Nevertheless, in between, other cases were reported in areas like 
Israel, Russia or South Korea. By the turn of the century the disease starts to be more 
noticed with a growing number of reports in Europe accompanied by a geographical 
expansion. This lead to the classification of besnoitiosis as an emergent disease in Europe 
by the EFSA. The genus Besnoitia comprises ten named species and has a worldwide 
distribution, but still with some questions regarding differentiation and taxonomic 
classification of these species. Only four Besnoitia species have their life cycle clarified, 
being similar to the closely related T. gondii and N. caninum: facultative heteroxenous with a 
predator as a definite host and a prey as intermediate host. For the remaining six species, 
where B. besnoiti is included, the life cycle is unknown. For these species no definitive host 
was identified and, although bovines were identified as intermediate hosts for B. besnoiti, the 
question whether they represent an accidental or the natural host remains to be answered. 
The disease in bovines can lead to important economic losses due to significant reduction in 
productivity, but is usually non-fatal, progressing to a debilitating chronic stage. There is no 
treatment and the use of the attenuated vaccines obtained in Israel and South Africa is 
geographically limited due to safety concerns. Therefore, control of disease is currently 
based solely on sanitary control methods. With so much to be known and clarified about this 
disease and parasite, arose the will to contribute to the building of knowledge on this 
subjects. And, for that matter, PDI had been recently pointed as an important protein, playing 
a key role in host cell invasion and in the host immune response, representing a promising 
drug target and/or vaccine candidate. PDI has been associated with adhesive functions and 
cell–cell and cell–pathogen interactions, and is now accepted that PDI is present at the 
surface of apicomplexan parasites, where it participates in host cell adhesion/invasion 
process. This process is crucial for the survival of these obligate intracellular parasites and 
we must consider that it is a mechanism driven solely by the parasite, where the host cell 
does not voluntarily participates, unlike phagocytosis for example. In this way, apicomplexan 
parasites need to carry with them all the tools to promote, first, adhesion, and then invasion. 
In this process they deploy a vast number of important proteins that exhibit an exceptional 
high number of disulfide bridges (Naguleswaran et al., 2005), that are responsible for their 
correct conformation and functionality. The pressure for quality control on the assembling of 
proteins is high, both at the endoplasmic reticulum and at the parasite surface. The exact 
mechanisms in which PDI is involved are unknown but certainly, and at least, it will be 
responsible for maintaining the structure and function of these crucial surface constituents 





In this way, our main goal was to characterize the PDI of B. besnoiti and evaluate its role 
in host cell adhesion/invasion process and in the bovine immune response. We identified the 
complete coding sequence for PDI in B. besnoiti, originating the first publication of a 
complete gene sequence for a protein and the first protein to be identified and characterized 
in the genus Besnoitia. The enzymatic activity of the recombinant protein produced was 
evaluated by a turbidimetric assay based on the reduction of insulin, catalyzed by PDI. This 
assay, that can be used in the future for batch screening of PDI inhibitors, revealed a 
functionally active protein that was inhibited by drugs and monoclonal antibodies produced in 
this work. The advent of mAb technology has provided a powerful tool for the generation of 
limitless amounts of highly specific antibodies with multiple applications in research, 
diagnosis, and therapy. The mAbs produced were raised against recBbPDI, through the 
fusion of hyperimmunized mice spleens with a myeloma cell line. This hybridoma technology, 
although established more than 35 years ago, is still applied because of its simple protocol. 
We purified and characterized four mAbs, showing differences in epitope recognition of 
truncated versions of PDI and in the cross reactivity with N. caninum and T. gondii. These 
represent a valuable tool for future studies not only on the role of PDI, but also on 
fundamental biology of B. besnoiti and related Apicomplexa. 
PDI is an immunodominant antigen as proteomics studies describe for other 
apicomplexan parasites and for B. besnoiti, where it is up-regulated in the tachyzoite stage 
(Garcia-Lunar, Regidor-Cerrillo, Gutierrez-Exposito, Ortega-Mora & Alvarez-Garcia, 2013b). 
Proteomic tools have allowed for the investigation of relevant biological processes as well as 
host immune responses associated with infections by other apicomplexan parasites of 
medical and veterinary importance. We addressed the diagnostic value of PDI, by performing 
ELISA over recBbPDI sensitized plates and also a competitive ELISA using mAbs. Despite 
initial results were encouraging, when starting to test a larger panel of sera, we soon realize 
that PDI is not a suitable antigen for this purpose due to lack of specificity (data not shown). 
Initially the panel tested included sera from chronically infected animals, recently infected 
animals, naïve animals, as well as sera from animals infected with the related N. caninum 
and T. gondii. Later we were able to add a well-defined batch of sera, from 4 animals 
followed during the course of disease, in a co-habitation trial (Gollnick et al., 2015; Schares 
et al., 2013). These animals were sampled at least from day 0 post seroconversion until 
approximately day 150. Since PDI is up-regulated in the tachyzoite phase, we would expect 
higher anti-PDI antibodies in the acute phase, that would decrease with the progression to 
the chronic stage. Nevertheless, although PDI was constantly identified in infected animals, 
no consistent variation was found in ELISAs throughout the course of disease (data not 
shown). Until the exact mechanism in which PDI intervenes is clarified we probably will not 





When evaluating the role of PDI in host cell adhesion/invasion, we could place this protein 
in the excretory-secretory compartment of B. besnoiti tachyzoites, highlighting the 
hypothesized importance of PDI in this process. Furthermore, when incubating B. besnoiti 
tachyzoites with the PDI inhibitors tested in the kinetic assay (both drugs and mAbs), we 
could negatively affect the in vitro development of the parasite, by diminishing its invasion 
rate. This, not only confirms that PDI plays a role in the adhesion/invasion of the host cell, 
but also points to the potential use of PDI as a drug target or vaccine candidate. In N. 
caninum, PDI has been tested as a vaccine candidate in a mouse model, and different 
results were obtained depending on the antigen formulation and route of delivery. Intranasal 
vaccination with recombinant N. caninum PDI conferred approximately 90% protection 
against the disease. Considering the close relation to B. besnoiti and specially the high 
identity level between PDIs of these two parasites, these results indicate that in besnoitiosis 
PDI, despite not being a suitable antigen for diagnostics, can still be a good candidate to 
include in immunogenic formulations. The above mentioned results, obtained with PDI in the 
N. caninum mouse model, clearly point to the need of addressing this question together with 
the adjuvant formulation and route of administration in bovine. 
In a therapeutic point of view, two complementary approaches can be used for further 
studies. One can be the in silico screening of new compounds to find suitable ligands for 
PDI, making use of the 3D model here developed. This can be a fertile field considering the 
large amount of compounds made available through the advent of combinatorial chemistry. 
The other approach can be the evaluation in vitro of the efficacy of selected compounds. 
These can first be tested in the insulin assay for their ability to inhibit PDI activity and then, 
best performing ones, can be used in invasion assays. Following these approaches we might 
be able to find good candidates for the treatment of B. besnoiti infections and possibly for the 
treatment of infections by other related Apicomplexa. 
This work represents an initial approach to better understand the role of PDI in the biology 
of B. besnoiti. While demonstrating that PDI is an important enzyme for successfully 
accomplish host cell invasion, the exact mechanisms in which it participates are not clarified. 
Future works should both try to clarify these mechanisms and look for the potential of PDI as 
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